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Summary  
Ageing is associated with a significant increase in Cardiovascular Disease (CVD) and 
mortality in both men and women. Because the onset of menopause in women 
correlates with a significant decrease in estrogen levels, it is hypothesized that 
estrogen reduction importantly contributes to the increase in cardiovascular mortality 
in postmenopausal women. Epidemiological and clinical studies provide strong 
evidence that estrogen protects women treated within five years of menopause 
onset, against CVD. The dynamic interaction of estrogens with cells within the vessel 
wall, Endothelial Cells (ECs) and Smooth Muscle Cells (SMCs), contributes to its 
anti-vasoocclusive actions. However, the mechanisms involved remain unclear. 
Although Estrogen Receptors ERα and ERβ are thought to mediate the 
vasoprotective actions via genomic or non-genomic mechanisms, the role of GPER, 
a newly discovered membrane G-protein coupled Estrogen Receptor, remains 
unknown.  
Hence, in this study we investigated the role of GPER in mediating the protective 
effects of estrogen on the vessel wall. Since endothelial dysfunction and abnormal 
growth of SMCs contribute to the vascular remodeling process leading to vascular 
occlusion in CVD, we investigated the role of GPER in modulating endothelial and 
SMC function and the underlying mechanisms mediating these effects. Using 
pharmacological (GPER specific agonist G1 and antagonist G15) and molecular 
(siRNA) approaches we assessed the role of GPER in regulating EC and SMC 
function. We demonstrate that GPER activation improves Human Umbilical Vein 
Endothelial Cell (HUVEC) function by inducing vasculogenesis, sprouting, migration 
and proliferation. Importantly, the effects are mediated via two key pro-vasculogenic 
pathways i.e. ALK1/ SMAD1/5/8 and PI3K/ Akt/ NO/ VEGF. Moreover, we show that 
crosstalk between these pathways is essential to facilitate vasculogenic actions of 
GPER. Finally, we provide evidence that GPER activation inhibits Human Coronary 
Artery Smooth Muscle Cell (HCASMC) proliferation and migration via downregulation 
of PI3K/ Akt, but not ALK1/ SMAD1/5/8, signaling. 
In summary, our findings demonstrate that GPER actively mediates the growth 
effects of estrogen on vascular ECs and SMCs. Importantly, GPER activation 
induces EC function and inhibits SMC function. These differential effects of GPER on 
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EC and SMC growth would prevent vascular remodeling associated with 
vasoocclusive disorders in CVD. In conclusion, we postulate that GPER might be a 
novel therapeutic target for developing new strategies to treat CVD in 
postmenopausal women. Since in contrast to ERα and ERβ, GPER function remains 
unaltered in ageing vessels, GPER ligands may be superior to the currently used 
estrogen therapies in inducing vasoprotective actions.  
 
Zusammenfassung 
 
11 
 
Zusammenfassung 
Der Alterungsprozess geht mit einem signifikanten Anstieg von kardiovaskulären 
Erkrankungen und einer damit verbundener Mortalität bei Männern sowie auch bei 
Frauen einher. Man vermutet einen Zusammenhang zwischen dem sinkenden 
Östrogenspiegel ab Einsetzen der Menopause und der erhöhten Sterblichkeit, 
aufgrund erhöhter Anfälligkeit für Herz-Kreislauf-Erkrankungen von älteren Frauen. 
Epidemiologische und klinische Studien stützen diese Hypothese und beweisen, 
dass Östrogen Frauen kardiovaskulär schützt, wenn die Therapie innerhalb der 
ersten fünf Jahre nach Einsetzen der Menopause begonnen wird. Die dynamische 
Interaktion von Östrogen mit vaskulären Gefässwandzellen (Endothelzellen und 
glatte Muskelzellen) trägt zu diesen schützenden, antivasookklusiven Effekten bei. 
Jedoch sind die involvierten Wirkmechanismen nach wie vor unbekannt. Obwohl man 
weiss, dass die Herz-Kreislauf-schützenden Effekte von Östrogen teils über die Kern-
Rezeptoren ERα und ERβ, über genetische und nicht-genetische Mechanismen, 
vermittelt werden, ist die Rolle des neu entdeckten G-Protein gekoppelten 
Östrogenrezeptors GPER weitgehend unerforscht.  
Das Ziel dieser Studie war, die Rolle von GPER als Vermittler von Östrogen und 
dessen schützende Effekte auf vaskuläre Blutgefässe und deren Wände zu 
untersuchen. Endotheliale Dysfunktion und abnormales Wachstum von glatten 
Muskelzellen führen zur vaskulären Okklusion und damit zu Herz-Kreislauf-
Erkrankungen. Wir ermittelten, ob GPER die Funktion von vaskulären 
Gefässwandzellen modulieren kann und analysierten die zugrunde liegenden, 
molekularen Mechanismen. Mittels pharmakologischer (GPER spezifischen Agonist 
G1 und Antagonist G15) und molekularer (siRNA) Methoden haben wir die 
regulierende Wirkung von GPER auf die Funktion von Gefässwandzellen untersucht. 
Wir konnten zeigen, dass die Aktivierung von GPER zur verbesserten Funktion von 
Human Umbilical Vein Endothelial Cells (HUVECs) führt, indem G1 Vaskulogenese, 
Migration und Proliferation induziert. Entscheidend ist, dass die zugrunde liegenden 
Signalwege, die zu diesen Effekte führen, identifiziert werden konnten: ALK1/ 
SMAD1/5/8 und PI3K/ Akt/ NO/ VEGF werden von G1 aktiviert. Auch entdeckten wir, 
dass beide Signalwege miteinander verbunden sind, sich gegenseitig regulieren, und 
dieser „Crosstalk“ für die vaskulogenen Effekte von GPER essentiell ist. Schliesslich 
konnten wir auch zeigen, dass die Aktivierung von GPER die Proliferation und 
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Migration von Human Coronary Artery Smooth Muscle Cells (HCASMCs) inhibiert, 
indem G1 PI3K/ Akt, aber nicht ALK1/ SMAD1/5/8, blockiert. 
Zusammenfassend zeigen unsere Ergebnisse, dass GPER aktiv die Effekte von 
Östrogen auf das Wachstum von vaskulären Gefässwandzellen reguliert. 
Hervorzuheben ist, dass GPER die Funktion von Endothelzellen induziert und die 
von glatten Muskelzellen inhibiert. Diese unterschiedlichen Effekte von GPER auf 
das Wachstum von Gefässwandzellen tragen dazu bei, vaskuläre Umbauprozesse, 
die zur Vasookklusion bei Herz-Kreislauf-Erkrankungen führen, zu unterbinden. 
Abschliessend postulieren wir, dass GPER ein Ziel für neue therapeutische Ansätze 
bzw. Medikamente sein könnte, um kardiovaskuläre Erkrankungen in 
postmenopausalen Frauen zu behandeln. Da die Funktion von GPER, im Gegensatz 
zu ERα und ERβ, in alternden Blutgefässen nicht beeinträchtigt ist, könnte ein 
spezifischer Ligand für GPER eine höhere vasoprotektive Wirkung erzeugen als 
herkömmliche Östrogentherapien. 
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Abbreviations 
2ME   2-Methoxyestradiol 
2OE   2-Hydroxyestradiol 
4ME   4-Methoxyestradiol 
4OE   4-Hydroxyestradiol 
AA   Antibioticum- Antimycoticum 
Akt   Proteinkinase B 
ALK   Activin Receptor-like Kinase 
ALK1Fc  ALK1 neutralizing antibody 
ATP   Adenosine TriPhosphate 
B   Batimastat, MMP-inhibitor 
BCA   Bichinonic Acid 
BMP   Bone Morphogenetic Protein 
BSA   Bovine Serum Albumin 
Ca2+   Calcium 
cAMP   3',5'-cyclic Adenosine Monophosphate  
cDNA   complementary Desoxyribonucleic Acid 
COMT  Catechol-O-methyltransferase 
CVD   Cardiovascular Diseases 
CYP 450s  Cytochrome P450 enzymes 
CY   Cycloheximide, translation inhibitor 
DAF-2DA  4,5-Diaminofluorescein diacetate 
DDA   2′,3′-Dideoxyadenosine, an adenylate cyclase specific inhibitor 
DMEM-F12   Dulbecco’s Modified Eagle Medium: Nutrient Mixture F12 
DMSO   Dimethylsulfoxide 
DTT    Dithiothreitol 
E1   Estrone 
E2   17-β Estradiol 
E3   Estriol 
EBM   Endothelial Basal Medium 
EC   Endothelial Cells 
ECFCs  Endothelial Colony Forming Cells 
EGF   Endothelial Growth Factor 
ELISA   Enzyme-linked Immunoassay 
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ER   Estrogen Receptor 
ERE   Estrogen Response Element 
FCS   Fetal Calf Serum 
G1   GPER specific agonist 
G15   GPER specific antagonist 
GDP   Guanosine DiPhosphate 
GPCR  G-protein coupled Receptor 
GPER   G-protein coupled Estrogen Receptor 
GRK   G-protein coupled Receptor Kinase 
GTP   Guanosine TriPhosphate 
HBSS   Hank`s Buffered Salt Solution 
HCASMCs  Human Coronary Artery Smooth Muscle Cells 
HCl   Hydrochloric acid 
HERS   Heart and Estrogen/ Progestin Replacement Study 
HHT   Hereditary Hemorrhagic Telangiectasia 
HRT   Hormone Replacement Therapy 
HSD   Hydroxysteroid Dehydrogenase 
HUVECs  Human Umbilical Vein Endothelial Cells 
ICI   ICI 182-780, fulvestrant, ER unspecific antagonist 
IL   Interleukin 
L-NAME  eNOS inhibitor 
L-NMMA  eNOS inhibitor 
LSGS   Low Serum Growth Supplements 
LY   LY294002, PI3K-inhibitor 
MEK   MAPK, mitogen activated protein kinase 
Mg2+   Magnesium 
mm-IBMX  8-Methoxymethyl-3-isobutyl-1-methylxanthine 
MMP   Matrix Metallo Proteinase 
MPP   Methyl-Piperidino-Pyrazole, ERα unspecific antagonist 
mRNA  messenger Ribonucleic Acid 
NO   Nitric Oxide 
PAH   Pulmonary Arterial Hypertension  
PBS   Phosphate Buffered Saline 
PDE   Phosphodiesterase 
PDGF   Platelet Derived Growth Factor 
PI3K    Phosphoinositide 3 Kinase 
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PDK1   Phosphoinositide-dependent kinase 1 
PKA   Protein kinase A 
PKI   PKI (5-24), a PKA-specific inhibitor 
PPT   Propy Pyrazole Triol, ERα specific agonist 
PTX   Pertussis Toxin 
RNA   Ribonucleic Acid 
ROS   Reactive Oxygen Species 
RT   Room Temperature 
RT-PCR  Real Time quantitative Polymerase Chain Reaction 
SDS    Sodium Dodecyl Sulphate 
SERDs  Selective Estrogen Receptor Downregulators 
SERMs  Selective Estrogen Receptor Modulators 
siRNA   small interfering RNA 
SJN   SJN2511, an ALK5 inhibitor 
SMCs   Smooth Muscle Cells 
SMGS  Smooth Muscle Growth Supplement 
TGFβ    Transforming Growth Factor Beta 
TNFα   Tumor Necrosis Factor alpha 
VEGF   Vascular Endothelial Growth Factor 
VEGFAb  neutralizing antibody for VEGF 
VSMCs  Vascular Smooth Muscle Cells 
WHI   Women`s Health Initiative  
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1 Introduction 
 Estrogens and their Physiology 1.1
Estrogens are the primary female sex hormones. The naturally generated estrogens 
in women are estrone (E1), 17-β estradiol (E2) and estriol (E3). Although E2, E3 and 
E1 are present in women of all age, in adult non-pregnant females E2 is 
predominant, while E1 are high in menopausal females and E3 levels dominate in 
pregnant females [1]. 
 Estrogen`s Biological Effects 1.1.1
Estrogens regulate growth and function of female reproductive organs and promote 
development of female secondary sex characteristics. Furthermore, they mediate the 
menstrual cycle and are critical for the fertilization processes and maintenance of 
pregnancy. Apart from an essential role in reproductive organs, estrogens also play a 
critical role in regulating physiology and biology of many other tissues. For example 
in the brain estrogen has neuroprotective effects and protects against Alzheimer`s 
disease; it improves cardiovascular function and protects against Cardiovascular 
Diseases (CVDs) (described in detail in section 1.5); estrogen ameliorates 
metabolism of cholesterol and lipoproteins in the liver; estrogen increases bone 
density and therefore protects against osteoporosis; in the gastrointestine estrogens 
reduce the risk of colon cancer; and estrogen improves skin aging [2, 3]. Apart from 
the beneficial effects of estrogen listed above; the pro-mitogenic characteristics of 
estrogen in breast and uterine can also induce uterus and breast cancer [4]. Although 
estrogens are primary female sex hormones, they also occur in males and influence 
the male reproductive system and fertility [2]. 
 Estrogen Synthesis 1.1.2
Estrogens are mainly produced within female ovaries [5], but other tissues can also 
synthesize estrogens. For example, estrogens are also produced in brain, liver, 
adipose tissue, skin, muscle, breast, vaginal mucosa and endometrium.  
Estrogens and other steroid hormones, like progestins and androgens, are 
synthesized from cholesterol. The synthesis starts by uptake of cholesterol into 
steroidogenic cells, in which specific cytochrome P450 enzymes (CYP 450s) convert 
it to pregnenolone. Via two different mechanisms pregnenolone is further processed 
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enzymatically to testosterone: either by the actions of 3-β hydroxysteroid 
dehydrogenase (HSD) and 17-β HSD or hydroxylation of 17-α position by 17-α-
hydroxylase to 17-α-hydroxypregnenolone, which is further converted by 17,20 lyase 
to dehydroepiandosterone and subsequently by 17-β HSD to testosterone. Finally, 
aromatase converts testosterone to 17-β estradiol (as depicted in Figure 1). 
 
Figure 1: Estrogen Synthesis [6]. C: Carbon molecules. 
Following synthesis estradiol is released into the circulation. It is present either in free 
form (2-3% of total amount) or bound to albumin or sex-hormone binding globulin. 
Circulating concentrations of estrogens range from 0.36 nmol/L in the follicular phase 
to 2.2 nmol/L in ovulation phase. The circulating levels of estrogens peak during 
pregnancy and reach up to 73 nmol/L and drop after menopause to 0.02 nmol/L, 
which is comparable to estrogen concentrations in men [7]. 
 Estrogen Metabolism 1.1.3
The elimination of estrogen is facilitated by its conversion to water-soluble 
metabolites, which are excreted via urine or feces. Estrogen is conjugated either to 
sulfates, to glucuronides or to fatty acids and subsequently degraded. Moreover, 
estrogen can also be metabolized into bioactive products: estrogen is converted into 
oxidative metabolites as described in Figure 2, e.g. 2-hydroxyestradiol (2OE) and 4-
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hydroxyestradiol (4OE) by CYP450, followed by methylation to 2-methoxyestradiol 
(2ME) and 4-methoxyestradiol (4ME) by catechol-O-methyltransferase (COMT). 
Mainly, this metabolism occurs in the liver, but CYP450 and COMT are ubiquitous 
enzymes, which are also present in other tissues, like vasculature, kidneys, 
gastrointestinal tract, spleen, brain and pancreas [8, 9]. Although the majority of 
estrogen metabolites are excreted, some of them have significant growth regulatory 
effects [8]. Consequently, 2ME has been reported to reduce neovascularization, 
tumor growth [10], neointima formation and proliferation of Smooth Muscle Cells 
(SMCs) [11]. 
 
Figure 2: Estrogen Metabolism, depicted and modified from Dubey et.al. [12] 
 Estrogen Receptors  1.2
 Estrogen Receptor α and Estrogen Receptor β 1.2.1
Estrogenic effects are mainly mediated via Estrogen Receptors (ERs). The classical 
ERs are ERα, which was discovered in 1960 and cloned for the first time in 1986 
[13], and ERβ, which was discovered in 1996 [14]. The genes of ERα and ERβ are 
located on chromosome 4 and 6 and encode for proteins containing 595 and 530 
amino acids, respectively [15]. 95% of ERα and ERβ are located inside the cell 
nucleus, while 5% are present in the cytoplasm [16].  
Like all members of classical nuclear receptors, ERα and ERβ inherit 6 conserved 
domains A-F, as depicted in Figure 3. A/B represent the N-terminal domain, which 
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contains the activating transcription function 1 (AF1), being responsible for ligand 
independent transcription activation. The highly conserved domain C is responsible 
for DNA binding via two zinc finger structures. D is the hinge region, responsible for 
recruiting and binding of co-modulators, while E and F contain the ligand-binding 
domain, which, together with activating transcription function 2 (AF2), is the ligand-
dependent activator of transcription [17]. Apart from the DNA-binding domain C, 
which is 95% similar, the homology in ERα and ERβ is low. However, the binding 
affinity of the endogenous ligand E2 to both ERα and ERβ is Kd=0.6 nmol/L [14]. 
 
Figure 3: Structure of ERα and ERβ [17] 
The tissue distribution of ERα and ERβ is diverse: while ERα is prevalent in the 
endometrium, breast cells and in the ovary, ERβ is mainly expressed in the kidney, 
the intestinal mucosa, bones, the lung and the prostate [2]. The effects of ER-ligand 
E2 depend on the regulation of ER, and E2 has been shown to induce ER expression 
in breast cancer cells [18, 19], retinal pigment epithelium [20] and osteoclasts [21].  
The investigation of differential effects and roles of ERα and ERβ is facilitated by 
commercially available agonists and antagonists: ICI 182-780 is an ER unspecific 
antagonist, MPP is an ERα specific antagonist, PPT is an ERα specific agonist, 
PHTPP is an ERβ specific antagonist and DPN is an ERβ specific agonist. 
 GPER, the G-protein Coupled Estrogen Receptor  1.2.2
In addition to the classical Estrogen Receptors α and β, a third membrane bound 
Estrogen Receptor has recently been identified. 
Subsequently, between 1996 and 1998, several laboratories independently 
discovered and cloned an orphan receptor [22-27], the ligand for which was unknown 
and named it GPR30 because it was thought to belong to the family of the classical 
seven-transmembrane G-protein coupled receptors.  
As depicted in Figure 4, the structure of classical G-protein coupled receptors is 
highly conserved and can be divided into three different parts. The extracellular 
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region consists of the N-Terminus and three extracellular loops ECL1-ECL3, the 
transmembrane region of seven α helices TM1-TM7, and the intracellular region of 
three intracellular loops ICL1-ICL3, an intracellular amphipathic helix H8 and the C 
terminus. Access of the ligand is modulated by the extracellular region, while the 
transmembrane region facilitates ligand binding and further transduces the 
information by changing the conformation of the intracellular region, which consists of 
the C-Terminus and interacts with cytosolic signaling proteins [28]. Those 
intracellularly bound signaling proteins are the G-proteins Gα and Gβγ, G protein-
coupled receptor kinases (GRKs) and β-arrestins [29, 30].  
 
Figure 4: Structure of the classical GPCRS, depicted and modified from Venkatakrishnan et al. [28] 
The model of GPCR signaling is depicted in Figure 5 and as follows: Upon ligand 
binding the GPCR conformation is switched to an active state, which leads to 
exchange of GDP to GTP, associated with the Gα subunit. The Gβγ dimer and Gα 
subunit dissociate from the GPCR, thus further binding and activating effectors, 
which themselves induce different kinds of second messengers. Gα possesses an 
intrinsic GTPase activity, converting GTP to GDP, thereby inactivating the G protein 
signaling cascade [31].  
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Figure 5: Classical Signal Transduction Model of GPCRs [31] 
Figure 6a depicts the action of other intracellular GPCR proteins. GRKs mediate the 
phosphorylation of GPCR`s serine residues at the C-terminus [32], leading to the 
recruitment and binding of β-arrestins. These β-arrestins are scaffolding proteins, 
which mediate the internalization of GPCR via Clathrin Coated Pits (CCPs). This 
internalization process is well characterized and believed to be responsible for 
desensitization and impairment of GPCR signaling by recycling or transporting the 
GPCR to the proteasome [33]. However, recent studies suggest that β-arrestins also 
transduce signals to multiple effector pathways [34]. Depending on the ligand bound 
to GPCR, β-arrestin-mediated signaling or “normal” G-protein mediated signaling will 
be activated. This differential effect is termed as functional selectivity or biased 
signaling (Figure 6b) [35]. 
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Figure 6: GRK- arresting Signaling of GPCR; Panel a: classical β-arrestin initiated internalization of 
GPCR, Panel b: β-arrestin-mediated signaling; depicted and modified from Rajagopal et al. [34] 
Depending on the subtype of G proteins, different signaling cascades are elicited. 
Activation of Gα proteins (Gα12/13, Gαs, Gαi/o or Gαq/11) regulates calcium, 
potassium channels, adenylyl cyclase, phospholipase C, phospholipase D and 
protein kinases. Additionally, the Gβγ dimer activates effectors like K+ channels, 
phospholipase C-β, phospholipase A2 and PI3K (Figure 7) [31, 36, 37]. 
 
Figure 7: Representative Scheme of Signaling Cascades downstream of G protein subtypes 
[https://www.mblintl.com/research/gpcr.aspx, 13.11.2015 11:58 a.m] 
In 2000 Filardo et al. discovered that GPR30 expression is necessary for estrogen-
mediated stimulation of ERK1/2 [38] and subsequently in 2002 reported its role in 
cAMP generation [39]. Estrogen binding to GPR30 was demonstrated in 2005 by 
Revankar et al. and Thomas et.al [40, 41], and estrogen was identified as the 
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endogenous ligand, leading to the change of nomenclature from GPR30 to G-protein 
coupled Estrogen Receptor (GPER) in 2007 [42]. GPER is suggested to belong to 
the class A rhodopsin like-GPCRs, which occlude their ligand binding pocket sites 
with the extracellular region, presuming that hydrophobic ligands like estrogens, are 
able to bind [43, 44]. The GPER-selective ligand/ agonist G1 was identified in 2006 
[45] and the GPER selective antagonist G15 discovered in 2009 [46], thereby 
facilitating to study the impact of GPER in mediating non-nuclear estrogenic effects. 
Recently, the number of studies addressing the possible cellular and physiological 
functions of GPER has increased exponentially.  
The gene for GPER is located on chromosome 7, and the protein consists of 375 
amino acids [47]. While the structure of GPER is still unknown, research suggests 
that GPER is linked to the G protein subtypes Gαs [41], inducing adenylyl cyclase 
activation and cAMP generation [39], and Gαi/o [42], which opposes Gαs as it inhibits 
adenylyl cyclase activation [48]. The cellular location of GPER remains unclear, while 
some studies state that GPER is a membrane receptor [41, 49], others suggest 
intracellular localization, mainly within the Endoplasmic Reticulum [40, 50, 51]. 
The expression and functions of GPER have been described in the reproductive, 
endocrine, urinary, nervous, immune, musculoskeletal and cardiovascular systems. 
Therefore, in combination with the estrogenic actions mediated by the classical ERs, 
GPER mediated actions add to the complexity of estrogen triggered signaling 
mechanisms and their biological and pathophysiological relevance.  
Because more than 50% of drugs worldwide are designed to target GPCRs and treat 
cardiovascular, metabolic, neurodegenerative, psychiatric, and oncologic diseases 
[52], it is important to fully elucidate the role of GPER, which is proposed to be 
clinically relevant in cardiovascular diseases. Since coronary artery disease is a 
leading cause of mortality in women, and timely estrogen therapy is protective, GPER 
might be an important target for developing new drugs against CVDs. 
 Estrogen`s Genomic and Non-Genomic Actions 1.3
As depicted in Figure 8, the genomic and non-genomic actions of estrogens are 
elicited via ER receptors. 
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 Genomic Actions 1.3.1
ERs are associated with chaperones to stabilize ER structure and mask C, the DNA 
binding domain. Classically, E2 is permeable and diffuses into the cell, binding to 
intracellular ERs and thereby triggers the disassociation from the chaperones and the 
homo- or heterodimerization of ERα and ERβ. This E2-ER complex translocates into 
nucleus and binds to a specific palindromic, cis-acting DNA sequence called 
Estrogen Responsive Element (ERE), which is positioned within the regulatory 
regions of target genes. Subsequently, the target-gene expression is either induced 
or repressed and regulated by coactivators or corepressors of ERs (Figure 8 A) [53]. 
There are also studies reporting that the E2-ER complex induces the expression of 
genes missing the ERE sequence. ERs interact with transcription factors Jun, Fos 
and Sp1 and thereby activate the respective regulatory elements [54]. Expression of 
Epidermal Growth Factor (EGF), EGF receptor and cyclin D1 is also upregulated by 
E2, although the promoter regions of their genes do not include ERE sequences 
(Figure 8 B) [55]. 
ERs can also be activated in a ligand-independent fashion. Cross-talk with 
extracellular growth factors like IGF-1 and EGF also stimulate the expression of ER 
target genes. Kato et al. suggested that phosphorylation of ERs contributes to this 
ligand-independent activation (Figure 8 C) [56]. 
 Non-Genomic Actions 1.3.2
Estrogen`s non-genomic effects are rapid actions, which do not involve direct ER-
mediated gene transcription. Estrogen-induced effects have been reported to occur 
within seconds to minutes, in contrast to the transcriptional mechanisms, which take 
hours to days, following stimulation. These rapid non-genomic effects have been 
reported to be initiated at the membrane level and potentially involve ERα [57] and 
GPER [41, 49], which have been identified within the plasma membrane of cells. 
Rapid effects of estradiol include regulation of mitogen-activated kinases ERK1 and 
ERK2 [58]; stimulation of eNOS and NO synthesis [59]; activation of cAMP formation, 
PKA and PKC; and increase in intracellular Ca2+ [60]. Those rapid effects also 
mediate different cellular functions and might eventually also lead to gene expression 
(Figure 8 D). 
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Figure 8: Genomic and Non-Genomic Actions of Estrogen Signaling. Panel A: Classical Genomic 
Action of Estrogen Signaling. Panel B: ERE-independent Genomic Action of Estrogen Signaling. 
Panel C: Ligand-independent Genomic Action of Estrogen Signaling. Panel D: Non Genomic Action of 
Estrogen Signaling. Depicted and modified from Kampas et al. [61]. 
 Cardiovascular Diseases 1.4
 Atherosclerosis and Cardiovascular Diseases 1.4.1
CVDs are the major cause of death worldwide [62]. The onset for the progress of 
CVDs is atherosclerosis, which has been correlated with the disruption of an 
anatomically and functionally intact endothelium [63] and abnormal differentiation and 
growth of Vascular SMCs (VSMCs) [64]. The steps leading to atherosclerosis are 
depicted and described in Figure 9. Briefly, damaged Endothelial Cells (ECs) secrete 
cytokines and express adhesion molecules, thereby attracting and binding 
monocytes. These monocytes translocate into the subendothelium and differentiate 
into macrophages, which digest Low Density Lipidproteins (LDL), resulting in their 
transformation to foam cells. Platelets are also present at the lesion site and secrete 
growth factors such as Platelet Derived Growth Factor (PDGF) and Transforming 
Growth Factor β (TGFβ). These factors stimulate the intimal Smooth Muscle Cells 
(SMCs) to migrate into the lesion site, proliferate and produce connective tissue 
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matrix. Moreover, SMCs can take up LDL and differentiate into foam cells, 
subsequently all these processes lead to neointima formation and thickening of the 
vessel wall. The resulting plaques are unstable and can rupture. Importantly, the 
thrombus formed can obstruct vessels, leading to ischemic stroke or myocardial 
infarction and eventually to death [65]. 
 
Figure 9: Schematic Representation of Steps, leading to the Onset and Progression of 
Atherosclerosis and subsequently to CVDs [65]. 
 Role of Vascular Cells in CVDs 1.4.2
Endothelial Cells 
As described above, endothelial damage or dysfunction initiates the onset of 
atherosclerosis, therefore accelerated recovery or substitution of damaged ECs may 
improve endothelial function and be essential to prevent the progression of 
atherosclerosis [63]. The hallmarks of endothelial function are viability, proliferation, 
and migration and the ability to form new vessels via vasculogenesis and/ or 
angiogenesis, to supply the tissue with oxygen and nutrients [66]. Angiogenesis is a 
process in which new vessels are generated from the existing ones and takes place 
during embryogenesis and in the adults. The term vasculogenesis describes the 
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assembly of angioblasts, which differentiate into endothelial cells and build vessels 
de novo [67-71]. This process was considered to only occur during embryogenesis, 
but in 1997 Asahara et al. discovered that Endothelial Colony Forming Cells 
(ECFCs), circulating in peripheral blood, participated in vasculogenic processes [72]. 
The common cell model for vasculogenesis assays and hence to assess endothelial 
function are Human Umbilical Vein Endothelial Cells (HUVECs) [73]. 
Smooth Muscle Cells 
Another key role in the progress of atherosclerosis is the abnormal proliferation, 
migration and differentiation of SMCs, leading to neointimal thickening [64] and 
plaque formation. These processes are stimulated by cytokines and growth factors, 
released by damaged ECs [65]. A healthy endothelium has an inhibitory effect on 
SMC growth, hence enhanced recovery of endothelial function can inhibit SMC 
proliferation and migration and this may prevent the progression of atherosclerosis 
and CVDs. The controlled and balanced crosstalk between ECs and SMCs is 
essential for the maintenance of a functional blood vessel [74]. 
 Estrogen`s Effects on the Cardiovascular System 1.5
The risk factors, promoting atherosclerosis and subsequently CVDs, are age, 
hypertension, diabetes, cholesterol, obesity, lifestyle and male gender [75]. As 
depicted in Figure 10, epidemiological studies have demonstrated that gender 
difference plays a role in the prevalence of CVDs. Moreover, elderly, 
postmenopausal women show a higher incidence of CVDs compared to younger, 
premenopausal women. These findings suggest that declining levels of endogenous 
estrogens upon onset of menopause (around the age of 55) are associated with 
increased risk of obtaining CVDs [76]. This notion is supported by the findings of 
Seroz et al., who showed an increased risk of CVDs in premenopausal women, 
undergoing surgically-induced menopause [77]. The protective effects of endogenous 
estrogens and Hormone Replacement Therapy (HRT) against the progression of 
CVDs are also supported by multiple epidemiological studies and small clinical trials 
[78-80]. However, no beneficial effects of estrogens on CVDs were obtained within 
the Women`s Health Initiative (WHI) trial and the Heart and Estrogen/ Progestin 
Replacement study (HERS) [79, 81, 82]. Although the reasons for the discordant 
findings are unclear, re-evaluation of the data from these studies demonstrated that 
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estrogen replacement therapy is indeed effective and protective in younger healthy 
women, in contrast to older study participants with established cardiovascular 
pathology [81, 82]. Studies in primates confirm this observation, reporting that 
estrogen replacement, started at the time of ovariectomy, reduced lesion formation 
by 70%, but showed no effects when the treatment was delayed by two years [83]. 
Taken together, these findings suggest that timing of HRT initiation after menopause 
is critical for estrogen-induced vasoprotection. 
 
Figure 10: Incidence of CVDs by Age and Sex (Framingham Heart Study, 1980–2003) [84] 
 Estrogen`s Effects on Vascular Cells 1.5.1
Several in vivo studies support beneficial effects of HRT and demonstrate that E2 
prevents pathological vascular remodeling processes like neointimal thickening, 
cholesterol induced atherosclerosis, balloon injury-induced neointima formation, and 
allograft-induced dysplasia [85-92]. Estrogen signaling elicits various pleiotropic 
effects, which affect the cardiovascular system by directly modulating vascular cell 
function or indirectly by inducing systemic effects [93].  
Direct estrogenic effects on vascular cells include the stimulation of proliferation and 
migration of ECs in vitro [94] and promotion/ regeneration of ECs after arterial injury 
[95, 96]. Moreover, E2 might contribute to the repair of the endothelium via 
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mobilization of Endothelial Colony Forming Cells (ECFCs), inflammatory immune 
cells and platelets [97, 98]. Additionally E2 stimulates angiogenesis, both in vitro and 
in vivo [99-101] by inducing the most important pro-angiogenic factors: Fibroblast 
Growth Factor (FGF), Vascular Endothelial Growth Factor (VEGF) and Nitric Oxide 
(NO) [99].  
These beneficial estrogenic actions on the endothelium might play the key role in 
inducing cardiovascular protection [102], however a controlled and balanced 
coordination between ECs and SMCs is also essential [74]. Acceleration of the 
endothelial integrity by estrogen can additionally contribute to its vasoprotective 
effects by inhibiting SMC proliferation. These anti-mitogenic effects of estrogens on 
SMCs are elicited via upregulation of second messengers like NO, cGMP [103], 
cAMP [104] and reducing the levels CA2+ [105]. Another protective effect of estrogen 
is that it blocks migration of SMCs [105, 106], which contributes to myointimal 
hyperplasia following injury [87, 88]. 
Additionally, estrogen treatment induces endothelial NO and prostaglandin synthesis, 
which is also responsible for the vasodilatatory and growth inhibitory effects of E2. 
Furthermore, E2 inhibits the production of vasoconstrictors angiotensin II, endothelin-
1 and catecholamine and thereby stimulates the vasodilation of vessels even more 
[78]. 
 GPER and the Cardiovascular System 1.6
An explanation for the controversial outcomes of the different trials on estrogen`s 
protective effects on CVDs may in part be the complexity of vascular estrogen 
signaling, which involves at least three different estrogen receptors: ERα, ERβ and 
GPER. Indeed all three receptors are expressed in the cells of the vascular system in 
both humans and animals of both sexes [25, 107-114]. Taken together, these 
findings suggest that in addition to ERα and ERβ, GPER may also play an important 
physiological role in regulating vascular and myocardial function.  
GPER is a transmembrane G-protein coupled receptor that mediates non-genomic, 
rapid estrogen signaling [38, 40, 41]. The first potential relevance of GPER in 
cardiovascular function was suggested by Takada et al, who cloned cDNA of GPER 
from RNA of human ECs, which were exposed to fluid shear stress [25]. The 
identification of the GPER-selective ligand/ agonist G1 in 2006 [45], the GPER 
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selective antagonist G15 in 2009 [46], and the generation of genetically modified 
animals has facilitated research to define the functional role of GPER within the 
cardiovascular system [115]. Vasodilatory properties of GPER were suggested in 
studies with mammary and porcine coronary arteries, rat aorta and mesenteric 
arteries and rat and murine carotid arteries, where G1 induced acute dilation [108, 
113, 114, 116, 117]. This G1-dependent effect on vasodilation was even more 
prominent than that of E2, indicating a complex crosstalk between GPER, ERα and 
ERβ [113]. The importance of GPER in controlling the vasomotor tone was 
underlined when the acute G1-induced vasodilation was lost in GPER knockout mice 
[113] or upon G15 pre-treatment [116, 118]. Moreover, the GPER-deficient mice were 
reported to develop hypertension [119]; and intravenous injection of G1 reduced 
mean arterial blood pressure [113] and lowered blood pressure in normotensive [114] 
and hypertensive rats [108]. Importantly, G1 treatment reduced the expression of 
angiotensin II type I receptor and angiotensin-converting enzyme in mRen2.Lewis 
rats, suggesting that G1 reduces high blood pressure in part by inhibiting vascular 
angiotensin II signaling [114]. Finally, emphasizing the importance of GPER for 
vascular tone, recently a hypofunctional genetic variant of GPER has been found to 
be associated with elevated blood pressure in women [120]. 
In summary, these studies provide evidence for an important role of GPER in 
regulating the vascular tone in response to estrogen, but the molecular mechanisms 
involved remain unclear and need to be further investigated. 
Recent findings suggest that GPER-mediated vasodilation is in part endothelium-
dependent and involves endothelium-derived NO, as the NOS inhibitor L-NAME 
could inhibit G1-induced relaxation in rat aorta, carotid, mesenteric and porcine 
coronary arteries [108, 116, 117]. Furthermore, GPER activation regulates potassium 
efflux, possibly via ERK and PI3K/ Akt signaling, and therefore induces endothelium-
independent vasodilation [121]. The vascular tone might also be reduced by GPER`s 
ability to scavenge Reactive Oxygen Species (ROS), because G1 inhibits ROS 
production [108]. An increase in ROS was shown to damage endothelial function, by 
attenuating NO bioavailability. Moreover, via ROS, angiotensin II type I receptor 
signals induces vasoconstriction [122]. In the presence of impaired endothelial 
function, due to hypertension or atherosclerosis, an additional beneficial mechanism 
of GPER might be the regulation of vascular tone by inhibiting ROS.  
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Taken together, estrogen induced vasodilation is mediated by ERα, ERβ and GPER, 
and largely involves endothelium/ NO-dependent vasodilation. In addition to its 
vasodilatory effects, GPER also regulates VSMC proliferation and apoptosis [110, 
113]. The fact that E2 inhibits the proliferation of VSMCs in ERα/ ERβ double 
knockout mice [123] suggests that the anti-mitogenic effects may have been GPER 
mediated and implies a protective role of GPER for atherosclerosis. This possible 
atheroprotective effect of GPER is underlined by a study with GPER-deficient mice, 
which exhibited increased adipogenesis, inflammatory activation and circulating lipid 
levels [124]. 
Cultured cardiomyocytes [125], murine [119] and human [126] myocardium express 
GPER. Contraction in murine cardiomyocytes as well as inhibition of calcium flux is 
mediated by E2, but independent of ERα and ERβ [127]. More recently, left-
ventricular dysfunction was observed in male, but not female GPER-deficient mice 
[128]. Furthermore, G1 treatment improved diastolic dysfunction, cardiac hypertrophy 
and decreased myocyte size [129]. Additionally, increased expression of GPER was 
mediated by Hypoxia-Inducible Factor HIF-1α in a murine cardiomyocyte-like cell 
line, suggesting an involvement of estrogen signaling via GPER in ischemic heart 
disease [125].  
Several groups, using cardiac ischemia/ reperfusion injury models, described 
additional cardioprotective effects, which were GPER-dependent. Treatment with G1 
attenuated infarct size and post-ischemic contractile dysfunction in rat hearts [109, 
111, 126, 130], independent of sex, but most likely mediated via the PI3K/ Akt 
signaling pathway [109]. Likewise, reduction of infarct size and amelioration of heart 
function in male mice was reported upon G1 treatment, which could be inhibited by 
ERK signaling blockers [107]. Furthermore, GPER mediated ERK activation was 
responsible for vasodilatory effects and induced eNOS phosphorylation [111], leading 
to an increase in NO bioavailability. Importantly, decreased levels of proinflammatory 
cytokines, including Tumor Necrosis Factor (TNF-α), Interleukin (IL)-1β and IL-6, 
have been correlated to improved heart function, upon G1 treatment [130]. 
In summary, activating GPER ameliorates functional recovery and infarct size after 
myocardial ischemia, which is in line with GPER`s dilatory effects. However, more 
research is needed to fully understand the molecular mechanism by which GPER 
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mediates its protective actions. In addition to the protective effects on the heart, 
GPER might be also beneficial after ischemic stroke [131] and liver injury [132]. 
Recent studies reported that several beneficial effects of estrogens on vascular and 
myocardial function are mediated by GPER. Estrogen signaling and cardiovascular 
response following estrogen treatment have become increasingly complex, due to the 
identification of three different estrogen receptors - ERα, ERβ and GPER. These 
three receptors with nuclear and extranuclear localization functionally interact with 
each other and activate many genomic and non-genomic signaling pathways [133]. 
Importantly, Selective Estrogen Receptor Modulators (SERMs) like tamoxifen and 
raloxifene, and Selective Estrogen Receptor Downregulators (SERDs) like ICI 
182,780 have been identified as GPER agonists [38, 40, 41, 134], resulting in the 
adjustment or reassessment of studies, in which these SERMs and SERDs were 
used as agonists/ antagonists and considered to solely target ERα and ERβ. The 
understanding of GPER`s role in the cardiovascular system comes from studies, 
which have used GPER selective ligand/ agonist G1. Identification of G15 [46] and 
generating GPER knockout mice [135] have facilitated in-depth studies to assess the 
individual roles of those three estrogen receptors ERα, ERβ and GPER within the 
cardiovascular system [133].  
This complexity of estrogen signaling, because of the involvement of three receptors, 
might explain in part the controversial outcomes of clinical trials, in which conjugated 
equine estrogens and medroxyprogesterone acetate were used as postmenopausal 
hormone therapy. These trials reported no beneficial effects of hormone therapy on 
the cardiovasculature; in fact increased incidence to develop breast cancer and 
venous thromboembolic events was detected and correlated to hormone therapy 
[136, 137]. Hence, it is essential to pharmacologically separate estrogen`s beneficial 
vascular signaling pathways from estrogen`s harmful effects. This might be achieved 
by using selectively targeting ER specific agonists, which do not elicit the negative 
side effect of estrogens. GPER agonist raloxifene has recently been shown to 
minimize the risk of cardiovascular events and breast cancer in younger menopausal 
women, whereas lasofoxifene had even greater effects [138-141]. However, it is not 
yet understood if this risk reduction is only due to GPER activation and therefore 
much more research is needed. Nevertheless, in aging animals, while levels of ERα 
and ERβ decline, GPER expression is prevalent and mediates estrogen signaling, 
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suggesting an important role of GPER in postmenopausal women [92]. Further, G1 
mimics the beneficial vascular effects of estrogen, without exhibiting the feminizing 
effects of estrogens and might be an interesting candidate for a new treatment 
strategy of CVDs in both genders. In summary, all these studies indicate that GPER 
is responsible for a variety of protective cardiovascular effects and may represent a 
very interesting target for developing effective treatments for CVDs. 
 The Molecular Mechanisms regulating Vascular Cell Function 1.7
 The TGFβ/ BMP Signaling and its Role on Vascular Cell Function 1.7.1
The superfamily of Transforming Growth Factor β (TGFβ) includes TGFβ1,-2,-3, the 
Bone Morphogenetic Protein (BMP) subfamily, Growth Differentiation Factors (GDF), 
activins, inhibins and myostatins. These family members and their downstream 
pathway components are highly conserved and regulate multiple diverse cellular 
functions such as growth, adhesion, migration, apoptosis and differentiation [142]. 
The TGFβs and BMPs have been intensively studied in human vascular diseases 
and play an important role in regulating vascular homeostasis [143].  
TGFβ signaling is mediated via two types of receptors: TGFβ type I and type II 
transmembrane receptors, both characterized by serine/ threonine kinase activity. In 
mammals there are five type II receptors and seven type I receptors, which are also 
termed as activin receptor-like kinases (ALKs). All members of the TGFβ family have 
to be cleaved by proteases and secreted to become active ligands [144]. Upon 
binding of the ligand to type II receptors, a heteromeric complex is formed with type I 
receptors, which is phosphorylated at specific serine and threonine residues in the 
intracellular juxtamembrane region. This activation leads to the recruitment and 
phosphorylation of receptor-regulated SMADs (R-SMADs) at two serine residues at 
their carboxyl termini [145-147]. In most cells, TGFβ signals via TGFβ type II receptor 
(TβRII) and ALK5. In ECs TGFβ also signals via ALK1, while BMPs elicit their 
signaling via BMP type II receptor (BMPRII), Activin type II receptors (ActRIIs) and 
ALK1, 2, 3 and 6 [148, 149]. Furthermore, BMP9 and BMP10 have recently been 
identified as ligands for ALK1 [150]. ALK4/ 5 phosphorylate R-SMAD2/3, while ALK1/ 
2/ 3/ 6 phosphorylate R-SMAD1/5/8. These activated R-SMADs form complexes with 
SMAD4 and translocate into the nucleus, where, with the help of other transcription 
factors, they trigger the transcription of their target genes (as depicted in Figure 11) 
[145-147]. ALK5/ SMAD2/3 signaling induces the expression of fibronectin and 
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Plasminogen Activator Inhibitor type 1 (PAI-1), which inhibits EC migration and 
proliferation and thereby prevents capillary-tube formation [149, 151, 152]. ALK1/ 
SMAD1/5/8 upregulates the expression of Inhibitor of Differentiation 1 (ID-1), leading 
to increased migration, proliferation and tube formation of ECs [149, 153]. ALK1- and 
ALK5- pathways elicit opposite responses, but interact with each other to 
counterbalance and achieve maximal activation [149]. Indeed, as stated by Goumans 
et al., ALK1 and ALK5 “provide ECs with a TGFβ-dependent switch to fine tune EC 
function” [154]. 
The activity of R-SMADs is regulated by inhibitory SMAD6/7 (I-SMAD), which 
compete with R-SMADs for type I interaction and induce proteosomal degradation or 
dephosphorylation of R-SMADs, hence inhibiting their signaling (as depicted in 
Figure 11) [155, 156]. 
Regulation of the access of TGFβ superfamily ligands to the signaling type I and type 
II receptors is maintained by soluble ligand binding receptor proteins and by 
accessory type III receptors. Examples for the soluble ligand-sequestering molecules, 
preventing TGF superfamily ligand binding, are Chordin/Short gastrulation (SOG), 
Noggin, Twisted gastrulation (Tsg), Crossveinless-2 (Cv-2), Sclerostin and Follistatin 
[157]. The most intensively studied accessory type III receptors are endoglin and 
betaglycan [144, 158], which facilitate the binding of TGFβ and BMPs to their 
receptors and potentiate their actions [150, 158-160].  
Interestingly, independent of SMAD-mediated transcription, the members of the 
TGFβ superfamily can also activate other cascades that either regulate activation of 
SMADs or trigger responses, which are unrelated to SMAD-linked signaling. TGFβ 
can also regulate pathways such as Erk, p38, MAPK, JNK, PI3K/ Akt and small 
GTPases (rhoA and Cdc42) [161, 162]. 
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Figure 11: The activation of TGFβ signaling and its downstream effectors [154]. TGFβ: Transforming 
growth factor β, BMP: Bone morphogenetic protein, TβRII: TGFβ type II receptor, ALK: Activin 
receptor-like kinases, BMPRII: BMP type II receptor, ActRIIA/ B: Activin type II receptors, I-Smad: 
Inhibitory Smad, TF: Transcription Factor 
The relationship between endothelium and SMCs plays a key role in vascular 
homeostasis. Recently, it has been shown that the TGFβ superfamily not only 
mediates effects on the endothelium, but also on VSMCs. 
Tight control and balanced coordination between ECs and SMCs are required for the 
mature vascular network [74], and TGFβ plays a key role in mediating this EC-SMC 
interaction [163]. While ECs mainly express ALK1, SMCs show higher expression of 
ALK5 [164], still both receptors have to interact, to fully elicit TGFβ and BMP 
signaling in the individual vascular cells [151, 165].The essential role of TGFβ within 
the VSMC-EC interaction was discovered due to mutations of several components in 
TGFβ-signaling.  
Aberrant development of SMCs and defect in primary capillary plexus of the yolk sac 
was observed in endoglin- and ALK1- deficient mice [144, 148, 166, 167]. Mutations 
in the genes encoding TβRII, SMAD1/5 or TGFβ1 lead to defects of the vasculature 
structure or blood vessel organization in mice, indicating deficiency in lining of EC 
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and SMC development [166]. In summary, TGFβ and BMPs are important regulators 
of the differentiation and proliferation of SMCs by inducing Matrix-Gla protein (MGP), 
α -smooth muscle actin (α-SMA) and calponin via ALK1 and ALK5 [165, 168-171]. 
The role of ALK1/ SMAD1/5/8 pathway within ECs and their function has been 
intensively studied with contraindicative outcomes. Mostly, it has been shown that 
upregulated expression of ALK1 and ID-1 correlates with increased proliferation, 
migration and tube formation of ECs [149, 153, 172, 173], while Mitchell et al. and 
Lamouille et al. demonstrated that ALK1 acts anti-angiogenic by inhibiting 
proliferation, migration and re-adhesion of ECs [174, 175]. These opposing results 
can be explained by the use of different cell types and contexts, but still demonstrate 
the involvement and essential role of ALK1 in maintaining EC function and 
angiogenesis.  
Furthermore, in vivo studies indicated an important role of ALK1/ SMAD1/5/8 
signaling in embryonic angiogenesis, since mutations in SMAD genes lead to severe 
defects in embryogenesis and early lethality. SMAD1 and SMAD5 knockout mice 
died due to allantois defects and lack of placenta formation and SMAD4 mutant mice 
suffered from lethal cardiovascular defects [176-178].  
The importance for intact ALK1/ SMAD1/5/8 signaling is further underlined by the 
clinical relevance in Hereditary Hemorrhagic Telangiectasia (HHT). HHT is 
characterized by a loss-of function mutation in ALK1, leading to leaky vessels with 
impaired endothelial integrity. HHT patients suffer from mucocutaneous 
telangiectasis, arteriovenous malformations in the brain, lung, liver and 
gastrointestinal tract, which lead to nose bleeding and gastrointestinal bleeding [154, 
179].  
In summary, the diversity of ligands, receptors and their various possible 
combinations reflects the complexity of TGFβ signaling. Furthermore, this signaling 
and the resulting effects are also context- and cell-type specific, which emphasizes 
the need of more in-depth studies to elucidate the full spectrum of TGFβ signaling. 
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 The PI3K/ Akt/ NO/ VEGF Pathway and its Role on Vascular Cell Function 1.7.2
The PI3K/ Akt/ NO/ VEGF pathway plays a central role in controlling cell viability by 
regulating multiple cellular functions such as metabolism, growth, proliferation, 
survival, transcription, protein synthesis and angiogenesis [180, 181]. This pathway is 
tightly regulated, but upon dysregulation implicated in several human diseases like 
diabetes, cancer and CVDs. Therefore, detailed research is necessary for 
understanding its signaling and may provide new avenues for therapeutic 
approaches [182]. 
The phosphatidylinositol-3 kinases (PI3Ks) are highly conserved intracellular lipid 
kinases, which upon activation phosphorylate phosphatidylinositol and 
phosphoinositides at their 3`OH group (PIP2PIP3) [180]. PI3Ks can be grouped 
into three classes, Class I, II and III, whereby Class I PI3K is prevalent in mammals 
and stimulated by growth factor Receptor Tyrosine Kinases (RTKs) or GPCRs [183]. 
Activation of PI3K by growth factors, such as VEGF [184, 185], result in accumulation 
of signaling proteins with pleckstrin-homology at these activation sites by directly 
binding to PIP3. These signaling proteins include serine-threonine kinase Akt, also 
called Protein Kinase B (PKB), and Phosphoinositide-Dependent Kinase 1 (PDK1). 
The close proximity facilitates PDK1 to phosphorylate and activate Akt [186], leading 
to phosphorylation of other signaling proteins as well as regulation of glucose 
homeostasis, cell migration, growth and proliferation [180, 182]. An important 
signaling protein downstream of PI3K/ Akt is eNOS, which generates NO upon 
phosphorylation [184, 187]. NO is both, a downstream and an upstream mediator of 
VEGF-mediated signaling. Under normoxic conditions, NO has been shown to induce 
VEGF expression [188], hence NO and VEGF stimulate each other in a reciprocal 
fashion (as depicted in Figure 12). The PI3K signaling is terminated by two different 
types of phosphatases, Scr-homology 2-containing phosphatase (SHP1 or SHP2) 
and phosphatase PTEN, which degrade PIP3 to PIP2 and therefore block Akt 
activation and further signaling [182]. 
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Figure 12: The PI3K/ Akt/ NO/ VEGF pathway. VEGF: Vascular Endothelial Growth Factor, IGF-1: 
Insulin-like Growth Factor-1, RTK: Receptor Tyrosin Kinase, GPCR: G-protein Coupled Receptor, 
PI3K: Phosphatidiylinositol-3 Kinase, PIP2: Phophatidylinositol-3,4,5-bisphosphate, PIP3: 
Phophatidylinositol-3,4,5-trisphosphate, Akt: Protein Serine-Threonine Kinase, eNOS: endothelial 
Nitric Oxide Synthase, NO: Nitric Oxide 
Vascular homeostasis is maintained by a balanced interaction between endothelial 
and smooth muscle cells. The PI3K/ Akt/ NO/ VEGF pathway has been shown to 
mediate effects on the endothelium as well as on VSMCs. Tight control and balanced 
coordination between ECs and SMCs is required for the mature vascular network [74] 
and several studies reported an important regulatory role of PI3K/ Akt/ NO/ VEGF in 
postnatal blood vessel formation and processes related to angiogenesis [181, 189-
192].  
The PI3K/ Akt signaling pathway controls EC viability [180, 181]. Migration and 
formation of capillary-like structures are essential for EC driven angiogenesis in vivo. 
The protein Akt accumulates in endothelial tip cells with increased migratory abilities 
[193], resulting in angiogenesis of ECs [181, 189, 190]. Due to its mitogenic and 
angiogenic role, PI3K/ Akt is also involved in tumorigenesis and has been shown to 
be highly stimulated in estrogen induced proliferation of ER+ breast cancer cells 
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[194, 195] and endometrial cancer cells [196]. Indeed, specific inhibitors for PI3K/ Akt 
are already used clinically as anti-angiogenic agents against cancer [197, 198] and 
breast cancer [195]. Moreover, PI3K/ Akt has also been shown to control the 
proliferation of SMCs in vitro [199, 200]. Additional confirmation comes from in vivo 
studies, where Akt1 knockout mice showed reduced proliferation, migration and 
protection against oxidative stress-induced apoptosis of VSMCs [201, 202]. These 
findings support the essential regulatory role of PI3K/ Akt signaling in vascular cell 
responses to acute or repetitive injuries, leading to restenosis and atherosclerosis. 
Additionally, Akt has been shown to regulate the vasomotor tone in vivo by inducing 
NO production. Overexpression of constitutively active Akt increases resting diameter 
and blood flow in intact animals, while dominant negative Akt inhibits acetylcholine-
induced vasodilation [203, 204]. 
The fundamental regulatory role of VEGF [191] and NO [192] in angiogenesis has 
also been intensively studied and established. Several studies highlight the 
importance of VEGF in embryogenesis. Moreover, inactivation of one VEGF allele 
has been shown to result in defective vascularization and embryonic lethality [205, 
206]; whereas a Cre-loxP approach to inactivate two isoforms of VEGF in mice 
resulted in 50% lethality, while the other 50% exhibited impaired myocardial 
contractility, heart enlargement and onset of ischemic cardiomyopathy [207]. 
Furthermore, several tumors, including ER+ breast cancer [208-211], show elevated 
mRNA levels of VEGF, and monoclonal antibodies targeting VEGF are clinically used 
as anti-cancer agents in therapy [212].  
NO angiogenic properties are implicated in promoting survival [213, 214], proliferation 
[215, 216] and migration [217, 218] of ECs. Studies using eNOS knockout mice 
revealed impaired morphogenesis and decreased stabilization of angiogenic vessels 
[219]. Moreover, vasodilation is dependent on endothelium-derived NO, which 
induces relaxation of SMCs and regulates vascular tone in isolated coronary arteries 
and vessels. Thereby, NO also stimulates blood flow and decreases systemic blood 
pressure [220-222]. Additionally, NO inhibits Matrix Metallo Proteinases (MMPs) 
[223-225], proliferation and migration of SMCs in vitro; thus preventing neointima 
formation after vessel injury [103, 226, 227]. 
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In summary, all these studies provide evidence for the essential role of PI3K/ Akt/ 
NO/ VEGF pathway in actively controlling cellular functions. This signaling pathway is 
highly active in cancer and therefore a preferred target of several clinically applied 
anti-carcinogenic drugs. More importantly, PI3K/ Akt/ NO/ VEGF signaling has been 
shown to maintain vascular homeostasis and to have beneficial effects on the 
cardiovascular system. Definitively, more research is needed to fully elucidate the 
complexity of PI3K/ Akt/ NO/ VEGF signaling and its impact on vasculature. Taken 
together, this pathway seems to be a promising target and may provide new avenues 
for therapeutic approaches against CVDs. 
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2 General Hypothesis and Objectives 
The impact of estrogen(s) on the cardiovascular system has been intensively studied; 
however the mechanism(s) involved remain unclear and subject of intensive 
research. Protective effects of endogenous estrogens and estrogen replacement 
therapy against the progression of CVDs in postmenopausal women are supported 
by multiple epidemiological and animal studies and small clinical trials [78, 79]. This 
contention was not supported by the results of two large clinical trials i.e. the WHI trial 
and the HERS [79, 81, 82]. However, re-evaluation of their data demonstrated that, in 
contrast to older study participants with established cardiovascular pathology, 
estrogen replacement therapy was effective and protective in younger healthy 
women [81, 82]. More importantly, the timing of estrogen therapy initiation following 
menopause within five years of reaching menopause seems to play a decisive role in 
defining its protective actions on the vasculature. The beneficial actions of estrogen 
on the endothelium [102] and it`s anti-mitogenic actions on VSMCs proliferation [105, 
106, 228, 229] play an important role in cardiovascular protection. These differential 
effects of estrogens on ECs and SMCs are potentially mediated by three different 
estrogen receptors, ERα, ERβ and GPER, which are expressed in vascular cells 
[112, 113, 230, 231]. Studies with ERα/ ERβ double knockout mice reported 
decreased proliferation of VSMCs upon estrogen treatment [123]; moreover we 
observed that capillary stimulating effects of E2 were mimicked by BSA-tagged E2, 
which is not membrane permeable [100]. Based on these observations, we 
hypothesize that the vascular actions of E2 may be potentially mediated via the newly 
discovered membrane bound GPER. 
The first aim of this study was to investigate the impact of GPER on endothelial 
cell function. To accomplish this, we assessed vasculogenesis, sprouting, migration 
and proliferation of HUVECs in response to the GPER specific agonist G1, the GPER 
specific antagonist G15 and to GPER silencing with specific siRNA. 
We further investigated and identified molecular mechanisms for GPER-induced 
vasculogenesis. Findings that mutations in ALK1 and SMADs lead to severe defects 
in embryogenesis and early lethality [176-178], suggest that ALK1/ SMAD1/5/8 
signaling plays a key role in embryonic angiogenesis. Thus, the second aim was to 
investigate and dissect the role of GPER activation on ALK1/ SMAD1/5/8 
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signaling and whether ALK1/ SMAD1/5/8 signaling mediates GPER-induced 
capillary formation by HUVECs. 
A classical GPCR mechanism of action is the activation of the enzyme adenylyl 
cyclase and the production of cAMP [232], moreover treatment with estrogen has 
been shown to induce cAMP in cells [104, 233-236]. Additionally, membrane-
permeable cAMP analogues have been reported to induce angiogenesis [191, 237-
239]. Hence, the third aim was to assess whether GPER activation induces cAMP 
generation in HUVECs and whether cAMP signaling modulates GPER-
stimulated capillary formation and ALK1/ SMAD1/5/8 signaling in these cells. 
Several studies have reported an important regulatory role of PI3K/ Akt in postnatal 
blood vessel formation and processes related to angiogenesis [181, 189, 190]. 
Furthermore, estrogen-stimulated angiogenesis has been shown to be mediated via 
the PI3K/ Akt pathway [100, 240, 241]. Hence, the fourth aim was to assess whether 
GPER activation induces PI3K/ Akt signaling and whether this pathway 
regulates GPER-mediated capillary formation. Moreover, we investigated 
whether there is a crosstalk between these two pro-angiogenic pathways PI3K/ 
Akt and ALK1/ SMAD1/5/8 in HUVECs, following GPER activation. 
Since abnormal growth of smooth muscle cells contributes to neointima formation, 
our fifth aim was to investigate whether GPER activation alters proliferation and 
migration of HCASMCs; and whether the growth modulatory effects of GPER in 
HCASMCs are mediated via ALK1/ SMAD1/5/8 and/ or PI3K/ Akt signaling. 
Overall, the findings of the present study will help in understanding the 
mechanism by which GPER influences vascular cells and subsequently the 
cardiovascular system. In addition, these findings would help to develop 
improved hormone replacement therapy for menopause associated 
cardiovascular disease. 
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Figure 13: Schematic Depicting the Aims of the Study. Panel A: The impact of GPER on endothelial 
cell function and the possible molecular mechanisms leading to GPER-induced improvement of 
endothelial function. We used HUVECs as our cell model. Panel B: The impact of GPER on smooth 
muscle cell function and the possible molecular mechanisms mediating GPER`s effect on proliferation 
and migration of SMCs. We used HCASMCs as our cell model. 
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3 Materials and Methods 
3.1 Materials 
 Cell Culture 3.1.1
Antibioticum-Antimycotium Life Technologies, Carlsbad, CA, USA (15240-096) 
Cell culture flasks, dishes, plates TPP, Trasadingen, CH 
Collagen (rat tail)   Roche Diagnostics, Mannheim, DE (11179179001) 
Cryotubes    Nalge Nunc International, USA (377224) 
DMEM/F12     Sigma-Aldrich, St. Louis, USA (21331-020) 
EBM-2 Basal Medium  Lonza, Walkersville, USA (CC-3156) 
ECFC     Lonza, Walkersville, USA (00189423) 
EGM-2 SingleQuots   Lonza, Walkersville, USA (CC-4176) 
FCS Charcoal Stripped  Thermoscientific, Waltham, MA, USA (SH30068.03) 
FCS     Thermoscientific, Waltham, MA, USA (SH30070) 
HBSS (without Ca2+ and Mg2+) Bioconcept, Allschwill, CH (3-02K34-I) 
HCASMCs    Life Technologies, CA, USA (C-017-5C) 
HUVEC    Lonza, Walkersville, USA (CC-2517) 
L-Glutamine    Life Technologies, Carlsbad, CA, USA (25030-024) 
LSGS     Life Technologies, Carlsbad, Ca, USA (S003-10) 
PBS tablets    Gibco BRL, Paisley, UK (18912-014) 
Reaction tubes (1.5ml), tips Eppendorf, Hamburg, DE 
SMGS    Cascade Biologics, Inc, USA (S-007-25) 
Trypsin    Sigma-Aldrich, St. Louis, USA (T-3924) 
 Cell Counting 3.1.2
Coulter Isoton II diluent Kantonsapotheke, Zürich, CH 
Coulter Clenz cleaning agent Kantonsapotheke, Zürich, CH 
 Antibodies and Peptides 3.1.3
Primary Antibodies 
Anti- β-Actin     Sigma, St. Louis, USA (A5441) 
Anti-Akt    Cell Signaling Technology, MA, USA (9272) 
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Anti-ALK1    Santa Cruz, Dallas, Texas, USA (sc-28976) 
Anti-ALK5    GeneTex, Taiwan, R.O.C. (GTX102784) 
Anti-BMP2/4    Santa Cruz, Dallas, Texas, USA (sc-137087) 
Anti-enos    Cell Signaling Technology, MA, USA (9586) 
Anti-GPER    Santa Cruz, Dallas, Texas, USA (sc-48525-R) 
Anti-Id1    Abcam, Cambrige, UK (ab66495) 
Anti-MEK    Cell Signaling Technology, MA, USA (9122) 
Anti-PAI-1    Millipore, Temecula, USA (09-726) 
Anti-pAKT (Ser473)   Cell Signaling Technology, MA, USA (9271) 
Anti-penos (Ser113)  Cell Signaling Technology, MA, USA (9575) 
Anti-pMEK (Ser217/221)  Cell Signaling Technology, MA, USA (9121) 
Anti-pSMAD1/5/8 (Ser463/465) Millipore, Temecula, CA (AB3848) 
Anti-Smad1/5/8   Abcam, Cambrige, UK (ab13723) 
Anti-VEGF A    Santa Cruz, Dallas, Texas, USA (sc-152) 
Secondary Antibodies 
Goat anti-Mouse IGF-Peroxidase Conj.  Pierce, Rockford, USA (31430) 
Goat anti-Rabbit IGF-Peroxidase Conj. Pierce, Rockford, USA (31460) 
IRDye 680 Conj. Goat anti-Mouse IgG  LI-COR, Nebraska, USA (926-32220) 
IRDye 800 Conj. Goat anti-Rabbit IgG  LI-COR, Nebraska, USA (926-32211) 
Peptides 
Human VEGF antibody  R&D Systems, Minneapolis, USA (MAB293) 
PDGF     Sigma-Aldrich, St. Louis, USA (P-3201) 
R&D Systems, Minneapolis, USA (370-AL-100) 
Recombinant Human ALK1 Fc Chimera  
Recombinant Human BMP2 Sigma-Aldrich, St. Louis, USA (H4791) 
Recombinant Human BMP9 R&D Systems, Minneapolis, USA (3209-BP) 
Recombinant Human EGF Sigma-Aldrich, St. Louis, USA (E9644) 
Recombinant Human TGFβ R&D Systems, Minneapolis, USA (240-B) 
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 RT-PCR 3.1.4
Quick-RNA Mini Prep  Zymo Research, USA (R1055) 
GoTaq 2-Step RT-qPCR System Promega, Wisconsin, USA (A6010) 
DEPC-treated water Life technologies, CA, USA 
 Primers 3.1.5
18sRNA_For AAGAGAGCCGAGGCAATTACC 
18sRNA_Rev GCTCGCATTTTGAGGCTGTTG 
VEGFa_For CATGCAGATTATGCGGATCAAAC  
VEGFa_Rev GGTCTGCATTCACATTTGTTGTG  
 
Self designed Primer and purchased at Microsynth, Balgach, Switzerland 
 Chemicals and Buffers 3.1.6
10x Tris/Glycine Buffer  Bio-Rad, Reinach, CH (161-0771) 
10x Tris/Glycine/SDS Buffer Bio-Rad, Reinach, CH (161-0772) 
5x siRNA Buffer   Dharmacon, Lafayette, USA (B-002000-UB-100) 
Actinomycin D   Calbiochem, San Diego, USA (114666) 
Ammonium Persulfate (APS)  Sigma-Aldrich, St. Louis, USA (A6761) 
Aprotinin    Sigma-Aldrich, St. Louis, USA (A-1153) 
Batimastat    Sigma-Aldrich, St. Louis, USA (SML0041) 
BCA Protein Assay Kit   Pierce, USA (23227) 
BD Matrigel    BD Biosciences, Franklin Lakes, USA (356237) 
Bovine Serum Albumin (BSA)  Sigma-Aldrich, St. Louis, USA (A-3059) 
Cell Lysis Buffer   Cell Signaling, Danvers, USA (9803) 
Cycloheximide    Sigma-Aldrich, St.Louis, USA (PS1002)  
DAF-2-DA    Sigma-Aldrich, St.Louis, USA (D225) 
DDA     Sigma-Aldrich, St.Louis, USA (D1285) 
DBcAMP    Sigma-Aldrich, St.Louis, USA (D0627)  
Dimethyl Sulfoxide (DMSO)  Sigma-Aldrich, St.Louis, USA (41640) 
Ethanol 70%    Kantonsapotheke Zurich 
Ethanol 100%   Kantonsapotheke Zurich 
17-β-estradiol (E2)   Steraloids, Newport, USA (E950) 
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Fibrinogen Type I   Sigma-Aldirch, St.Louis, USA (F0895) 
Fluo-4, AM    Molecular Probes, Eugene, OR, USA (F14201) 
Flutamide    Sigma-Aldrich, St.Louis, USA (F9397) 
G1     Calbiochem, Darmstadt, Germany (371705) 
G15     Sigma-Aldrich, St. Louis, USA (G6548) 
Hyperfilm ECL    Amersham, Dübendorf, CH (RPN2103K) 
ICI 182-780    Tocris, Bristol, UK(1047) 
Loading Butter (5x)   Fermentas, Burlington, Canada (R0891) 
LY0294002    Calbiochem, Merck, Darmstadt, D (440202) 
L-NAME    Sigma-Aldrich, St.Louis, USA (N5751) 
L-NMMA    Sigma-Aldrich, St.Louis, USA (M7033) 
Methanol     Sigma-Aldrich, St.Louis, USA (32213) 
MPP     Tocris, Bristol, UK (1991) 
mm-IBMX    Calbiochem, San Diego, USA (454202) 
Noggin    R&D Systems, Minneapolis, MN, USA (6057-NG-
025) 
PDGF                                           Sigma-Aldrich, St.Louis, USA (P-3201) 
Pertussis Toxin   Sigma-Aldrich, St.Louis, USA (P7208) 
PKI (5-24)    Santa Cruz, Dallas, Texas, USA (CAS 99534-03-9) 
Ponceau S Solution (2%)   Sigma-Aldrich, St.Louis, USA (P-7767) 
Precision Plus Dual Color Standard  Biorad, Reinach CH (161-0374) 
SJN2511    Tocris, Ballwin, MO, USA (3211) 
Sodium Chloride (NaCl)   Sigma-Aldrich, St.Louis, USA (71381) 
Sodium Dodecyl Sulfate (SDS)  Sigma-Aldrich, St.Louis, USA (L-5750) 
Sodium Hydroxyde (NaOH)  Sigma-Aldrich, St.Louis, USA (S-8045) 
SuperSignal West Dura    Pierce, Rockford, USA (34075) 
SuperSignal West Pico   Pierce, Rockford, USA (34080) 
Temed     Sigma-Aldrich, St.Louis, USA (T-9281) 
Thrombin    Sigma-Aldrich, St.Louis, USA (T-4648) 
Triton X-100    Sigma-Aldrich, St.Louis, USA (X100) 
Tween 20     Sigma-Aldrich, St.Louis, USA (P-7949) 
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Cytodex beads 3   GE Healthcare, Uppsala, Sweden (17-0485-01) 
DharmaFECT 4   Fischer Scientific, Wohlen, CH (T-2004-03) 
0.5M Tris/HCl pH 6.8   Biorad, Reinach, CH (161-0799) 
1.5M Tris/HCl pH 8.8   Biorad, Reinach, CH (161-0799) 
Rotiphorese Gel 30   Carl Roth GmbH, Karlsruhe, D (3029.1) 
 siRNAs 3.1.7
On-TARGETplus non-targeting Pool, Thermo Scientific Dharmacon, Lafayette, USA 
(D-001810-10-20) 
(UGGUUUACAUGUCGACUAA, 
UGGUUUACAUGUUGUGUGA, 
UGGUUUACAUGUUUUCUGA, 
UGGUUUACAUGUUUUCCUA) 
On-TargetplusSMARTPool GPER1, Thermo Scientific Dharmacon, Lafayette, USA 
(L-005563-00-0005) 
(GGGUGAAGCGCCUCAGUUA, 
AACAGAAGCAGGCCUCGUC, 
CCAGUCGUGAGGUUUCCUA, 
UAGCGGUCGAAGCUCAUCC) 
 
  
On-TARGETplusSMARTpool Smad1, Thermo Scientific Dharmacon, Lafayette, USA 
(L-012723-00-0005) 
(GCUCUAUUGUCUACUAUGA, 
GGCGGUUGCUUAUGAGGAA, 
CAACAAUCGUGUGGGUGAA, 
CAAAUGGGUUCACCUCAUA) 
 
 ELISA 3.1.8
Direct cAMP ELISA kit Enzo Life Sciences, Lausen, Switzerland (ADI-900-066) 
 Instruments and Software 3.1.9
5417R Centrifuge Eppendorf, Hamburg, DE 
90SE Ultracentrifuge, Sorvall Thermo Fisher Scientific Inc, USA 
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Bio-Rad CFX Real-Time PCR Detection System BioRad 
Coulter Z1, Cell Counter     Coulter Electronics, Luton, UK 
H54AR Precision balance Mettler-Toledo, USA 
Hera Cell 150, Cell incubator Thermo electron corporation,  
Image Studio Lite     LI-COR, Nebraska, USA 
ImageJ       
LI-COR Odyssey 3.0 Infrared Imaging System  LI-COR, Nebraska, USA 
Magellan 6       Tecan, Salzburg, Austria 
Mini-PROTEAN 3 Electrophoresis Cell   Biorad, Reinach, CH 
Mini-Trans-Blot Electrophoretic Transfer Cell  Biorad, Reinach, CH 
NanoDrop system Tecan, Salzburg, Austria 
Odyssey 3.0      LI-COR, Nebraska, USA 
Olympus BX61 Microscope Olympus, Volketswil, CH 
Olympus CKX41 Microscope, Bright field Olympus, Volketswil, CH 
Olympus IX81 Microscope, Fluorescence Olympus, Volketswil, CH 
Power Pac 200, Power Supplier    Biorad, Reinach, CH 
Rotina 46R Centrifuge Hettich, Bäch, CH 
Sonicator Bandelin electronics, Berlin, D 
StatView, Version 5.0.1     SAS Institute, Cary, USA 
Tecan Infinite series M200    Tecan, Salzburg, Austria 
Xcellence pro     Olympus, Volketswil, CH 
 
 Methods 3.2
 Cell Culture 3.2.1
Human Umbilical Vein Endothelial Cells (HUVECs) were cultivated up to passage 9 
in 75 cm2 flasks with HUVECs complete growing medium (DMEMF12, supplemented 
with L-Glutamine, LSGS, Antibioticum- Antimycoticum (AA) and 10% FCS) under 
standard tissue culture conditions (5% CO2 at 37°). Medium was renewed every two 
days and upon confluency cells were washed with HBSS –Ca2+/ -Mg2+, trypsinized for 
two minutes at 37oC and neutralized in the double amount of the complete medium, 
finally centrifuged at 1200rpm for five minutes and re-plated at a split of 1:4 in flasks, 
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culture dishes or well-plates. For experiments, HUVECs were starved ON with 
HUVECs starving media (DMEMF12, supplemented with L-Glutamine, AA and 1% 
BSA) and also treated within this starving media. For vasculogenesis studies 
DMEMF12, supplemented with L-Glutamine, AA and 0.4% BSA was used. 
Endothelial Colony Forming Cells (ECFCs) were cultivated up to passage 8 in 
Collagen-coated 75 cm2 flasks with ECFC complete growing medium (EGM-2, 
supplemented with SingleQuots, AA and 10 % FCS) under standard tissue culture 
conditions (5% CO2 at 37°C). Medium was renewed every two days and upon 
confluency cells were washed with HBSS –Ca2+/ -Mg2+, trypsinized for two minutes at 
37oC and neutralized in the double amount of the complete medium, finally 
centrifuged at 1200rpm for five minutes and re-plated at a split of 1:4 in flasks, culture 
dishes or well-plates. For experiments, ECFCs were starved ON with ECFCs starving 
media (EGM-2, supplemented with AA and 1% BSA) and also treated within this 
starving media. For vasculogenesis studies EGM-2, supplemented with AA and 0.4% 
BSA was used. 
Human Coronary Artery Smooth Muscle Cells (HCASMCs) were cultivated up to 
passage 8 in 75 cm2 flasks in HCASMCs complete growing medium (M231, 
supplemented with SMGS and AA) under standard tissue culture conditions (5% CO2 
at 37°C). Medium was renewed every two days and upon confluency cells were 
washed with HBSS –Ca2+/-Mg2+, trypsinized for two minutes at 37oC and neutralized 
in the double amount of the complete medium and re-plated at a split of 1:4 in flasks, 
culture dishes or well-plates. For experiments, HCASMCs were starved ON in 
HCASMCs starving media (M231, supplemented with AA and 1% BSA) and also 
treated within this starving media.  
Cryopreservation of Cells 
Confluent cells were trypsinized and centrifuged as described above. The resulting 
cell pellet was resuspended in 4 ml ice-cold complete growing medium containing 
10% DMSO, serving as cryoprotective agent. Aliquots of 1 ml, in cryotubes, were 
gradually frozen to –80°C in a Mr. Frosty box (freezing container filled with 2-
propanol). For long-term storage the cells were kept in liquid nitrogen (-196°C).  
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Cell Defrosting 
HUVECs, ECFCs and HCASMCs in cryotubes were taken from the liquid nitrogen 
tank and rapidly thawed within a warm water bath. The cell suspension was slowly 
transferred into a 75 cm2 culture flasks, containing 10 ml of the respective complete 
growing medium and incubated under standard tissue culture conditions. The 
medium was renewed after 24 hours. 
 Vasculogenesis Studies 3.2.2
To assess EC- induced microvessel formation, vasculogenesis studies were 
performed with HUVECs and ECFCs. HUVECs and ECFCs were trypsinized and 
treated with various experimental agents, 30 minutes pre-treatment with antagonist or 
inhibitors, followed by 30 minutes with agonists or ligands. Medium, used for 
HUVECs and ECFCs, was DMF12, supplemented with L-Glutamine, AA and 0.4% 
BSA or EBM2, supplemented with AA and 0.4% BSA, respectively. 
Aliquots of 50 µl, containing 4000 cells, were transferred onto µ-slides, coated with 
Matrigel and incubated ON in 5% CO2 at 37°C. After ON incubation, microvessel 
formation was analyzed using an Olympus inverted microscope (CKX41, 10x 
magnification), with which photomicrographs were taken. Capillary length was 
randomly measured at three separate locations using the Xcellence pro-software 
(Olympus) and the average compared to the untreated control. DMSO at a final 
concentration of 0.1% was used as untreated (vehicle) control. 
 Sprout Formation Studies 3.2.3
To investigate whether our treatments induce sprout formation in HUVECs Cytodex3 
beads in fibrin gels were used. HUVEC-coated beads were resuspended in a 
fibrinogen/ aprotinin-solution (500 beads/ ml). Per well of a 24-well plate 0,625 U/ ml 
of Thrombin/ was added, followed by 0.5 ml of beads/ fibrinogen/ aprotinin-solution 
and gently mixing. For complete polymerization, the plate was incubated for five 
minutes at RT followed by 15 minutes at 37°C. For the treatment antagonists were 
applied 30 minutes prior to agonists in 500 µl of DMF12, supplemented with L-
Glutamine, AA and 0.4% BSA. After four days photomicrographs of the gels were 
taken using the Olympus inverted microscope (10x magnification) and sprouting 
number was measured using the Xcellence pro-software. 
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 Migration Studies 3.2.4
To investigate whether migration of HUVECs was induced with our treatments or 
migration of HCASMCs was inhibited, a scratch assay was performed. Therefore 
cells were grown until confluency in 24-well plates. After ON starvation with starving 
media, a scratch was performed using the blue pipette tip, followed by 2x washing 
with PBS to remove swimming cells. For the treatment antagonists were applied 30 
minutes prior to agonists, within this starving media. In HCASMCs the starving media 
for the experiment additionally contained 20 ng/ml of Platelet Derived Growth Factor 
(PDGF) to induce migration. 
Photomicrographs were taken using the Olympus inverted microscope at timepoint 0, 
when scratch was performed, and at timepoint 1, after 24 hours of incubation and 
wound area was measured using the Xcellence pro-software and values calculated 
accordingly: (area T1- area T0)/ area T0. 
 Cell Proliferation Studies 3.2.5
Effect of our treatments on cell proliferation of HUVECs or HCASMCs was assessed 
by counting the cell number. Plating was performed as follows: 20 000cells/ well for 
HUVECs and 80 000cells/ well for HCASMCs in a 12-well plate on day-2. On day -1 
the cells were starved using starving medium ON and on day 0 treatment was 
performed within the same media, antagonists were applied 30min prior to agonists. 
In HCASMCs the starving media for the experiment additionally contained 20 ng/ml 
of PDGF to induce proliferation. Treatment was renewed every two days and lasted 
four days in HUVECs and six days in HCASMCs. To stop the experiment cells were 
washed with HBSS –Ca2+ / -Mg2 and trypsinized with 200 µl for five minutes. This 
suspension was transferred into cuvettes and cell number assessed using the 
Coulter Counter. 
 Protein Expression Studies 3.2.6
Expression of GPER, ALK1, ID-1, ALK5, PAI-1, β-Actin, phosphorylation of 
SMAD1/5/8, AKT, eNOS and release of BMP2 and VEGF A were analyzed by 
Western Blotting. Briefly HUVECs, ECFCs and HCASMCs were grown till confluency 
in 28 cm2-dishes and were starved ON. Subsequently cells were treated for 30 min 
with antagonists or inhibitors, followed by 45 minutes agonists within starvation 
media, if not stated otherwise. For the actual experiment time in HCASMCs, the 
starvation media contained 20 ng/ml PDGF. Cells were washed with cold PBS and 
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lysed in 50 µl Lysis Buffer. Protein concentration was assessed using the BCA 
protein assay kit, 30 µg of protein was mixed with Laemmli Sample Buffer and DTT, 
incubated for five minutes at 95°C and resolved electrophoretically with 10% SDS-
gels. Separated proteins were transferred onto nitrocellulose membranes at 32 A 
during 60 minutes. To prevent unspecific binding, membranes were blocked using 
5% milk in PBS-Tween. Primary Antibody for protein of interest was added onto 
membrane in 1:1000 dilution in 5% BSA in PBS-Tween and incubated ON at 4°C, 
subsequently followed by incubation of secondary LICOR- or HRP-anchored 
antibody, with 1:10 000 and 1:25 000 dilution, respectively, in 1% milk in PBS-Tween, 
for 1 hour at RT. After washing for 30 minutes with PBS-T, the blots were analyzed 
with LI-COR system or were covered with SuperSignal West Dura LuminolSubstrate 
for five minutes and then exposed to Hyperfilm ECL films.  
Membrane Fractionation 
HUVECs were grown till confluency in 28 cm2-dishes and harvested using 50 µl Lysis 
Buffer. This cell suspension was centrifuged at 1000 g for 10 min at 4°C, resulting 
supernatant was transferred into new Eppi, diluted with 4 ml of Lysis Buffer and 
centrifuged 10’000 g for 1 hour at 4°C using the ultracentrifuge. This time the 
resulting supernatant was discarded, as it contained cytosolic fraction, and the 
remaining pellet, containing membrane fraction, resuspended in 50 µl Lysis Buffer 
and used for BCA and Western Blotting, as described in Protein Expression Studies. 
Protein Release Studies 
Release of BMP2 into the supernatant of HUVECs was assessed using Western 
Blotting. HUVECs were grown till confluency in 28 cm2-dishes and were starved ON. 
HUVECS were washed twice with PBS and treated with the antagonist for 30 min, 
followed by another 30 min with the agonist within the volume of 200 µl plain 
DMEMF12. Supernatant was collected and cells were lysed as described above. 24 
µl of supernatants and 30 µg of cell-lysate protein were separated electrophoretically 
in 12% SDS-gels. Further steps were performed according to protocol, already 
described in Protein Expression Studies.  
 NO Measurement 3.2.7
Generation of NO by HUVECs was measured, using DAF-2DA, as it`s cleavage and 
increased fluorescence is correlating with increased NO levels within the cells. 
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HUVECs were seeded in 6-well plates, grown until confluency and starved ON using 
starving medium. DAF-2DA was added to a final concentration of 10 µmol/L and 
incubated for 1 hour at Room Temperature (RT) in the absence of light. 
Subsequently cells were washed 2x with HBSS and treated with G1 or E2 for 15 min 
within the starving media. NO generation was measured at 450 nm at the TECAN 
plate reader. 
 siRNA Transfection 3.2.8
HUVECs were grown in 28 cm2-dishes till 60- 70% confluency, followed by ON 
starvation with DMEMF12, supplemented with L-Glutamine, LSGS, 1% BSA but 
without AA prior to the transfection. GPER, Smad1 and non-targeting On-Target Plus 
Smart Pool siRNA were applied with a final concentration of 50 nmol/L, using 5 μmol/ 
L Dharmafect. siRNA stock solutions (100 μmol/L) were diluted in 1x Buffer. 
DMEMF12, supplemented with L-Glutamine, was used to prepare siRNA and 
Dharmafect solutions and incubated for five minutes at RT, followed by combining 
both solutions and incubation for 20 minutes at RT. The solutions were transferred 
onto the cells and growing media, without AA, was added on top. After 24 hours of 
incubation with the transfecting agents, the medium was replaced to complete 
growing medium. Silencing of the target genes was observed after 72 hours of 
transfection, which was confirmed by Western blotting. Further experiments were 
conducted after those 72 hours. For Protein Expression Studies transfected cells 
were pre-starved for four hours, followed by according treatment and lysis. For 
vasculogenesis studies transfected cells were trypsinized after 72 hours, and the 
procedure applied, as described in vasculogenesis studies. 
HCASMCs were plated in a density of 80 000 cells/ well in a 12-well plate, followed 
by starvation ON the next day with DMEMF12, supplemented with L-Glutamine, 
LSGS, 1% BSA and without AA prior to transfection. GPER and non-targeting On-
Target Plus Smart Pool siRNA were applied with a final concentration of 50 nmol/L 
using 5 μmol/L Dharmafect. siRNA stock solutions (100 μmol/L) were diluted in 1x 
Buffer. DMEMF12, supplemented with L-Glutamine, was used to prepare siRNA and 
Dharmafect solutions and incubated for five minutes at RT, followed by combining 
both solutions and incubation for 20 minutes at RT. The solutions were transferred 
onto the cells in the morning and growing media, without AA, was added on top. After 
24 hours of incubation with the transfecting agents, the medium was replaced to 
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complete growing medium. Silencing of the target genes was observed after 72 hours 
of transfection, which was confirmed by Western blotting. 
To assess cell proliferation within GPER silenced HCASMCs media was changed in 
the evening of transfection day to HCASMCs starvation medium, containing 20 ng/ml 
PDGF and the agonist. Treatment media was renewed every day and cell counting 
performed on day 3, 72 hours after transfection as described in the Cell proliferation 
studies. 
 RT-PCR Gene Expression Studies 3.2.9
To asses gene expression quantitative PCR was performed using total RNA, 
extracted from HUVECs. These cells were grown in 28 cm2-dishes, starved ON using 
starving media and treated with antagonist for 30 minutes, followed by the agonist for 
45 minutes within the same media. To perform RNA extraction the Quick-RNA 
MiniPrep Kit was used according to the protocol. Briefly the cells were dissolved in 
300 μl RNA- Lysis Buffer, followed by many centrifugation steps, one DNA digesting 
step and many washing steps. Finally the purified RNA was eluted with 30 µl DNase/ 
RNase free water at top speed for 30 seconds, and then quantified with the 
NanoDrop-Tool of the Tecan Platereader. Synthesis of cDNA and determining mRNA 
expression levels were performed with the GoTaq 2-Step RT-qPCR System using 50 
ng/µl of RNA and according to the protocol. In table 1 you see the program of thermo 
cycles used for synthesizing cDNA. 
Step Temperature Time 
Annealing 25° 10 min 
Extending 48° 30 min 
Inactivating 98° 5 min 
Chill 4° / 
Table 1: Program of the Thermo cycler for cDNA synthesis 
Transcribed cDNA was then diluted accordingly to the necessary amount (1:4 in 
DEPC treated water) and mixed with GoTaq Mastermix, the Forward and the 
Reverse Primer, according to the Protocol. Table 2 shows the Program of the 
Thermo Cycler for the quantitative PCR.  
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Repetition Temperature Time 
1 95° 2 min 
1 95° 3 sec 
40 60° 30 sec 
Table 2: Program of the Thermo cyclcer for quantitative cDNA synthesis 
The GoTaq 2-Step RT-qPCR System was used for determining gene expression 
values of VEGF-A by cycle threshold levels and normalized to 18s RNA. The 
sequence of these self-designed primers was chosen out of literature and is listed in 
Table 3. 
Primer sequence 
FWD VEGF A CATGCAGATTATGCGGATCAAAC 
REV VEGF A GGTCTGCATTCACATTTGTTGTG 
FWD 18 sRNA AAGAGAGCCGAGGCAATTACC
REV 18 sRNA GCTCGCATTTTGAGGCTGTTG
Table 3: Sequences of Primers, used for RT-PCR 
 ELISA cAMP Measurment 3.2.10
Generation of cAMP in HUVECs was assessed using a direct cAMP ELISA kit. Cells 
were plated in a density of 400 000 cells/ well in a 6-well plate and starved ON the 
following day. Treatment was performed accordingly: 10 minutes with PDE-inhibitor 
mm-IBMX, followed by antagonist or vehicle for another 10 minutes and finally 15 
minutes with agonist or vehicle, all in DMEMF12, supplemented with L-Glutamine. 
Supernatant was stored for eventual further analyzing at -80°C and the cells lysed 
with 300 µl of 0.1 M HCl+0.1% Triton X-100 for 20 minutes. As the samples were 
acetylated, we also applied the acetylation step at the standards of the kit. All further 
steps were performed according to the protocol. Finally the optical density was 
measured at 405 nm with the Tecan platereader and analyzed using the Magellan 
software. The obtained values of cAMP (pmol/ ml) were normalized to the 
corresponding total protein concentration, assessed with the BCA protein assay kit.  
 Statistical Analysis 3.2.11
Data was analyzed using ANOVA and statistical significance (p<0.05) was calculated 
according to Fisher’s Least Significant Difference test. 
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4 Results  
4.1 GPER Activation improves Endothelial Cell Function  
Objective 
The beneficial effects of estrogens on the endothelium have been well established, 
however, the role of GPER in mediating these effects remains unclear. Hence, under 
this specific aim, we examined the impact of GPER activation on EC function.  
Introduction 
Initiation of atherosclerosis and subsequent progression of CVDs is associated with 
both anatomical and functional disruption of vascular endothelium. [63]. Moreover, 
endothelial repair or regeneration by local ECs or by circulating ECFCs is suggested 
to protect against vascular remodeling associated with atherosclerosis and CVDs 
[242-244].  
Results from several in vivo studies provide strong evidence in support for the 
vasoprotective actions of estrogens. Indeed, estradiol significantly inhibits injury-
induced and pathological vascular remodeling processes [92]; induces endothelial 
growth/ proliferation, migration[102, 245] and capillary formation [99] and improves 
endothelium-dependent vascular relaxation. The formation of capillaries 
(angiogenesis or neovascularization) is a carefully balanced process controlled by 
multiple growth factors and signalling pathways. RTK activators like VEGF, 
Hepatocyte Growth Factor (HGF), Stromal Derived growth Factor-1 (SDF-1), second 
messengers like NO, calcium and cAMP are important molecules that stimulate ECs 
to form capillaries [191, 192, 246, 247].  
Based on our previous finding that the capillary stimulating effects of E2 are 
mimicked by its non-permeable analogue, BSA-tagged E2 [100], we hypothesize that 
these actions are potentially mediated via the newly discovered membrane bound 
GPER. In this study, we assessed the effects of GPER activation on EC function. We 
addressed this question using several in vitro techniques to study vasculogenesis, 
migration and proliferation of HUVECs. 
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As described in section 3.2. 
Results 
 GPER Activation induces Capillary Formation  4.1.1
To investigate the effects on vasculogenesis we used two different assays. The 
presence of GPER in HUVECs was confirmed by Western Blotting of membrane 
fractions, isolated by ultracentrifugation from HUVECs. Briefly, HUVECs, expressing 
GPER (Figure 14A) in the cell membrane, were employed to study capillary formation 
and sprouting, using a 2D-matrigel based assay and a Cytodex bead assay, 
respectively. 
In cells treated with either the GPER specific agonist G1 (10 nmol/L) or 17-β estradiol 
(E2; 10 nmol/L), capillary formation increased from 100±22 % to 210±41% and 
517±46%, respectively (p<0.05 relative to control; Figure 14B). The stimulatory 
effects of G1 on capillary formation were abrogated in the presence of the GPER- 
specific antagonist G15 (100 nmol/L) and the ER unspecific antagonist ICI 182,780 
(100 nmol/L). G1-induced capillary formation was reduced from 210±41% to 52±5.8% 
and 63±9%, respectively, whereas E2-induced capillary formation was reduced from 
517±46% to 67±12.4% and 72±7.5%, respectively (p<0.05 relative G1 or E2 treated 
HUVECs; Figure 1B). Taken together our findings provide evidence for a specific role 
of GPER in inducing capillary formation by HUVECs.  
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Similar results were obtained with the sprouting assay, where we observed an 
upregulation of sprout number per bead by G1 and E2 from 6.9±0.62 to 12.2±0.5 and 
9.33±1, respectively (p<0.05 relative to control; Figure 15A). Co-treatment with G15 
or ICI inhibited G1-stimulated sprout number from 12.2±0.5 to 5.9±0.31 and 6.2±0.41, 
respectively (p<0.05 relative to G1 treated HUVECs; Figure 15B).  
Figure 14. Panel A, Representative Western Blot, showing that HUVECs express GPER in the cell 
membrane preparations. Panel B, Bar graphs and representative photomicrographs showing the 
effects on capillary formation by HUVECs. The cells were treated with GPER specific agonist (G1; 10 
nmol/L) or estradiol (E2; 10 nmol/L) in the presence or absence of GPER specific antagonist (G15; 
100 nmol/L) or ER-unspecific antagonist ICI 182,780 (ICI; 100 nmol/L). HUVECs were pre-treated for 
30min with antagonist, followed by 30 min treatment with agonists and plated at a density of 4000 
cells/ 50 µl per well on a matrigel–coated 15-well µ- slides. After incubation overnight the capillary 
formation was assessed microscopically (see Method section 3.2.2). Values represent mean±SEM, 
n=6 *P<0.05 relative to control, §P<0.05 relative to G1 or E2 treated HUVECs, using ANOVA test.  
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The role of GPER in regulating endothelial function was further confirmed using 
Pertussis Toxin (PTX), an unspecific G-protein inhibitor. At a concentration of 0.1 
ng/ml, PTX significantly reduced the stimulatory effects of G1 and E2 (both 10 
nmol/L) from 210±41% to 20±9.9% and from 517±46% to 15±8%, respectively 
(p<0.05 relative to G1 or E2 treated HUVECs; Figure 16A).  
Next, we silenced the expression of GPER in HUVECs, by transfecting them with 
GPER-specific siRNA (50 nmol/L). As shown in Figure 16B, GPER protein 
expression was significantly reduced by approximately 77% (p<0.05 compared to 
scrambled control). The silencing of GPER abrogated the capillary stimulating effects 
of G1 and E2. As shown in Figure 16C, capillary formation by G1 (10 nmol/L) and E2 
(10 nmol/L) changed from 186±17% in GPER silenced control to 182±12% and 
198±21% not significant, respectively. In contrast to HUVECs, treated with scrambled 
siRNA, G1 and E2 still induced capillary formation from 100% to 159±10% and 
146±8%, respectively (p<0.05 relative to scrambled control, Figure 16C). These 
findings suggest that stimulation of the capillary formation in HUVECs is GPER 
Figure 15. Bar graphs and representative photomicrographs showing the effects on sprout 
formation. HUVEC-coated Cytodex3 beads were plated in fibrin gels and cultured in DMEMF12 
medium. They were treated with (Panel A), GPER specific agonist (G1; 10 nmol/L) or estradiol (E2; 
10nmol/L) alone or in the presence of (Panel B), GPER specific antagonist (G15; 100 nmol/L) or 
ER-unspecific antagonist ICI 182,780 (ICI; 100 nmol/L). Cells were pretreated with antagonists for 
30 min, subsequently G1 was added. After two days of incubation gels were photographed and the 
sprouts counted using Excellence Pro software. Values represent mean±SEM, n=5, *P<0.05 relative 
to control, §P<0.05 relative to G1 treated HUVECs, using ANOVA test. 
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specific, and thereby might induce the beneficial effects of estrogens in 
cardiovascular repair process. 
 
 
 
 
 
 
 
 Figure 16. Bar graph and representative photomicrographs showing the effects of Panel A, GPER 
specific agonist (G1; 10 nmol/L), estradiol (E2; 10 nmol/L) and Pertussis Toxin (PTX; 0.1ng/ ml) on 
the capillary formation by HUVECs. Cells were plated at a density of 4000 cells/ 50 µl per well on a 
matrigel–coated 15-well µ- slides and pretreated with PTX for 30 min, subsequently G1 or E2 was 
added. After incubation overnight, the capillary formation was assessed microscopically (see Method 
section 3.2.2). The values represent mean±SEM, n=4, *P<0.05 relative to control, §P<0.05 relative to 
G1/ E2 using ANOVA test using ANOVA test. Panel B, Bar graph and representative Western Blot, 
showing the efficacy of silencing GPER in HUVECs using the transfection with scrambled siRNA (50 
nmol/L) and GPER siRNA (50 nmol/L). Values represent mean±SEM, n=3; *P<0.05 relative to 
scrambled control using ANOVA test. Panel C, Bar graph and representative photomicrographs 
showing the effects of GPER specific agonist (G1; 10 nmol/L), and estradiol (E2; 10 nmol/L) on 
capillary formation by HUVECs, transfected with scrambled siRNA (50 nmol/L) or GPER siRNA (50 
nmol/L). HUVECs were plated at a density of 4000 cells/ 50 µl per well on a matrigel–coated 15-well 
µ- slides. After incubation overnight the capillary formation was assessed microscopically (see 
Method section 3.2.2). Values represent mean±SEM, n=3, *P<0.05 relative to scrambled control 
using ANOVA test. 
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 GPER Activation induces Migration and Proliferation  4.1.2
Endothelial damage due to mechanical force or inflammation contributes to the onset 
for the initiation/ progression of CVD. Therefore, increased migration and proliferation 
of endothelial cells to repair and reestablish an intact endothelium is essential for 
preventing vaso-occlusive disorders. 
To investigate the effects of GPER activation on migration/ wound closure, we 
performed scratch assays. Monolayers of HUVECs were “wounded” and treated with 
10 nmol/L G1 or 10 nmol/L E2. After 24 hours we observed accelerated wound 
closure from 100% to 145±11% and to 144±6.6% in G1 and E2 treated cells, 
respectively (p<0.05 relative to control; Figure 17A). Moreover, G1-induced wound 
closure was significantly reduced by G15 (100 nmol/L) and ICI 182,780 (100 nmol/L) 
from 145±11% to 93±9.4% and 79±9.3%, respectively (p<0.05 relative G1 treated 
HUVECs; Figure 17B).  
 
 
 
 
 
Figure 17. Bar graphs and representative photomicrographs showing the effects on wound closure. 
After scratching a confluent monolayer of HUVECs, wound closure was monitored following 
treatment with Panel A, GPER specific agonist (G1; 10 nmol/L), estradiol (E2; 10 nmol/L), Panel B, 
GPER specific antagonist (G15; 100 nmol/L) and ER-unspecific antagonist ICI 182,780 (ICI; 100 
nmol/L). Cells were pretreated with antagonists G15 and ICI for 30 min and subsequently G1 was 
added for 24 h. Pictures were taken at timepoint 0 and 24 h afterwards and analysed using 
Excellence Pro software. Shown are mean±SEM, n=4, *P<0.05 relative to control, §P<0.05 relative 
to G1 treated HUVECs, using ANOVA test. 
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The impact of GPER activation on proliferation of endothelial cells was assessed by 
counting the cell number. In HUVECs treated for four days with G1 (10 nmol/L), cell 
proliferation was induced from 100±2.2% to 117±6.6% (p<0.05 relative to control). 
This increasing cell proliferation was suppressed by G15 (100 nmol/L) to 77±3.2% 
(p<0.05 relative G1 treated HUVECs; Figure 18). These observations suggest an 
important mediator role of GPER in migration and proliferation of HUVECs, which 
may underlie the beneficial effects of estrogens in cardiovascular repair process. 
 
Discussion 
The role of estrogens in the cardiovascular system is well established; however the 
mechanisms involved remain unclear.  
Estrogen stimulates endothelial function by activating ERα and/ or ERβ [78, 102]. 
Recently, a third estrogen receptor, GPER has been identified [38], which seems to 
have an important regulatory role within the cardiovascular system. GPER is 
expressed within the vasculature [248], intact arteries [112] and ECs [25, 249].  
Hence, using the HUVECs as a model, we assessed the role of GPER activation in 
regulating EC function. The development of GPER specific agonist G1 in 2006 [45] 
and GPER specific antagonist G15 in 2009 [46] facilitated our investigation to 
distinguish the estrogenic effects, solely elicited via GPER. Here we studied the 
effects of the GPER specific agonist G1 and of E2 on capillary formation, using two 
different in vitro models.  
In the matrigel-based vasculogenesis assay G1 and E2 significantly stimulated 
microvessel formation by HUVECs. These observations are consistent with the 
Figure 18. Bar graph showing the effects 
of a GPER specific agonist (G1; 10 
nmol/L) or GPER specific antagonist 
(G15; 100 nmol/L) on proliferation of 
HUVECs. Cells (20,000cells/ well) were 
plated in 12-well plates and fed with 
complete media. After 48 h cells were 
starved overnight and pretreated with 
GPER antagonist G15 for 30 min and 
subsequently with G1. Treatment was 
renewed every 2 days and the 
experiments stopped after 4 days and 
cell number counted, using the Coulter 
Counter. Shown are mean±SEM, n=3, 
*P<0.05 relative to control, §P<0.05 
relative to G1 treated HUVECs, using 
ANOVA test. 
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findings of Baruscotti et al. and De Francesco et al. [100, 250]. Because the 
stimulatory effect of E2 was 2.5 fold higher than the effect of G1, we speculate that a 
possible crosstalk of GPER and ERα, as recently suggested in BG-1 ovarian cancer 
and uterine epithelial cells [251, 252], might be responsible for this additive effect. 
The stimulatory effects on capillary formation were abolished by the GPER specific 
inhibitor G15 and the ER unspecific inhibitor ICI 182,780, further supporting our 
hypothesis for a GPER- ERα interaction. Surprisingly, other groups have observed 
that ICI 182,780 acts like an agonist for GPER and induces GPER signaling in breast 
cancer cell lines [40, 253]. However, in our HUVEC model we observed significant 
inhibition of the G1-stimulated effects with ICI 182,780. A possible explanation for 
these contraindicative observations might be the use of different cell lines. To further 
elucidate the stimulatory role of GPER in capillary formation, we applied the broad 
spectrum GPCR inhibitor Pertussis Toxin (PTX), which inactivates the GPCR 
subunits Gαi and Gαo [254]. While PTX alone induced angiogenesis of murine brain 
ECs [255], studies showed that PTX blocked GPER induced proliferation of OVCAR5 
cells [256] and Akt activation in HEC-1A cells [257]. In line with these observations, 
we were able to block the stimulatory effects of G1 and E2 on capillary formation by 
HUVECs with PTX. This result suggests that the stimulatory effects of G1 and E2 on 
capillary formation are indeed mediated via classical GPCR mechanisms. To further 
confirm this notion, we silenced GPER in HUVECs by transfecting them with GPER 
specific siRNA. Silencing of GPER abolished the stimulatory effects of G1 and E2 on 
capillary formation. In contrast, G1 and E2 significantly induced microvessel 
formation in HUVECs transfected with scrambled siRNA. However, compared to cells 
treated with scrambled control, treatment with GPER silenced control surprisingly 
exhibited a significant increase in capillary formation. Other studies using GPER 
siRNA observed a significant decrease in G1-induced proliferation of CAFS [258] and 
proliferation, migration and invasion of SKOV3 cells [259] upon silencing of GPER. A 
possible explanation for these contrasting outcomes could be again the use of 
different cell lines. The use of different GPER siRNAs can be excluded as a pooled 
GPER siRNA was used within this present study.  
GPER is a typical GPCR and as such coupled to heterotrimeric G-proteins Gα/ Gβ/ 
Gγ, each leading to specific signaling. Different subtypes exist from these 
heterotrimeric G-proteins, for GPER mediated signaling the subtypes Gαs [41] and 
Gβγ [38] have been suggested. We propose that upon silencing GPER, still unknown 
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pro-angiogenic or pro-survivor subunits of GPER may have been exposed, thereby 
contributing to this increased capillary formation in HUVECs. Nevertheless, upon 
silencing GPER, the stimulatory effects of G1 and E2 were lost, indicating the 
importance of GPER`s role in mediating estrogenic effects on capillary formation in 
HUVECs. 
To form new blood vessels, ECs have to differentiate into tip and stalk cells with 
increased proliferative and migratory properties, leading to sprouting of ECs [260]. 
Therefore, we investigated the effects of G1 and E2 on sprouting of HUVECs using 
the Cytodex Bead assay. We observed increased sprouting in the presence of G1 
and E2, which was significantly blocked by G15 and ICI 182,780. Taken together, our 
results provide evidence that GPER activation exerts stimulatory effects on 
vasculogenesis by HUVECs, by inducing microvessel/ capillary formation and 
sprouting.  
Following endothelial denudation rapid repair of vascular wounds by increased 
migration and proliferation of ECs contributes to the pro-angiogenic and 
vasoprotective effects of E2 [102, 245]. To study the migration of HUVECs, we used 
the in vitro scratch assay method, where a monolayer of cells is “wounded” and the 
area of wound closure assessed, as previously described [261]. Similar to the effects 
of E2, we observed a significant increase in wound closure activity of HUVECs upon 
treatment with G1. The “wound closure” effects of G1 were abolished in presence of 
G15 and ICI 182,780, suggesting that GPER plays an important role in mediating the 
stimulatory effects of estrogens EC migration. Additionally, we assessed the effect of 
G1 on HUVECs proliferation and found a significant increase in cell number in 
response to G1, supporting its pro-mitogenic actions. Since we could block this 
increase in proliferation with G15, this indicates a high specificity of GPER in 
inducing HUVECs proliferation. Together, these results provide evidence that GPER 
stimulated migration and proliferation potentially contribute to its pro-vasculogenic 
effects in the HUVECs. 
Many studies have observed positive effect of estrogen on proliferation and migration 
of endothelial cells in vitro [94], promotion of endothelial regrowth after arterial injury 
[95] and acceleration of re-endothelialization [96]. Additionally, mobilization of 
ECFCs, inflammatory immune cells and platelets by E2 might also contribute to the 
repair of the endothelium [97, 98]. Moreover, E2 stimulates angiogenesis in vitro and 
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in vivo [99-101] by inducing the most important pro-angiogenic factors: Fibroblast 
growth factor 2 (FGF2), VEGF and NO [99]. 
In contrast to our findings, some studies have shown that activation of GPER inhibits 
EC proliferation [38, 249], thus suggesting an anti-angiogenic effect. However, the 
positive effect of GPER in the cardiovascular system is indirectly supported by the 
fact that: 1) infusion with GPER specific agonist G1 lowers blood pressure in 
normotensive [114] and hypertensive rats [108]; 2) G1 treatment improves diastolic 
dysfunction, cardiac hypertrophy and decreases myocyte size [129]; and 3) GPER 
induces vasodilatory action [108, 113, 114] in a NO-dependent fashion [113, 114, 
117]. Apart from its vasodilatory effect, NO also stimulates angiogenesis [192] and 
therefore could be responsible for GPER`s stimulatory effect on capillary formation in 
our HUVEC model.  
With regard to our findings in HUVECs, we postulate that stimulation of GPER 
induces endothelial function by promoting proliferation, migration and angiogenesis in 
ECs. In summary, GPER might play an important role in mediating the protective 
effects of estrogen on the cardiovascular system. GPER specific agonist G1 may be 
of therapeutic and clinical relevance in targeting vasoocclusive disorders. Since G1 is 
non-feminizing, it could be of therapeutic interest in both men and women.  
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 The ALK1/ SMAD1/5/8 Pathway mediates GPER-induced 4.2
Capillary Formation in Endothelial and Progenitor Cells 
Objective 
Our findings from capillary formation experiments demonstrated that the pro-
vasculogenic effects of estradiol are mimicked by G1, a GPER specific agonist in 
HUVECs. Hence, we further investigated the potential underlying mechanisms. Since 
ALK1/ SMAD1/5/8 signaling pathway plays an important role in angiogenesis, we 
investigated its role in mediating GPER-induced vasculogenesis in HUVECs and 
ECFCs.  
Introduction 
The superfamily of TGFβ proteins includes TGFβ, the BMP subfamily, activins, and 
GDFs. The different ligands and their downstream pathway components are highly 
conserved and regulate multiple diverse cellular functions such as growth, adhesion, 
migration, apoptosis and differentiation [142]. Members of the TGFβ family dimerize 
and activate heteromeric complexes of type I and type II transmembrane receptors, 
leading to an activation of the downstream transcription factors SMADs [262, 263]. 
Depending on the cell type and the context, diverse responses can be triggered upon 
binding of the same member of the TGFβ family by recruiting a distinct set of 
receptors [264]. ECs highly express ALK1, which is a type I transmembrane receptor 
and activates SMAD1/5/8 [164]. Research suggests a key role of this ALK1/ 
SMAD1/5/8/ signaling in embryonic angiogenesis, since mutations in ALK1 and 
SMADs lead to severe defects in embryogenesis and early lethality [176-178]. The 
ALK1/ SMAD1/5/8 pathway might also play a role in maintaining homeostasis of the 
vasculature, as patients with HHT, suffering from telangiectasis, arteriovenous 
malformations, nose bleeds and gastrointestinal bleeding, show mutations in ALK1 
[144]. 
In summary, the impact of ALK1 signaling in ECs, vasculogensis and vascular 
integrity is evident. In the present study, we investigated whether activation of GPER 
modulates ALK1/ SMAD1/5/8 signaling in HUVECs and whether this pathway 
contributes to G1-induced vasculogenesis. 
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Methods 
As described in section 3.2. 
 Activation of ALK1/ SMAD1/5/8 Pathway  4.2.1
The ALK1/ SMAD1/5/8-pathway is known to be pro-angiogenic and, as shown in 
Figure 19A, treatment of HUVECs with G1 (100 nmol/l) induced ALK1 and ID-1 
expression by more than 1.5 fold (from 100±4.5% to 168±21.2% and from 100±9.7% 
to 179±26.2%, respectively; p<0.05 relative to control), while the expression of ALK5, 
which opposes ALK1 actions, was decreased and the expression of PAI-1, which is a 
downstream target of ALK5, was not altered (from 100±4.2% to 63±8.5% and from 
100±1% to 103±4.67%, respectively; p<0.05 relative to control; Figure 19B).  
Activation of ALK1 leads to phosphorylation of SMAD1/5/8. Since we observed an 
upregulation of ALK1 expression by G1, we further studied changes in SMAD1/5/8 
phosphorylation following GPER activation. We observed increased phosphorylation 
of SMAD1/5/8 from 100% to 208±36% (p<0.05 relative to control, Figure 20A) upon 
treatment of HUVECs with G1 (10 nmol/ L) for 45 min. Pre-treatment with G15 (100 
nmol/L), a GPER specific antagonist, or ICI 182,780 (100 nmol/L), a non-specific ER 
antagonist, reduced the G1-stimulated phosphorylation of SMAD1/5/8 from 208±36% 
to 117±23.7% and 131±27.8%, respectively (p<0.05 relative to G1 treated HUVECs; 
Figure 20A).  
The regulatory role of GPER on SMAD1/5/8 phosphorylation was further confirmed in 
HUVECs, where GPER was silenced. Indeed, treatment with G1 (10 nmol/L) and E2 
(10 nmol/L) had no effect on the phosphorylation of SMAD1/5/8 (from 74±4.5% to 
76±12.2% and 36±27.7%, respectively) as compared to GPER silenced controls, 
while both G1 and E2 induced the phosphorylation of SMAD1/5/8 in HUVECs treated 
with scrambled siRNA from 100% to 135±5.5% and 131±2.3%, respectively (p<0.05 
relative to scrambled control, Figure 20B). 
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Figure 19. Bar graph and representative Western Blots demonstrating the effects of treatment 
with GPER specific agonist (G1, 100 nmol/L) on protein expression of ALK1, ID-1 (Panel A) and 
of ALK5 and PAI-1 (Panel B). HUVECs were starved ON and treated for 24h. Values represent 
mean±SEM, n=3, *P<0.05 relative to control using ANOVA test. 
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Recent studies provide evidence that circulating progenitor ECs are capable of 
repairing the damaged endothelium and form capillaries in response to E2. To 
confirm the regulatory role of GPER on the ALK1/ SMAD1/5/8 pathway and the 
impact on capillary formation in progenitor ECs, we investigated this pathway also in 
ECFS. As shown in Figure 21A, treatment of ECFCs with G1 (100 nmol/L) induced 
ALK1 and ID-1 expression by 2-fold (from 100±9.8% to 202±24.8% and from 
100±5.4% to 207±24.8%, respectively; p<0.05 relative to control). In contrast to ALK1 
and ID-1, G1 attenuated ALK5 and PAI-1 expression from 100±12.4% to 85±9.2% 
and from 100±10% to 76±13.96%, respectively (p>0.05 relative to control; Figure 
21B). The phosphorylation of SMAD1/5/8 was increased in ECFCs treated with G1 
(10 nmol/L) from 100% to 212±3% (p<0.05 relative to control), and this was 
significantly reduced upon pre-treatment with G15 (100 nmol/L) and ICI 182-780 (100 
nmol/L) to 120±11% and 101±5.8%, respectively (p<0.05 relative to G1 treated 
Figure 20. Bar graphs and representative Western Blots demonstrating the effects of GPER 
activation on SMAD1/5/8 phosphorylation. Panel A, depicts the effects of GPER specific agonist (G1; 
10 nmol/L), GPER specific antagonist (G15; 100nmol/L) and ER-unspecific antagonist ICI 182,780 
(ICI; 100 nmol/L) on the phosphorylation of SMAD1/5/8. Pre-starved HUVECs were treated with 
antagonists for 30min, subsequently G1 was added for 45min. Values represent mean±SEM, n=5, 
*P<0.05 relative to control, §P<0.05 relative to G1 using ANOVA test. Panel B, depicts effects of 
GPER specific agonist (G1; 10 nmol/L) and estradiol (E2; 10 nmol/L) on the phosphorylation of 
SMAD1/5/8 in pre-starved HUVECs, transfected with scrambled siRNA (50 nmol/L) or GPER siRNA 
(50 nmol/L). Values represent mean±SEM, n=3, *P<0.05 relative to scrambled control, using ANOVA 
test. 
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ECFCs; Figure 21C). These results in ECFCs also reflect and support our data 
obtained in HUVECs, suggesting that GPER activation induces the ALK1/ 
SMAD1/5/8 pathway in both HUVECS and ECFCs. 
 
 
 
 
 Role of ALK1/ SMAD1/5/8 Pathway in GPER-induced Capillary Formation  4.2.2
Our results suggest that GPER activation induces the ALK1/ SMAD1/5/8 pathway, 
which is known to induce capillary formation in endothelial cells. Therefore, we 
studied the role of G1- induced SMAD1/5/8 signaling in mediating vasculogenesis in 
ECs.  
For this purpose, we applied ALK1Fc (100 ng/ml), which is a specific antagonizing 
antibody and pharmacological inhibitor for ALK1, and SJN2511 (SJN, 100 nmol/L), a 
specific antagonist of ALK5, and examined their impact on the G1-induced 
phosphorylation of SMAD1/5/8. As shown in Figure 22A, treatment with G1 induced 
Figure 21. Bar graphs and representative Western Blots demonstrating the effects of the GPER 
specific agonist (G1, 100 nmol/L) in ECFCs treated for 24 h on protein expression of (Panel A), ALK 1 
and ID-1, and (Panel B), ALK 5 and PAI-1. Panel C shows the phosphorylation of SMAD1/5/8 in pre-
starved ECFCs. The cells were treated with the GPER specific antagonist (G15; 100nmol/L) or the 
ER-unspecific antagonist ICI 182,780 (ICI; 100 nmol/L) for 30min. Subsequently, G1 (10 nmol/L) was 
added for 45 min. Values represent mean±SEM, n=3, *P<0.05 relative to control, §P<0.05 relative to 
G1 using ANOVA test. 
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SMAD1/5/8 phosphorylation and this effect was significantly abrogated by ALK1Fc 
from 189±26% to 24±8.9%, whereas pre-treatment with SJN had no modulatory 
effect and altered SMAD1/5/8 phosphorylation from 189±26% to 166±45.6%, (p<0.05 
relative to G1 treated HUVECs).  
Next we applied the same antagonists prior to G1 treatment in HUVECs and 
assessed microvessel formation. ALK1Fc (100 ng/ml) significantly blocked G1-
induced capillary formation by 94% (p<0.05 relative to G1 treated HUVECs), but SJN 
(100 nmol/L) was ineffective and did not alter capillary formation, which was 
156±8.2% to 159±19.5% respectively, in the absence or presence of SJN (p>0.05 
relative to G1 treated HUVECs; Figure 22B).  
The importance of the ALK1/ SMAD1/5/8 pathway in GPER mediated capillary 
formation was further confirmed by silencing SMAD1 in HUVECs transfected with 
SMAD1 specific siRNA. High silencing efficacy was obtained, as SMAD1/5/8 
expression was decreased by 41% and SMAD1/5/8 phosphorylation following BMP9 
treatment (10 ng/ml) was reduced by approximately 70% (p<0.05 relative to 
scrambled control; Figure 23A). In capillary formation experiments, silencing of 
SMAD1 abrogated the stimulatory effects of G1 (10 nmol/L) and E2 (10 nmol/L), 
which changed from 77±5.3% to 94±6.8% and 92±10.2% (p>0.05 relative to SMAD1 
silenced control). In contrast, in HUVECs, treated with scrambled siRNA, G1 and E2 
induced capillary formation from 100% to 159±10% and 146±8%, respectively 
(p<0.05 relative to scrambled control, Figure 23B). These data suggest that GPER- 
induced vasculogenesis in ECs is mediated via the ALK1/SMAD1/5/8 pathway and 
confirms the importance of this pathway in capillary formation. 
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Figure 22. Panel A, Bar graph and representative Western Blot demonstrating the effects of GPER 
specific agonist (G1; 10 nmol/l), ALK5 specific antagonist (SJN; 100 nmol/L) and ALK1 specific 
antagonizing antibody (Alk1Fc; 100 ng/ml) on the phosphorylation of SMAD1/5/8. HUVECs were 
starved for 4 h and treated with the antagonists for 30 min, G1 was then added for 45 min. Values 
represent mean±SEM, n=6, *P<0.05 relative to control, §P<0.05 relative to G1, using ANOVA test. 
Panel B, Bar graph and representative photomicrographs showing the effects of GPER specific 
agonist (G1; 10 nmol/L), ALK 5 specific antagonist (SJN; 100 nmol/L) and ALK1 specific 
antagonizing antibody (Alk1Fc; 100 ng/ml) on capillary formation by HUVECs. The cells were plated 
at a density of 4000 cells per well on a matrigel–coated 15-well µ-slides and pretreated with the 
antagonists for 30 min, subsequently G1 was added. After overnight incubation, the capillary 
formation was assessed microscopically (see Method section 3.2.2). Values represent mean±SEM, 
n=6, *P<0.05 relative to control, §P<0.05 relative to G1 using ANOVA test.  
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We also investigated the impact of G1- induced ALK1/ SMAD1/5/8 signaling in 
mediating vasculogenesis by ECFCs. Similar to our observations in HUVECs, 
treatment of ECFCs with ALK1Fc (100 ng/ml) abrogated G1-induced SMAD1/5/8 
phosphorylation from 205±19% to 118±15.2. (p<0.05 relative to G1 treated ECFCs; 
Figure 24A). Moreover, treatment with G1 (10 nmol/L) induced capillary formation 
from 100% to 135±10.7% (p<0.05 relative to control) and pre-treatment with ALK1Fc 
significantly blocked G1-induced capillary formation from 135±10.7% to 58±17% 
(p<0.05 relative to G1 treated ECFCs; Figure 24B). In summary, our results from the 
ECFCs experiments confirm our observations in HUVECs and suggest that GPER 
induced- vasculogenesis is mediated via activation of the ALK1/ SMAD1/5/8 
pathway. 
Figure 23. Panel A, Bar graph and representative Western Blot showing the efficacy of transfection 
with scrambled siRNA (50 nmol/L) and SMAD1 siRNA (50 nmol/L) in HUVECs. Values represent 
mean±SEM, n=4, *P<0.05 relative to scrambled control using ANOVA test. Panel B, Bar graph and 
representative photomicrographs showing the effects of GPER specific agonist (G1; 10 nmol/L), and 
estradiol (E2; 10 nmol/L) on capillary formation by HUVECs transfected with scrambled siRNA (50 
nmol/L) or SMAD1 siRNA (50 nmol/L). HUVECs were plated at a density of 4000 cells per well on a 
matrigel–coated 15-well µ- slides. After overnight incubation the capillary formation was assessed 
microscopically (see Method section 3.2.2). Values represent mean±SEM, n=3, *P<0.05 relative to 
scrambled control using ANOVA test. 
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 GPER-induced Capillary Formation and SMAD1/5/8 Phosphorylation 4.2.3
involves BMP2 
BMP2 is an endogenous ligand for BMP receptor type I [265], which leads to 
dimerization of TGFβ receptor I (e.g. ALK1) with the type II receptor and receptor 
activation with subsequent activation of the signaling cascade. An endogenous 
counterplayer of BMP2 is Noggin, which blocks BMP2 and inhibits its binding to the 
BMP receptor type I [266]. Both molecules were employed to confirm our 
observations that the ALK1/ SMAD1/5/8 pathway plays an important and active role 
in the capillary formation of HUVECs. Indeed, treatment of HUVECs with BMP2 (10 
ng/ml) induced the phosphorylation of SMAD1/5/8 from 100% to 322±43.1% and 
capillary formation from 100% to 133±4.2% (p<0.05 relative to control). Moreover, 
these effects of BMP2 were blocked significantly by Noggin (100 ng/ml) to 90±23.4% 
and to 109±13.5%, respectively (p<0.05 relative to BMP2 treated HUVECs; Figure 
25A/ B). Next, we investigated whether Noggin affects G1 (10 nmol/L) -induced 
capillary formation and SMAD1/5/8 phosphorylation in HUVECs. Noggin blocked G1-
Figure 24. Panel A, Bar graph and representative Western Blot demonstrating the effects of A, 
GPER specific agonist (G1; 10 nmol/l) and ALK 1 specific antagonizing antibody (Alk1Fc; 100 ng/ml) 
on the phosphorylation of SMAD1/5/8. Pre-starved ECFCs were pretreated with the antagonists for 
30min, subsequently G1 was added for 45min. Values represent mean±SEM, n=3, *P<0.05 relative 
to control, §P<0.05 relative to G1 using ANOVA test. Panel B, Bar graph and representative 
photomicrographs showing the effects of GPER specific agonist (G1; 10 nmol/L) and ALK 1 specific 
antagonizing antibody (Alk1Fc; 100 ng/ml) on capillary formation by ECFCs. The cells were plated at 
a density of 4000 cells per well on a matrigel–coated 15-well µ- slides and pretreated with the 
antagonists for 30min. G1 was then added for incubation overnight and capillary formation assessed 
microscopically (see Method section 3.2.2). Values represent mean±SEM, n=3, *P<0.05 relative to 
control, §P<0.05 relative to G1 using ANOVA test.
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induced capillary formation from 141±7.1% to 103±9.4% and phosphorylation of 
SMAD1/5/8 from 190±25.8% to 28±9.4% (p<0.05 relative to G1 treated HUVECs; 
Figure 25C/ D). These findings led us to suggest that G1-induced capillary formation 
and SMAD1/5/8 phosphorylation potentially involves BMP2. 
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Figure 25. Panel A, Bar graph and representative Western Blot, demonstrating the effects of 
TGFβ Receptor II specific agonist (BMP2; 10 ng/ml), and BMP inhibitor (Noggin, 100 ng/ml) 
on the phosphorylation of SMAD1/5/8. Pre-starved HUVECs were treated with Noggin for 30 
min, subsequently BMP2 was added for 45 min. Values represent mean±SEM, n=4, *P<0.05, 
relative to control, §P<0.05 relative to BMP2, using ANOVA test. Panel B, Bar graph and 
representative photomicrographs showing the effects of TGFβ Receptor II specific agonist 
(BMP2; 10ng/ml), and BMP inhibitor (Noggin, 100ng/ml) on capillary formation by HUVECs. 
Cells were plated in a density of 4000 cells per well on a matrigel–coated 15-well µ- slide and 
treated with the inhibitor for 30 min, subsequently BMP2 was added. After incubation 
overnight capillary formation was assessed microscopically (see Method section 3.2.2). 
Values represent mean±SEM, n=4, *P<0.05 relative to control, §P<0.05 relative to BMP2 
using ANOVA test. Panel C, Bar graph and representative Western Blot, demonstrating 
effects of GPER specific agonist (G1; 10 nmol/L) and BMP inhibitor (Noggin, 100ng/ml) on the 
phosphorylation of SMAD1/5/8. Pre-starved HUVECs were treated with inhibitor for 30 min, 
subsequently G1 was added for additional 45 min. Values represent mean±SEM, n=5, 
*P<0.05, relative to control, §P<0.05 relative to G1 using ANOVA test. Panel D, Bar graph and 
representative photomicrographs showing the effects of GPER specific agonist (G1; 10 
nmol/L) and BMP inhibitor (Noggin, 100ng/ml) on capillary formation by HUVECs. Cells were 
plated in a density of 4000 cells per well on a matrigel–coated 15-well µ- slide and treated with 
inhibitor for 30min, subsequently G1 was added. After incubation overnight capillary formation 
was assessed microscopically (see Method section 3.2.2). Values represent mean±SEM, n=5, 
*P<0.05 relative to control, §P<0.05 relative to G1 using ANOVA test. 
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 Activation of BMP2 Secretion 4.2.4
Our observation that Noggin blocks the effects of G1 on capillary formation and 
SMAD1/5/8 phosphorylation suggested a link between G1 and BMP2. Therefore, we 
investigated whether GPER activation results in the release of BMP2 from cultured 
cells into the supernatant. Indeed, analysis of the supernatant from G1 (10 nmol/L) -
treated HUVECs revealed an increase in BMP2 level by 370±63.4% (p<0.05 relative 
to control) and this effect was significantly blocked by G15 (100 nmol/L) to 
103±55.8% (p<0.05 relative to G1 treated HUVECs; Figure 26). Taken together our 
data provide evidence that G1 induces the phosphorylation of SMAD1/5/8 by 
triggering the release of BMP2 via a putative short term effect, which subsequently 
activates the signaling cascade leading to increased vasculogenesis. 
 
 
 
Figure 26. Bar graph and representative Western Blot, demonstrating the effects of GPER specific 
agonist (G1; 10 nmol/L) and GPER specific antagonist (G15; 100 nmol/l) on the release of BMP2 
from HUVECS into the supernatant. For normalization, β-Actin was detected in whole cell lysates 
since it is not present in the supernatant. Pre-starved HUVECs were treated with the antagonist for 
30 min in a volume of 200 µl. G1 was then added for 30 min. Values represent mean±SEM, n=3, 
*P<0.05, relative to control, §P<0.05 relative to G1, using ANOVA test.
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Discussion 
The ALK1/ SMAD1/5/8 signaling pathway is important in regulating endothelial cell 
function. It has been shown to be essential in human embryogenesis where it 
regulates angiogenic processes. Mutations in ALK1 or SMAD1/5/8 have been shown 
to cause early lethality due to vascular abnormalities in murine embryos [176-178]. 
Moreover, many studies demonstrated a prominent role of ALK1/ SMAD1/5/8 in 
modulating postnatal angiogenesis [160, 267-269]. 
ALK1 is mainly expressed in ECs [164, 270] and we found that GPER activation 
stimulated ALK1 expression in HUVECs and ECFCs. Moreover, G1 increased the 
expression of ID-1, the downstream target of SMAD1/5/8 activation, which is 
responsible for inducing migration and tube formation in ECs [153]. Interestingly, in 
both EC types we observed no change in ALK5 expression and its downstream 
target PAI-1 following G1 treatment. Activation of the ALK5- pathway, in contrast to 
the ALK1- pathway, leads to inhibition of EC proliferation, tube formation and 
migration [149, 151], thereby blocking angiogenesis.  
Furthermore, we observed a significant increase in the phosphorylation of 
SMAD1/5/8 in HUVECs and ECFCs upon G1 treatment, further emphasizing an 
activation of this signaling pathway. Consistent with our observations, other studies 
already showed induction of SMAD1/5/8 phosphorylation by estradiol in mouse 
MC3T3-E1 cells and myoblastic C2C12 cells [271, 272]. 
In our study, SMAD1/5/8 phosphorylation was inhibited by GPER specific antagonist 
G15 in both HUVECS and ECFCs. Moreover, in HUVECs, transfected with GPER 
specific siRNA, the stimulatory effects of G1 and E2 on pSMAD1/5/8 were abolished. 
While Matsumoto et al. previously demonstrated the stimulatory effects of estrogens 
on SMAD1/5/8 phosphorylation [271, 272], to our knowledge, we are the first 
demonstrating the regulatory role of GPER in mediating the estrogenic effects on the 
phosphorylation of SMAD1/5/8. 
In summary, the above findings suggest a potentially prominent role of GPER in 
activating ALK1/ SMAD1/5/8, but not ALK5, signaling. 
Although the ALK1- and the ALK5- pathways elicit opposite responses, these two 
proteins are physically interacting and each is essential for maximal activation of the 
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other [151]. Based on this reported crosstalk, we used inhibitors for ALK1 and ALK5 
to study their role in GPER-induced phosphorylation of SMAD1/5/8 and 
vasculogenesis in HUVECs and ECFCs.  
We were able to block both G1-induced pSMAD1/5/8 and G1- stimulated capillary 
formation in both HUVECs and ECFCs with ALK1Fc, a specific neutralizing antibody 
for ALK1. These observations are consistent with other studies, which previously 
demonstrated a blocking effect of ALK1Fc on angiogenesis of HMVECs [174] and on 
the expression of ALK1`s downstream product ID-1 [149, 174, 273]. However, in 
HUVECs stimulated with G1, treatment the ALK5- inhibitor SJN251 had no reducing 
effects on the phosphorylation of SMAD1/5/8 and vasculogenesis. This is in line with 
the reported role of ALK5 in inhibiting angiogenesis [149, 151] and suggests that 
GPER-stimulated vasculogenesis and SMAD1/5/8 phosphorylation is mediated via 
ALK1, and that this is not dependent on crosstalk with ALK5 in our HUVEC model. 
Recently, knocking out SMAD1 in endothelial and smooth muscle cells has been 
shown to be linked to Pulmonary Arterial Hypertension (PAH) [274], which is 
associated with abnormal angiogenesis [275]. Taking these results into account and 
to further elucidate the importance of ALK1/ SMAD1/5/8 in GPER- stimulated 
vasculogenesis, the HUVECs were transfected with SMAD1 specific siRNA. Indeed, 
silencing of SMAD1 completely abrogated the stimulatory effects of G1 and E2 on 
capillary formation of HUVECs.  
In summary, this result emphasizes and reaffirms the essential role of ALK1/ 
SMAD1/5/8 signaling in mediating GPER-induced capillary formation by ECs.  
Studies have shown that BMP2 and BMP4, belonging to the TGFβ superfamily, play 
important roles in endothelial cell function, by inducing differentiation, proliferation, 
migration and cell survival [276-278]. Consistent with other studies [279-281], we 
observed a significant increase in capillary formation of HUVECs upon BMP2 
treatment. Moreover, the stimulatory effect of BMP2 on vasculogenesis was blocked 
by Noggin, an endogenous sequestering molecule, that inhibits the binding of BMP2 
and BMP4 to their receptors and thereby blocks further signaling [266]. Moreover, the 
phosphorylation of SMAD1/5/8 was induced in HUVECs treated with BMP2 and 
significantly reduced upon pre-treatment with Noggin. BMP2 binds and activates the 
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BMP type I receptors ALK3 and ALK6 [265, 282], and phosphorylation of SMAD1/5/8 
in response to BMP2 has already been observed and established in ECs [283].  
Surprisingly, Noggin also inhibited G1-induced capillary formation and 
phosphorylation of SMAD1/5/8, which suggests a link between GPER and BMP2. 
Interestingly, BMP2 effects on differentiation of C2C12 cells could be significantly 
blocked with the GPCR-unspecific inhibitor PTX [284], suggesting that BMP2 
functions are mediated via G-protein coupled mechanisms.  
As described in the previous section 4.1, we were also able to block the effects of 
GPER, a classical GPCR, on vasculogenesis using PTX in HUVECs. This further 
supports the notion for a potential link between GPER activation and BMP2 signaling. 
Therefore to substantiate this, we investigated whether GPER activation induces the 
release of BMP2. Indeed, a significant increase in BMP2 was observed within the 
supernatant of HUVECs treated with G1. This significant effect could be blocked 
using G15, indicating high GPER specificity in stimulating BMP2 release.  
Taken together, the above findings and our observation that GPER activation 
stimulates ALK1 expression and SMAD1/5/8 phosphorylation and leads to increased 
capillary formation, suggest that the vasculogenic effects of G1 are triggered/ initiated 
by G1-induced release of BMP2, via a putative short term effect, in HUVECs.  
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 The Role of cAMP in GPER-induced Capillary Formation and 4.3
ALK1/ SMAD1/5/8 Pathway in Endothelial Cells 
Objective 
Cyclic AMP plays an important role in mediating the biological effects of sex 
hormones. It is well established that the beneficial effects of estradiol on the 
cardiovascular system are in part mediated by cAMP. Indeed, stimulation of cAMP 
production induces endothelial function and inhibits SMC proliferation. Recently, it 
has been suggested that non-vascular and vascular cells generate cAMP upon 
GPER activation. Therefore we investigated whether GPER stimulates cAMP 
generation in HUVECs and whether cAMP signaling plays a role in GPER-stimulated 
ALK1/ SMAD1/5/8 pathway and vasculogenesis. 
Introduction 
It is well established that estrogen mediates rapid intracellular signaling events [233, 
285-288], such as activation of adenylyl cyclase, leading to production of 3', 5'-cyclic 
adenosine monophosphate (cAMP). Cyclic AMP generation in response to estradiol 
was reported for the first time in rat uterus 1967 [234]. Subsequently, many other 
studies demonstrated that estrogen induces cAMP levels [104, 233-236], which 
triggers vasodilation [236, 289, 290] and inhibition of SMC proliferation [104, 291]. 
Keung et al. reported that ER-antagonist ICI 182,780 could not block estrogen-
induced cAMP in vascular SMC [236] and suggested that stimulatory effects of 
estrogen on adenylyl cyclase might be mediated via a GPCR-dependent mechanism 
[292, 293]. The above studies suggest that the recently identified membrane GPER, 
a classical GPCR, might be responsible for the stimulatory effects of estradiol on 
cAMP. This notion was confirmed by several studies, which detected increased 
adenylyl cyclase activity and cAMP upon GPER activation in non-vascular cells [39, 
41, 294] and vascular cells [295]. Furthermore, Amano et al. detected increased 
angiogenesis in in vivo models upon injection with 8-bromo-cAMP [191], indicating a 
pro-angiogenic mediator role of the cAMP signalling pathway. 
Based on the above findings we hypothesized and assessed whether GPER 
activation stimulates cAMP production in HUVECs and whether cAMP signaling 
mediates GPER-induced vasculogenesis and ALK1/ SMAD1/5/8 signaling in 
HUVECs. 
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Methods 
As described in section 3.2. 
Results 
 Activation of cAMP Generation  4.3.1
To determine if cAMP plays a role in vasculogenesis or phosphorylation of 
SMAD1/5/8 we first assessed whether GPER activation leads to cAMP generation in 
HUVECs. Therefore we used a direct competitive cAMP ELISA. HUVECs were pre-
treated with mm-IBMX (100 nmol/L), a phosphodiesterease inhibitor, before the 
addition of G15 (100 nmol/L) or G1 (100 nmol/L). Activation of GPER with G1 
induced cAMP generation from 100±2% to 122±3.3% (p<0.05 relative to control), and 
this effect was significantly abrogated by G15 to 87±4.5% (p<0.05 relative to G1 
treated HUVECs, Figure 27). Since GPER activation induced cAMP generation in 
HUVECs, it may play an important role in vasculogenesis via the phosphorylation of 
SMAD1/5/8. 
   
 
 
 
 
 
Figure 27. Bar graph of direct cAMP ELISA, demonstrating the effects of GPER specific agonist (G1; 
100 nmol/L) and GPER specific antagonist (G15; 100 nmol/L) on the generation of cAMP. HUVECs 
were starved overnight and pre-treated with PDE-inhibitor mm-IBMX (100 nmol/L) for 10min, followed 
by G15 for 10 min and G1 for additional 15 min. ELISA was performed according to protocol, 
including the acetylation step, and measured at the TECAN plate reader at 405 nm. The cAMP 
concentration (pmol/mg) was normalized to total protein concentration (mg/ ml), obtained by BCA. 
The corresponding value for the control (100%) is 18.12 pmol cAMP/ mg of total protein. Values 
represent mean±SEM, n=3, *P<0.05 relative to control, §P<0.05 relative to G1, using ANOVA test.  
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 GPER-induced Capillary Formation and SMAD1/5/8 Phosphorylation 4.3.2
depends on cAMP/ PKA  
To study the impact of cAMP-signaling on the ALK1/ SMAD1/5/8 pathway and 
vasculogenesis in HUVECs we employed different pharmacological inhibitors, i.e. 
DDA, an adenylate cyclase specific inhibitor, and PKI (5-24), a PKA-specific inhibitor. 
As shown in Figure 28A, G1 (10 nmol/L)-induced phosphorylation of SMAD1/5/8 was 
significantly inhibited in the presence of DDA (1 µmol/L) from 210±17.4% to 65±7.9% 
(p<0.05 relative to G1 treated HUVECs). Similar results were obtained for capillary 
formation, where DDA (1 µmol/L) abrogated the stimulatory effects of G1 by 83% 
(p<0.05 relative to G1 treated HUVECs, Figure 28B). Next, we applied PKI (5-24) (10 
nmol/L) and observed a decrease in G1-induced pSMAD1/5/8 from 205±16.4% to 
100±7.9% and capillary formation from 141±5.7% to 78±13.2% (p<0.05 relative to G1 
treated HUVECs, Figure 28C/ D). These findings provide evidence that Gαs-
Adenylylcyclase-cAMP is the signaling cascade via which GPER induces SMAD1/5/8 
phosphorylation and capillary formation in HUVECs. However, based on our findings, 
the precise mechanism by which PKA targets the ALK1/ SMAD1/5/8 pathway 
remains unclear. 
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Figure 28. Panel A, Bar graph and representative Western Blot, demonstrating effects of GPER 
specific agonist (G1; 10 nmol/L) and Adenylate cyclase specific inhibitor (DDA, 1µmol/L) on the 
phosphorylation of SMAD1/5/8. Pre-starved HUVECs were treated with the inhibitor for 30 min, 
and subsequently G1 was added for additional 45 min. Values represent mean±SEM, n=4, 
*P<0.05, relative to control, §P<0.05 relative to G1, using ANOVA test. Panel B, Bar graph and 
representative photomicrographs showing the effects of GPER specific agonist (G1; 10 nmol/L), 
and Adenylate cyclase specific inhibitor (DDA, 1µm/L) on capillary formation by HUVECs. Cells 
were plated in a density of 4000 cells per well on a matrigel–coated 15-well µ- slides and 
pretreated with the inhibitor for 30 min, subsequently G1 was added. After incubation overnight 
the capillary formation was assessed microscopically (see Method section 3.2.2). Values 
represent mean±SEM, n=4, *P<0.05 relative to control, §P<0.05 relative to G1 using ANOVA test. 
Panel C, Bar graph and representative Western Blot, demonstrating effects of GPER specific 
agonist (G1; 10 nmol/L) and PKA inhibitor PKI (5-24) (PKI, 10 nmol/L) on the phosphorylation of 
SMAD1/5/8. Pre-starved HUVECs were pretreated with inhibitor for 30 min, subsequently G1 was 
added for additional 45 min. Values represent mean±SEM, n=5, *P<0.05, relative to control, 
§P<0.05 relative to G1 using ANOVA test. Panel D, Bar graph and representative 
photomicrographs showing the effects of GPER specific agonist (G1; 10 nmol/L) and PKA inhibitor 
PKI (5-24) (PKI, 10 nmol/L) on capillary formation. Cells were plated in a density of 4000 cells per 
well on a matrigel–coated 15-well µ- slides and pretreated with inhibitor for 30 min, and 
subsequently BMP2 was added. After incubation overnight the capillary formation was assessed 
microscopically (see Method section 3.2.2). Values represent mean±SEM, n=4, *P<0.05 relative 
to control, §P<0.05 relative to G1 using ANOVA test.
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 Role of cAMP/ PKA in Capillary Formation and ALK1/ SMAD1/5/8 4.3.3
Pathway 
To investigate whether ALK1 or pSMAD1/5/8 is a target of PKA in HUVECs, we used 
DBcAMP (a stable autolog of the endogenous cAMP), Noggin (the endogenous 
antagonistic ligand of BMP receptor type I) and ALK1Fc (the specific antagonizing 
antibody for ALK1). We first studied the role on pSMAD1/5/8 and observed induction 
upon DBcAMP (100 µg/ml) treatment to 221±21.13% (p<0.05 relative to control). 
ALK1Fc (100 ng/ml) significantly abrogated DBcAMP-induced phosphorylation of 
SMAD1/5/8 from 221±21.13% to 98±37.6%, whereas Noggin (100 ng/ml) further 
increased the stimulatory effects of DBcAMP to 287±56.1 % (p<0.05 relative to 
DBcAMP treated HUVECs, Figure 29A). Next, the modulatory effects of the same 
antagonists were tested on DBcAMP-induced microvessel formation by HUVECs. 
DBcAMP (100 µg/ml) treatment induced capillary formation by 74%±10.9% (p<0.05 
relative to control), and this effect was abrogated by ALK1Fc (100 ng/ml) to 84±7.4% 
but not altered by Noggin (100 ng/ml) to 173±8.5% (p<0.05 relative to DBcAMP 
treated HUVECs, Figure 29B). Based on these findings the participation of TGFβ 
receptor II, as a target of PKA, can be excluded, because the effects of DBcAMP on 
SMAD1/5/8 phosphorylation or capillary formation were not altered by Noggin. In 
contrast, ALK1Fc decreased both DBcAMP-induced pSMAD1/5/8 and capillary 
formation, suggesting that PKA directly activates ALK1 and therefore stimulates 
SMAD1/5/8 signaling and vasculogenesis in HUVECs. 
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  Figure 29. Panel A, Bar graph and representative Western Blot, demonstrating the effects of cell permeable cAMP analogue (DBcAMP; 100µg/ml), BMP inhibitor (Noggin, 100 ng/ml) and ALK1 
specific antagonizing Antibody (Alk1Fc; 100 ng/ml) on the phosphorylation of SMAD1/5/8. Pre-
starved HUVECs were treated with the inhibitors for 30 min, subsequently DBcAMP was added for 
additional 45 min. Values represent mean±SEM, n=3, *P<0.05, relative to control, §P<0.05 relative 
to DBcAMP, using ANOVA test. Panel B, Bar graph and representative photomicrographs showing 
the effects of cell permeable cAMP analog (DBcAMP; 100 µg/ml), BMP inhibitor (Noggin, 100 
ng/ml) and ALK1 specific antagonizing Antibody (Alk1Fc; 100 ng/ml) on capillary formation by 
HUVECs. Cells were plated at a density of 4000 cells per well on a matrigel–coated 15-well µ- 
slides and pretreated with the inhibitors for 30min, subsequently DBcAMP was added. After 
incubation overnight capillary formation was assessed microscopically (see Method section 3.2.2). 
Values represent mean±SEM, n=3, *P<0.05 relative to control, §P<0.05 relative to DBcAMP using 
ANOVA test.   
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Discussion 
The second messenger cAMP is an omnipresent signal transducer for cells and its 
production is induced upon estrogen treatment [104, 233-236]. Upon binding of a 
ligand to a GPCR coupled to a Gαs subunit, cAMP is synthesized from adenosine 
triphosphate (ATP) by the enzyme adenylyl cyclase. Generation of cAMP in turn 
activates several proteins like nucleotide-gated ion channels and protein kinase A 
(PKA). Subsequently, PKA phosphorylates effector proteins at serine or threonine 
residues and therefore activates them [232]. These activated effector proteins further 
mediate the inhibitory actions on the proliferation of SMCs [104, 291], vasodilation of 
arteries in vivo [236, 290, 295] and the improvement of endothelial function by 
inducing barrier function [296, 297]. Additionally, membrane-permeable cAMP 
analogues have been shown to induce VEGF expression and activate the PI3K/Akt 
and eNOS/NO pathway, thereby inducing angiogenesis [191, 237-239]. Based on 
these findings, it is generally accepted that the protective effects of estrogens on the 
cardiovascular system are in part mediated by the induction of cAMP signaling [104, 
236, 289-291]. Recent studies provide evidence that estrogen signaling via GPER 
induces cAMP production in MCF7 cells [39, 41], murine pancreatic islets [294] and 
VSMCs of hypertensive mREN2.Lewis rats [295]. 
To our knowledge, to date, there are no reports demonstrating that GPER stimulates 
cAMP signaling in ECs. Hence we investigated whether GPER activation results in 
cAMP production by cultured HUVECs. We quantified cAMP levels following ligand 
treatment by using a direct competitive ELISA and observed a significant increase in 
cAMP in HUVECs treated with G1. This G1-induced cAMP formation was inhibited by 
pre-treatment with GPER specific antagonist G15, suggesting a specific role of 
GPER in the induction of cAMP in HUVECs. Consistent with the findings of other 
studies [39, 41, 294, 295], our results indicate that GPER activation increases cAMP 
levels. More importantly, this is the first study to report induction of cAMP production 
in endothelial cells following GPER activation. 
Several studies have shown that cell-permeable analogues of cAMP induce the 
expression of VEGF and activate pro-angiogenic signaling such as the PI3K/ Akt and 
the eNOS/ NO pathway, thereby inducing angiogenesis [191, 237-239]. Hence, we 
decided to investigate whether cAMP mediates GPER induced ALK1/ SMAD1/5/8 
signaling and vasculogenesis in HUVECs. To achieve this goal, pharmacological 
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inhibitors for the components of the cAMP signaling pathway, i.e. for adenylyl cyclase 
and for PKA, were applied. We were able to block G1-induced SMAD1/5/8 
phosphorylation and G1- stimulated capillary formation with DDA, a specific adenylyl 
cyclase inhibitor, and with PKI (5-24), a specific PKA inhibitor. These findings indicate 
that GPER-induced vasculogenesis and phosphorylation of SMAD1/5/8 in HUVECs 
are potentially mediated via cAMP signaling.  
In this context, De Lorenzo et al. reported decreased tumorigenesis in adenylyl 
cyclase deficient mice [298] and Namkoong et al. reported that forskolin-induced 
angiogenesis was impaired after PKA-inhibitor PKI application [239]. In line with 
these findings and several other studies showing that cAMP and estrogens are 
important for capillary formation in ECs [100, 191, 237-239, 250], we postulate that 
cAMP is involved in GPER-induced vasculogenesis in HUVECs.  
Furthermore, our observation that DBcAMP mediates G1-stimulated phosphorylation 
of SMAD1/5/8 is supported by the finding that cAMP enhances BMP4-induced gene 
expression of ID-1, which is the target gene of pSMAD1/5/8 [299]. Moreover, Ghayor 
et al. reported that cAMP increases BMP2 signaling in osteoclasts via PKA and 
MKP1 dependent mechanism [300]. The fact that the promoter region of the ID-1 
gene contains both, a BMP-responsive element BRE and a cAMP responsive 
element CRE [301-303], suggests a synergy between cAMP and TGFβ/ BMP 
signaling and, as well as the other above findings, support our hypothesis that cAMP 
might partly be responsible for GPER induced ALK1/ SMAD1/5/8 signaling. More 
experiments, including the assessment whether cAMP induces BMP2 secretion, are 
needed to fully elucidate this synergy/ crosstalk between cAMP and TGFβ/ BMP/ 
ALK1/ SMAD1/5/8 in ECs. 
ALK1 is activated following phosphorylation of serine and threonine residues at the 
GS domain by TGFβRII. Upon activation, ALK1 recruits and phosphorylates 
SMAD1/5/8 at the C-terminal serine 463 and serine 465 residues [304], leading to the 
formation of complex with SMAD4. This complex translocates into the nucleus and 
activates transcription of the target gene ID-1 [145-147], which induces migration, 
proliferation and tube formation in ECs [149, 153]. Activation of PKA by cAMP results 
in phosphorylation of effector proteins at serine or threonine residues and their 
activation [232]. Hence, it is possible that PKA also catalyzes the phosphorylation of 
ALK1 and/ or SMAD1/5/8. With regard to the observation that pharmacological 
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inhibition of PKA reduced G1-stimulated pSMAD1/5/8, we hypothesize that PKA 
might play a role in activating ALK1 or SMAD1/5/8.  
To distinguish whether PKA targets ALK1 or SMAD1/5/8, we applied DBcAMP 
(analogue of endogenous cAMP), Noggin (endogenous antagonistic ligand of BMP 
receptor type I) and ALK1Fc (specific antagonizing antibody for ALK1). Capillary 
formation and phosphorylation of SMAD1/5/8 were significantly stimulated with 
DBcAMP treatment in HUVECs. Moreover, pre-treatment with ALK1Fc significantly 
decreased DB-cAMP induced vasculogenesis and SMAD1/5/8 phosphorylation, 
whereas Noggin had no effect. These results suggest that cAMP-activated PKA 
stimulates ALK1, but not SMAD1/5/8. However, it is possible that cAMP induces BMP 
production/ secretion and thereby activates ALK1/ SMAD1/5/8 signaling. But the fact, 
that Noggin blocked the stimulatory effects of DBcAMP on capillary formation and 
SMAD1/5/8 phosphorylation, argues against a role of BMP in mediating these 
effects. Still, further experiments are required to rule out a potential production/ 
secretion of BMP upon treatment with DB-cAMP in HUVECs. Ji and Andrisani et al. 
showed that PKA stimulates pSMAD1 by activating ERK, which in turn leads to 
phosphorylation of SMAD1 [305], supporting our notion that cAMP- stimulated PKA 
may activate ALK1/ SMAD1/5/8 signaling.  
In summary, the above findings indicate that there is a functional crosstalk between 
cAMP/ PKA and TGFβ signaling. However, more in depth research is needed to fully 
elucidate the interactions within this signaling cascade. Our results, obtained in 
HUVECs, suggest that PKA activates ALK1 directly, leading to SMAD1/5/8 
phosphorylation and thereby stimulating vasculogenesis. More importantly, we 
propose that GPER induced cAMP production activates PKA and thus initiates the 
ALK1/ SMAD1/5/8 signaling cascade, leading to increased capillary formation in 
HUVECs. 
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 The PI3K/ Akt Pathway mediates GPER-induced Capillary 4.4
Formation in Endothelial Cells  
Objective 
The PI3K/ Akt pathway is a prominent pathway, which regulates multiple cellular 
functions including metabolism, growth, proliferation, survival, transcription, protein 
synthesis and angiogenesis. Since GPER activation induced capillary formation, we 
wanted to investigate whether GPER activates PI3K/ Akt signaling pathway is 
involved in GPER-induced vasculogenesis and ALK1/ SMAD1/5/8 signaling. 
Introduction 
The PI3K/ Akt pathway plays a central role in controlling endothelial cell viability [180, 
181]. Migration and formation of capillary like structures is essential for endothelial 
cells to form angiogenesis in vivo. Moreover, Akt protein accumulates in endothelial 
tip cells with increased migratory abilities [193]. The important role of the PI3K/ Akt 
pathway in mediating angiogenesis has been supported by several studies [181, 189, 
190]. Due to its mitogenic and angiogenic role, PI3K/ Akt signaling is also involved in 
tumorigenesis and regulates estrogen induced cell proliferation in ER+ breast cancer 
[194, 195] and endometrial cancer [196]. Importantly, specific PI3K/ Akt inhibitors are 
used clinically as anti-angiogenic agents in cancer [197, 198] and breast cancer 
therapy [195]. Furthermore, estrogen stimulated angiogenesis has been reported to 
be mediated via the PI3K/ Akt pathway [100, 240, 241]. Recently, it has also been 
shown that GPER mediated estrogen signaling promotes survival of MCF-7 cells 
[306] and migration of renal carcinoma cells in a PI3K/ Akt dependent fashion [307]. 
Taken together these findings implicate PI3K/ Akt as a key player in angiogenesis. 
Hence, in the present study we assessed whether GPER activation induces PI3K/ 
Akt signaling in HUVECs and stimulates vasculogenesis. Moreover, we studied 
whether there is an association between the two pro-angiogenic pathways PI3K/ Akt 
and ALK1/ SMAD1/5/8 in our HUVECs model. 
Methods 
As described in Section 3.2. 
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Results 
 Activation of PI3K/ Akt Pathway 4.4.1
Treatment with G1 (10 nmol/L) significantly induced Akt phosphorylation in HUVECs 
from 100% to 178±24.4% (p<0.05 relative to control). Upon pre-treatment with G15 
(100 nmol/L), G1-induced Akt phosphorylation was reduced to 43±8.6% (p<0.05 
relative to G1 treated HUVECs, Figure 30A). The regulatory role of GPER on Akt 
phosphorylation was further confirmed in GPER-silenced HUVECs, in which the 
treatment with G1 (10 nmol/L) and E2 (10 nmol/L) mildly attenuated the 
phosphorylation of Akt from 223±72.9% to 169±30.1% and 127±12.5%, respectively 
(p>0.05 relative to GPER silenced control). Whereas, G1 and E2 induced the 
phosphorylation of Akt in HUVECs, treated with scrambled siRNA, from 100% to 
162±31.2% and 127±12.5%, respectively (p<0.05 relative to scrambled control, 
Figure 30B). 
 
 
 
 
 
Figure 30. Bar graphs and representative Western Blots showing the effect on Akt phosphorylation 
Panel A, Effects of GPER agonist (G1; 10 nmol/L) and GPER antagonist (G15; 100 nmol/L), Panel 
B, Effects of GPER specific agonist (G1; 10 nmol/L) and estradiol (E2; 10 nmol/L) in HUVECs, 
transfected with scrambled siRNA (50 nmol/L) or GPER siRNA (50 nmol/L). Pre-starved HUVECs 
were treated for 30 min with the inhibitor, followed by additional 45 min with G1. Values represent 
mean±SEM, n=3, *P<0.05 relative to control or scrambled control, §P<0.05 relative to G1 treated 
HUVECs using ANOVA test.  
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 Role of PI3K/ Akt Pathway in GPER-induced Capillary Formation 4.4.2
Our findings that GPER activation induces the PI3K/ Akt pathway, together with the 
fact that PI3K/ Akt induces capillary formation by ECs led us to postulate and assess 
the role of G1- induced Akt signaling in mediating vasculogenesis of HUVECs.  
In order to scrutinize this role, we utilized the pharmacological PI3K inhibitor 
LY294002 (LY; 5 µmol/L). First we assessed the impact on G1 (10 nmol/L) -induced 
Akt phosphorylation, which was abrogated upon LY treatment from 194±20% to 
77±20.8% (p<0.05 relative to G1 treated HUVECs, Figure 31A). Similar results were 
obtained in capillary formation, where the stimulatory effect of G1 was reduced by LY 
from 152±3.7% to 54±18.5% (p<0.05 relative to G1 treated HUVECs, Figure 31B). 
Our data suggests that GPER-induced vasculogenesis is mediated via the activation 
of the prominent pro-angiogenic PI3K/ Akt pathway.  
 
 
 
 
 
 
 
Figure 31. Bar graphs, representative Western Blot and representative photomicrographs showing 
the effects on the phosphorylation of Akt and capillary formation in HUVECs. Panel A, Effect of 
GPER agonist (G1; 10 nmol/L) +/- PI3K-inhibitor LY294002 (LY; 5 µmol/L) on the phosphorylation of 
Akt. Pre-starved HUVECs were treated for 30 min with the inhibitor, followed by 45 min with G1. 
Values represent mean±SEM, n=3, *P<0.05 relative to control §P<0.05 relative to G1 using ANOVA 
test. Panel B, Bar graph and representative photomicrographs showing the effects of GPER specific 
agonist (G1; 10 nmol/L) and PI3K-inhibitor (LY294002; 5 µmol/L) on capillary formation. The cells 
were plated at a density of 4000 cells per well on a matrigel–coated 15-well µ- slides and pretreated 
with the inhibitor for 30min, G1 was then added. After incubation overnight, capillary formation was 
assessed microscopically (see Method section 3.2.2). Values represent mean±SEM, n=5, *P<0.05 
relative to control, §P<0.05 relative to G1 using ANOVA test. 
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 GPER-induced Capillary Formation depends on Crosstalk between 4.4.3
ALK1/ SMAD1/5/8 and PI3K/ Akt Pathway  
Our findings show that GPER- induced vasculogenesis is mediated via two important 
pro-angiogenic pathways: the ALK1/SMAD1/5/8 and the PI3K/Akt pathway. 
Vasculogenesis is a complex, fragile action of ECs and involves many different 
signaling pathways and cellular mechanisms. Since both pathways are important for 
GPER-induced vasculogenesis, we examined whether there is a link between ALK1/ 
SMAD1/5/8 and PI3K/ Akt pathways in HUVECs.  
To accomplish this goal we utilized ALK1Fc (100 ng/ml) a specific antagonizing 
antibody and pharmacological inhibitor for ALK1, and SJN2511 (100 nmol/L), a 
specific antagonist for ALK5, and assessed their impact on phosphorylation of Akt in 
HUVECs. As shown in Figure 32A, treatment with G1 (10 nmol/L) induced Akt 
phosphorylation and this stimulatory effect was significantly abrogated by Alk1Fc 
from 178% to 79±13.1% (p<0.05 relative to G1 treated HUVECs), whereas SJN did 
not alter G1-induced Akt phosphorylation, which was 178% and 174±25% in absence 
and presence of SJN (p>0.05 relative to G1 treated HUVECs). To further investigate 
the possible link, we silenced SMAD1 in HUVECs, by transfecting them with SMAD1 
specific siRNA (50 nmol/L). Upon treatment with BMP9 (10 ng/ml) phosphorylation of 
Akt was significantly reduced in SMAD1-silenced HUVECs as compared to HUVECs 
transfected with scrambled siRNA, from 100% in scrambled control to 50±18.7% in 
SMAD1 silenced (p<0.05 relative to scrambled control, Figure 32B). Next, we applied 
the pharmacological PI3K inhibitor LY294002 (LY; 5 µmol/L) prior to G1-treatment 
and observed a significant decrease in phosphorylation of SMAD1/5/8 by 117% 
(p<0.05 relative to G1 treated HUVECs, Figure 32C). Taken together, these 
observations suggest a crosstalk between ALK1/ SMAD1/5/8 and PI3K/ Akt, 
moreover we hypothesize that this interaction is at the level of SMAD1/5/8 and Akt, 
as silencing of SMAD1 abrogated phosphorylation of Akt.  
Results 
 
95 
 
 
 
 
 
 
 
 GPER-induced Capillary Formation and SMAD1/5/8 Phosphorylation 4.4.4
does not depend on MMP 
One of the signaling cascades leading to PI3K/Akt activation is the Matrix Metallo 
Proteinase (MMP). Stimulation of MMP induces EGF release and activates the EGF-
Receptor, which subsequently stimulating MAPK or PI3K and their downstream 
signals. To completely understand the role of PI3K/ Akt in GPER-induced 
Figure 32. Bar graphs and representative Western Blots demonstrating the effects on 
phosphorylation of AKT in HUVECs by (Panel A), GPER specific agonist (G1; 10 nmol/l)+/- ALK 5 
specific antagonist (SJN; 100 nmol/L) or ALK 1 specific antagonizing antibody (Alk1Fc; 100 ng/ml); 
and effects of (Panel B), BMP9 (10 ng/ml) in cells, transfected with SMAD1 specific siRNA (50 
nmol/L) or scrambled siRNA (50 nmol/L). HUVECs were starved and pre-treated with the antagonists 
for 30 min, G1 or BMP9 was then added for 45 min. Panel C, Bar graph and representative Western 
Blot showing the effects of GPER agonist (G1; 10nmol/L) and PI3K inhibitor LY294002 (LY; 5 µmol/L) 
on the phosphorylation of SMAD1/5/8. Pre-starved HUVECs treated for 30 min with the inhibitor, 
followed by 45min with G1. Values represent mean±SEM, n=3, *P<0.05 relative to control or 
scrambled control, §P<0.05 relative to G1, using ANOVA test. 
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vasculogenesis and phosphorylation of SMAD1/5/8 we investigated the impact of 
MMP. To accomplish this, we applied Batimastat (B; 5 µm/L), the MMP specific 
inhibitor. As shown in Figure 33A/ B, treatment with B mildly increased G1 (10 
nmol/L)-induced phosphorylation of SMAD1/5/8 and capillary formation from 
255±35.2% to 344±34% and from 157±0.5% to 166±18%, respectively (p<0.05 
relative to control). These results reveal that GPER-induced vasculogenesis and 
phosphorylation of SMAD1/5/8 is not dependent of MMP, even though it is known to 
activate PI3K/ Akt signaling. 
 
 
 
 
 
 
Discussion 
The PI3K/ Akt/ pathway is highly conserved and controls multiple cellular functions 
including cell metabolism, growth, proliferation, survival, transcription, protein 
synthesis and angiogenesis [180, 181]. Several studies have reported the important 
regulatory role of PI3K/ Akt in postnatal blood vessel formation and processes related 
to angiogenesis [181, 189, 190]. Furthermore, the PI3K/ Akt pathway has been 
Figure 33. Panel A, Bar graph and representative Western Blot demonstrating the effects of GPER 
specific agonist (G1; 10 nmol/l) and MMP specific inhibitor Batimastat (B; 5 µm/L) on SMAD1/5/8 
phosphorylation. HUVECs were starved and pre-treated with the antagonists for 30 min and G1 was 
then added for 45 min. Values represent mean±SEM, n=3, *P<0.05 relative to control using ANOVA 
test. Panel B, Bar graph and representative photomicrographs showing the effects of GPER specific 
agonist (G1; 10 nmol/L) and MMP specific inhibitor Batimastat (B; 5 µm/L) on capillary formation by 
HUVECs. The cells were plated at a density of 4000 cells per well on a matrigel–coated 15-well µ- 
slides and pretreated with the inhibitor for 30min, G1 was then added. After incubation overnight the 
capillary formation was assessed microscopically (see Method section 3.2.2). Values represent 
mean±SEM, n=3, *P<0.05 relative to control using ANOVA test. 
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shown to be an important mediator of estrogen stimulated angiogenesis in ECs [100, 
240, 241]. Very recently, it was reported that GPER mediated estrogen signaling is 
transduced via the PI3K/ Akt pathway and induces survival of MCF-7 cells [306] and 
migration of renal carcinoma cells [307].  
Therefore, the aim of this study was to investigate whether GPER activation induced 
PI3K/ Akt signaling in HUVECs. Our finding that treatment with GPER specific 
agonist G1 significantly increased Akt phosphorylation, suggests that G1 activates 
PI3K/ Akt signaling. This is in line with the finding of Guan et al., who showed that G1 
treatment specifically increases Akt phosphorylation in renal carcinoma cells, thereby 
promoting metastasis [307]. Our observation that GPER specific antagonist G15 
significantly inhibited G1-induced Akt phosphorylation, indicates a prominent and 
specific role of GPER in activating PI3K/ Akt signaling. This is further supported by 
the finding that in HUVECs, transfected with GPER specific siRNA, the stimulatory 
effects of G1 and E2 were lost. In contrast to GPER siRNA treated HUVECs, G1 and 
E2 significantly induced Akt phosphorylation in HUVECs, transfected with scrambled 
siRNA. Interestingly, compared to HUVECs treated with scrambled controls, pAKT 
was significantly upregulated in GPER silenced controls. Other studies using GPER 
siRNA have observed a decrease in G1-stimulated proliferation of CAFs [258] and 
reduction in proliferation, migration and invasion of SKOV3 cells [259]. These 
contrasting outcomes could possibly be due to the use of different cell lines. 
Moreover, contribution of the use of different GPER siRNAs as a possible 
explanation can be excluded as pooled GPER siRNAs were used in the present 
study.  
GPER is coupled to heterotrimeric G-proteins Gα/ Gβ/ Gγ, each exhibiting specific 
signaling cascades. Different subtypes exist from these heterotrimeric G-proteins and 
for GPER the subtypes Gαs [41] and Gβγ [38] have been proposed. With regard to 
our results, we suggest that upon silencing of GPER, still unknown pro-angiogenic or 
pro-survivor subunits of GPER may have been exposed, thereby leading to the 
stimulation of Akt phosphorylation in HUVECs. Nevertheless, silencing of GPER 
abrogated the stimulatory effects of G1 and E2, indicating the importance of GPER in 
mediating the stimulation of Akt phosphorylation by estrogens in HUVECs. 
Although the regulatory role of PI3K/ Akt signaling in estrogen-mediated 
angiogenesis has already been proven [100, 240, 241], it is still not known whether 
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this pathway mediates GPER-stimulated capillary formation. Hence, we investigated 
whether PI3K/ Akt signaling regulates G1-induced vasculogenesis in HUVECs. Using 
a specific PI3K inhibitor, LY294002, we observed a significant inhibition of both, G1-
induced phosphorylation of Akt and G1-stimulated vasculogenesis in HUVECs. 
These observations are consistent with other reports, demonstrating the inhibitory 
effect of LY294002 on G1-induced upregulation of MMP9 in AHCN and OS-RC-2 
cells [307]. Furthermore, application of wortmannin, another specific PI3K inhibitor, 
significantly abolished G1-mediated improvement of functional recovery and reduced 
infarct size in isolated hearts of Sprague Dawley rats [109]. In summary, these 
findings indicate that the PI3K/ Akt pathway plays a potential role in GPER-mediated 
estrogen signaling. The PI3K/ Akt pathway is known to be an important pro-
angiogenic pathway and PI3K inhibition may generally inhibit vasculogenesis, also in 
response to other factors. But the fact that G1- induced phosphorylation of Akt was 
inhibited by pre-treatment with G15, suggests that GPER-stimulated vasculogenesis 
in HUVECs is, in part, mediated by PI3K/ Akt signaling.  
Recently, TGFβ pathway components have been shown to interact with other 
signaling pathways [308]. In section 4.2 we showed that GPER-activation induces 
ALK1/ SMAD1/5/8 signaling and in this section we demonstrate that GPER-activation 
promotes PI3K/ Akt signaling, suggesting that both pathways are partly responsible 
for G1-stimulated vasculogenesis. Hence, we further assessed whether GPER-
mediated PI3K/ Akt and ALK1/ SMAD1/5/8 interact with/ or regulate each other in 
HUVECs. To investigate this interaction/ regulation, we employed ALK1Fc 
(neutralizing antibody for ALK1), SJN2511 (specific ALK5- inhibitor) and LY294002 
(specific PI3K inhibitor). Our findings that G1-induced Akt phosphorylation was 
significantly inhibited by ALK1Fc, whereas SJN had no modulatory effects on the 
phosphorylation of Akt, provides evidence for an interaction between GPER-induced 
PI3K/ Akt signaling with ALK1/ SMAD1/5/8 but not ALK5 signaling. This contention is 
further supported by the fact that silencing of SMAD1 in HUVECs was accompanied 
with a significant reduction in pAkt upon BMP9 treatment; moreover, G1-induced 
phosphorylation of SMAD1/5/8 was abolished upon pre-treatment with LY294002. 
Taken together, our results suggest that both GPER-induced pro-vasculogenic 
pathways PI3K/ Akt and ALK1/ SMAD1/5/8 interact with each other to induce 
vasculogenesis by HUVECs. Based on our observations that pAkt is reduced upon 
SMAD1 silencing, we suggest that the interaction and regulation occurs at the level 
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of Akt and SMAD1/5/8. Several studies have shown that TGFβ signaling also 
activates non-SMAD pathways. For example PI3K/ Akt activation [161, 162] has 
been implicated in TGFβ induced cell survival and epithelial-to-mesenchymal-
transition (EMT), which leads to the acquirement of motile and invasive properties 
[309, 310], needed for angiogenesis. Lee et al. [311] reported activation of PI3K/ Akt 
signaling upon BMP9 treatment was independent of ALK1 and ALK5, but dependent 
on endoglin, an accessory type III receptors of TGFβ signaling. In summary, based 
on our observations and the above findings a crosstalk/ interaction between these 
two pathways is evident, however more research is needed to dissect the 
mechanisms. Nevertheless, to our knowledge, our findings provide the first evidence 
for an interaction between PI3K/ Akt and ALK1/ SMAD1/5/8 and a possible regulation 
of each other at the level of Akt and SMAD1/5/8 in HUVECs. 
Stimulation of MMP by several growth factors triggers EGF release, which activates 
the EGF receptor and subsequently MAPK or PI3K and their downstream signals 
[181]. To complete the understanding of PI3K/ Akt signaling in GPER-induced 
vasculogenesis and GPER-mediated phosphorylation of SMAD1/5/8, we also 
investigated the impact of MMP. To achieve this goal, we applied Batimastat, a 
pharmacologically specific inhibitor for MMP, and observed no reduction of G1-
induced SMAD1/5/8 phosphorylation and G1-stimulated vasculogenesis. This finding 
is in contrast to other studies, which showed that Batimastat inhibited in vivo 
angiogenesis in liver metastases of B16F1 melanoma cells [312] and in murine 
hemangioma [313]. Furthermore, Wang et al. indicated that MMP activates TGFβ 
signaling in VSMCs of rats [314]. These discordant findings may be due to the use of 
different experimental models, or due to the effects which are specifically associated 
with G1 or its impact on MMP. Our findings suggest that MMP may not be involved in 
GPER-mediated stimulation of SMAD1/5/8 and GPER-induced vasculogenesis, even 
though the downstream PI3K/ Akt signaling cascade importantly regulates these 
processes. However, the lack of a positive control for Batimastat activity does not 
enable us to conclude this for certain. Therefore, the activity of Batimastat has to be 
assessed using enzymatic activity assays in future studies.  
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 The Role of NO/ VEGF-A Pathway in GPER-induced Capillary 4.5
Formation by Endothelial Cells 
Objective 
Our earlier findings suggest that GPER-induced vasculogenesis is in part dependent 
on the activation of PI3K/ Akt pathway. PI3K/ Akt signaling is important for generating 
NO and inducing VEGF-A expression. Both VEGF-A and NO are important 
endothelial survival factors, which induce EC proliferation, migration and 
angiogenesis and stimulate/ regulate each other in a reciprocal fashion. Hence, we 
investigated whether GPER activation induces eNOS activity and NO production and 
whether GPER upregulates VEGF expression. Moreover, we assessed the role of 
NO and VEGF on GPER-stimulated vasculogenesis in HUVECs. 
Introduction 
The formation of new capillaries (angiogenesis or neovascularization) is a carefully 
balanced process, controlled by a multitude of growth factors and signalling 
pathways. The fundamental regulatory role of VEGF [191] and NO [192] in 
angiogenesis has been intensively studied and established. The loss of a single 
allele of the VEGF gene is associated with defective vascularization and embryonic 
lethality [205, 206], and angiogenic properties of NO are implicated in promoting 
survival [213, 214], proliferation [215, 216] and migration [217, 218] of endothelial 
cells. Moreover, the reciprocal interaction of VEGF and NO has been reported to be 
essential for angiogenesis. NO is both, a downstream and an upstream mediator of 
VEGF-mediated capillary formation. VEGF activates PI3K/ Akt, leading to activation 
of eNOS and NO generation. Under normoxic conditions, NO has been shown to 
induce VEGF expression [188], thereby enhancing EC cell proliferation [215, 216] 
and inducing capillary formation. More importantly, estrogen induced angiogenesis 
has been reported to be dependent on VEGF and NO [99]. Studies also suggest that 
GPER-mediated vasodilation is reliant on endothelium-derived NO, resulting in 
relaxation of rat aorta, carotid, mesenteric and porcine coronary arteries [108, 116, 
117].  
Hence, we assessed whether GPER activation induces eNOS phosphorylation, 
thereby leading to NO production and whether GPER modulates VEGF-A expression 
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in HUVECs. Furthermore, we investigated the role of NO and VEGF in GPER-
induced vasculogenesis in HUVECs. 
Methods 
As described in section 3.2. 
Results 
 Activation of eNOS and NO Production  4.5.1
We examined whether GPER activation phosphorylates eNOS and leads to increase 
in NO production by HUVECs. Treatment with G1 (10 nmol/L) induced eNOS 
phosphorylation from 100% to 149%, and this effect was abrogated by G15 (100 
nmol/L) and ICI 182,780 (100 nmol/L) to 47% and 27%, respectively (Figure 34A). 
Moreover, we observed a significant increase in NO formation by HUVECs treated 
with G1 (10 nmol/L) and E2 (10 nmol/L), which increased from 100±2.6% to 189±3% 
and 175±2.3%, respectively (p<0.05 relative to control, Figure 34B). In summary, 
these findings provide evidence that activation of GPER induces eNOS and NO 
generation.  
 
 
 
 
 
Figure 34. Panel A, Bar graph and representative Western Blot showing the effects of GPER 
specific agonist (G1; 10 nmol/L), in the presence or absence of the GPER specific antagonist (G15, 
100 nmol/L) or the ER unspecific inhibitor ICI 182-780 (ICI, 100 nmol/L) on the phosphorylation of 
eNOS. Pre-starved HUVECs were pretreated with the inhibitors for 30 min, subsequently G1 was 
added for 45 min. n=1; Panel B, Bar graph representing the effects of GPER specific agonist (G1, 10 
nmol/L) and estradiol (E2; 10 nmol/L) on NO production. Pre-starved HUVECs were treated with 
DAF-2DA (1 µmol/L) in the absence of light for 45 min, followed by treatment with G1 or E2 for 
15min. Excitation was measured at the TECAN plate reader with 450 nm. Values represent 
mean±SEM, n=3, *P<0.05 relative to control using ANOVA test.  
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 Activation of VEGF-A Secretion  4.5.2
Next we studied the impact of GPER activation on VEGF-A protein expression. In 
HUVECs treated with G1 (10 nmol/L) for 45 min a significant increase in VEGF-A 
levels was observed and was increased by 97±31.7% (p<0.05 relative to control). 
G1-stimulated VEGF-A expression was inhibited in cells pre-treated with G15 (100 
nmol/L) by 118±20% (p<0.05 relative to G1 treated HUVECs, Figure 35A). Because 
the treatment time of 45 min is too short for protein expression, we also assessed the 
mRNA levels of VEGF-A using RT PCR: As shown in Figure 35B treatment with G1 
(10 nmol/L) for 45 min did not modulate VEGF-A mRNA expression, which changed 
from 1 to 1.08 fold change, while pre-treatment with G15 (100 nmol/L) even 
increased VEGF-A mRNA to 1.15 fold change (p<0.05 relative to control). To exclude 
translation of VEGF-A mRNA, we pre-incubated the cells with the translation inhibitor 
Cycloheximide (CY, 10 µmol/L) prior to G1 treatment and examined VEGF-A protein 
levels. Indeed G1-upregulated VEGF-A protein was not significantly decreased by CY 
pre-treatment from 145±16.6% to 114±19.7% (p<0.05 relative to G1 treated 
HUVECs, Figure 22C). Our findings suggest that GPER activation does not activate 
VEGF-A expression, but rather stimulates the release of VEGF-A out of intracellular 
storage vesicles.  
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 Role of NO/ VEGF-A Pathway in GPER-induced Capillary Formation 4.5.3
Using different pharmacological inhibitors for eNOS L-NAME (1µmol/L), L-NMMA 
(1µmol/L) and a specific neutralizing antibody for VEGF-A (500 ng/ml) we assessed 
the role of NO and VEGF-A in vasculogenesis. As shown in Figure 36 G1 (10 nmol/L) 
Figure 35. Panel A, Bar graph and representative Western Blot showing the effects of GPER 
specific agonist (G1; 10 nmol/L), in presence and absence of GPER specific antagonist (G15, 100 
nmol/L) on VEGF-A- protein expression. Pre-starved HUVECs were treated with G15 for 30 min, 
and subsequently G1 was added for additional 45 min. Values represent mean±SEM, n=3, 
*P<0.05, relative to control, §P<0.05 relative to G1 using ANOVA test. Panel B, Bar graph 
representing the effects of GPER specific agonist (G1, 10 nmol/L) +/- GPER specific antagonist 
(G15, 100 nmol/L) on VEGF-A-mRNA expression. Pre-starved HUVECs were treated with G15 for 
30 min, followed by treatment with G1 for 45min. RT-PCR was performed using SYBR green and 
Primers VEGF-A Fwd: CATGCAGATTATGCGGATCAAAC and VEGF-A REV: 
GGTCTGCATTCACATTTGTTGTG. Values represent mean±SEM, n=3, *P<0.05 relative to control 
using ANOVA test. Panel C, Bar graph and representative Western Blot showing the effects of 
GPER specific agonist (G1; 10 nmol/L) and translation inhibitor Cycloheximide (CY, 10 µmol/L) on 
VEGF-A -protein expression. Pre-starved HUVECs were treated with the inhibitor for 30 min, and 
subsequently G1 was added for another 45 min. Values represent mean±SEM, n=3, *P<0.05, 
relative to control using ANOVA test.  
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induced capillary formation, which was significantly inhibited by both NO synthesis 
inhibitors L-NAME and L-NMMA, from 166±17% to 78±11% and 83±19.3%, 
respectively (p<0.05 relative to G1 treated HUVECs). Similary, treatment with VEGF 
Ab abrogated G1-induced vasculogenesis from 166±17% to 32±6.3% (p<0.05 
relative to G1 treated HUVECs). These observations provide evidence that the NO/ 
VEGF-A pathway is another molecular mechanism, via which GPER activation 
induces capillary formation by HUVECs. However, additional experiments are 
required to further confirm whether G1 triggered secretion of VEGF-A is responsible 
for the long term effects of GPER activated capillary formation by ECs. 
 
 
 
 
 
 
Discussion 
Physiologically, the formation of new capillaries is tightly controlled, if not, the 
pathological processes, such as tumor formation, inflammatory diseases, 
gynecological diseases and diabetic retinopathy may occur permanently. VEGF and 
NO are both effective and critically induce angiogenesis [188, 191, 192], by 
promoting EC survival, proliferation and migration [184, 213-218, 315]. Moreover, 
Figure 36. Bar graph and representative photomicrographs showing the effects of the GPER 
specific agonist (G1; 10 nmol/L), in the presence or absence of eNOS inhibitors L-NAME (1 
µmol/L), L-NMMA (1 µmol/L) and of a VEGF-A specific neutralizing antibody (VEGF Ab, 500 ng/ml) 
on capillary formation by HUVECs. Cells were plated at a density of 4000 cells per well on a 
matrigel–coated 15-well µ- slides and pretreated with the inhibitors for 30min, subsequently G1 was 
added. After incubation overnight the capillary formation was assessed microscopically (see 
Method section 3.2.2). Values represent mean±SEM, *P<0.05 relative to control, §P<0.05 relative 
to G1 using ANOVA test.   
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VEGF and NO interact reciprocally and stimulate each other. NO is both, a 
downstream and an upstream mediator of VEGF-mediated capillary formation. VEGF 
stimulates PI3K/ Akt signaling, leading to the activation of eNOS and subsequently to 
the generation of NO. Under normoxic conditions, NO induces VEGF expression 
[188], thereby increasing EC cell proliferation [215, 216] and stimulating 
angiogenesis. Furthermore, VEGF and NO are targets of estrogenic molecules. 
Treatment with estradiol has been shown to upregulate VEGF expression in uterine 
tissue, vascular tissue [316-318] and breast cancer [208-211]. Moreover, estrogen 
mediated acceleration of endothelial recovery has been shown to be associated with 
increased VEGF expression [319]. The stimulation of eNOS is one of the best 
described examples for rapid estrogenic actions, which subsequently enhances NO 
production and thereby induces endothelial-dependent vasodilation [82]. More 
importantly, it has also been shown that VEGF and NO are essential mediators of 
estrogen-induced angiogenesis [99]. Studies further suggest that GPER-mediated 
vasodilation is in part dependent on endothelium-derived NO, because L-NAME, an 
eNOS inhibitor, inhibited G1-induced relaxation in rat aorta, carotid, mesenteric and 
porcine coronary arteries [108, 116, 117]. Hence, we assessed whether GPER 
activation induces eNOS phosphorylation and increases NO production in HUVECs. 
Treatment of HUVECs with the GPER specific agonist G1 increased phosphorylation 
of eNOS, and this effect was significantly blocked by the GPER specific antagonist 
G15 and by ER unspecific antagonist ICI (182,780). Moreover, in HUVECs 
significantly elevated levels of NO were detected upon treatment with G1 and E2. 
Our observations are consistent with findings of others, who reported that G1 
treatment activates eNOS and induces NO production in human ECs [320] and in the 
left ventricular tissue of rats [321]. These findings suggest that GPER mediated 
estrogen signaling activates eNOS, thereby resulting in NO production by HUVECs. 
Several studies specify the important role of VEGF in embryogenesis. The 
inactivation of one VEGF allele has been shown to result in defective vascularization 
and embryonic lethality [205, 206]. A Cre-loxP approach to inactivate two specific 
VEGF isoforms in mice resulted in 50% lethality, while the other 50% exhibited 
impaired myocardial contractility, heart enlargement and onset of ischemic 
cardiomyopathy [207]. Furthermore, several tumors, including ER+ breast cancer, 
show elevated VEGF mRNA levels, and estrogen stimulates VEGF expression [208-
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211]. Recently, it has been reported that GPER/ HIF1α signaling induces the 
expression of VEGF in CAFs and SkBr3 cells, in vitro and in a murine xenograft 
model [250, 322]. Therefore, we assessed whether GPER mediated estrogen 
signaling stimulates VEGF expression in HUVECs. 
In HUVECs, treated for 45 min with G1, we observed a significant increase in VEGF 
protein, which was specifically blocked by G15. Since treatment time of 45 min is too 
short for de novo protein expression, we further assessed VEGF mRNA expression. 
The results of qPCR revealed that mRNA levels of VEGF remained unaltered 
following G1 treatment. Surprisingly, increased VEGF mRNA expression was evident 
in HUVECs treated with G1 in the presence of G15, suggesting that G1 does not 
stimulate VEGF mRNA expression. To exclude a possible increase in translation of 
existing VEGF mRNA upon G1 treatment, we applied the translation inhibitor 
Cycloheximide CY [323] and observed no change in G1-induced VEGF-A protein 
expression. This finding indicates that GPER activation does not increase the 
translation of VEGF mRNA. De Francesco et al. revealed that GPER/ HIF1α 
signaling stimulated the expression of VEGF mRNA and the activation of VEGF 
promoter reporter in CAFs and SkBr3 cells, by silencing GPER and HIF1α and 
treating them with CoCl2 [250, 322]. In contrast to De Francesco et al., we applied G1 
in HUVECs and detected no change in VEGF mRNA, but an increase in VEGF 
protein level, which was abrogated with G15, but unaltered with CY. Hence, our 
findings suggest that GPER activation does not change the expression or translation 
of VEGF mRNA, but promotes the secretion of VEGF protein from intracellular 
vesicles in HUVECs. Ovarian cancers have been reported to secrete VEGF, serving 
as a biomarker of increased risk for metastasis [324] and blockade of VEGF 
secretion has been shown to inhibit angiogenesis in vivo [325]. These studies 
support our contention that G1 induces VEGF secretion in HUVECs, however, more 
in depth experiments are necessary to confirm this possibility, including the 
assessment of VEGF levels in the supernatant of G1-treated HUVECs. Moreover, the 
role of VEGF-A in mediating the long term vasculogenic/ capillary inducing effects of 
G1 via GPER activation remains to be further investigated.  
 
Angiogenesis is mediated by VEGF and NO [188, 191, 192], furthermore, both 
molecules have been shown to be essential for estrogen-induced angiogenesis [99]. 
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Previously, we demonstrated that GPER activation induces vasculogenesis, hence, 
in the present study we assessed whether GPER-mediated capillary formation by 
HUVECs is mediated by VEGF and NO. 
To determine the role of NO and VEGF, we applied eNOS inhibitors L-NAME and L-
NMMA and a VEGF specific neutralizing antibody VEGF Ab. G1-induced 
vasculogenesis in HUVECs was significantly inhibited by the eNOS inhibitors L-
NAME, L-NMMA and by VEGF Ab. Our observation is consistent with the findings of 
others, showing that L-NAME and L-NMMA blocked substance P-induced 
angiogenesis of ECs [217] and that eNOS knock out mice have impaired 
morphogenesis and decreased stabilization of angiogenic vessels [219]. 
Furthermore, monoclonal antibodies targeting VEGF are clinically applied and used 
as anti-angiogenic agents in cancer therapy [212]. More importantly, Lindsey et al. 
reported that L-NAME inhibited G1-stimulated vasorelaxation in Lewis female rats 
[295]. In summary, all these studies support our results and the notion that NO and 
VEGF are important mediators for GPER-induced vasculogenesis. We propose that 
GPER mediated estrogen signaling triggers eNOS activation, which subsequently 
induces NO production and the secretion of VEGF protein. These factors in concert 
with each other induce capillary formation of ECs and may accelerate endothelial 
recovery. 
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 BIAS Signaling of GPER in Endothelial Cells 4.6
Objective 
GPCR internalization was long believed to be responsible for the termination of its 
signaling, however recent findings provide evidence that internalized GPCRs can 
actually signal further. This internalized signaling or bias signaling is of high 
importance for the pharmaceutical industry, as the majority of drugs target GPCRs. 
Bias signaling is induced upon binding of a specific biased ligand, mostly not the 
“common” ligand, which induces the classical G-protein signaling cascade. GPER is 
a GPCR, hence we also wanted to scrutinize if bias signaling occurs upon activation 
with G1. 
Introduction 
A classical GPCR perceives different intracellular signaling proteins, which mediate 
distinct signaling. One class of those signaling proteins are GRKs. GRKs mediate the 
phosphorylation of GPCR`s serine residues at the C-terminus [32], which leads to the 
recruitment and binding of scaffold proteins called β-arrestins. These proteins 
mediate the internalization of GPCR via CCPs. This internalization procedure was 
long believed to be responsible for the desensitization and impairment of GPCR 
signaling by recycling or by transporting the GPCR to the proteasomes [33]. 
However, recent studies suggest that β-arrestins can also transduce signals via 
multiple effector pathways [34]. Depending on the ligand bound to GPCR, β-arrestin-
mediated signaling or “normal” G-protein mediated signaling will be activated, and 
this is known as functional selectivity or biased signaling [35]. Within the ligand-
receptor complex, both could be biased. A biased ligand prefers one signaling 
pathway over the other, meaning that it either signals via G-proteins or via β-
arrestins. Compared to biased ligands, the endogenous ligand triggers a G-protein 
signaling cascade, which is terminated by receptor internalization and is therefore 
termed neutral [34]. Recent studies suggest that biased agonists have weaker 
interaction with GPCRs than endogenous agonists. However, biased agonists are 
thought to not only bind to the usual binding site at TM5, but to additional residues at 
TM7 and ECL2. This “minor” binding site might be involved in biased signaling [326]. 
On the other hand, a biased receptor, to which a ligand (be it biased or endogenous) 
is binding, only signals via a distinct subset of pathways, which are available to this 
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class of receptor [34]. Studies do not provide a complete picture and a lot more 
research is needed to fully understand biased signaling.  
GPER is a classical GPCR, hence we wanted to assess whether biased signaling 
occurs when GPER is activated by G1 (a GPER specific ligand/ agonist) in HUVECs.  
Methods 
As described in section 3.2. 
Results 
The protein targeted as a marker for bias signaling was MEK, which is 
phosphorylated upon GPCR bias signaling. HUVECs were treated with two different 
concentrations of G1 (10 and 100 nmol/L) for different times (30 min to 12 h). In 
another experimental setup, HUVECs were treated with increasing concentrations of 
G1 (10 to 1000 nmol/L) for 30 min; treatment with epidermal growth factor EGF (100 
ng/ml) for 30 min was used as the positive control in all three experiments. As shown 
in Figure 37A, neither 10 nmol/L nor 100 nmol/L G1 induced MEK phosphorylation at 
any time point, while the positive control EGF significantly induced phosphorylation of 
MEK. Moreover, higher concentrations of G1 were also unable to induce MEK 
phosphorylation (Figure 37B). Based on these observations, bias signaling of GPER 
in HUVECs seems unlikely.  
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Discussion 
The key steps of the classical GPCR signaling model involving: 1) ligand binding 
induced conformational change; 2) the exchange of GDP for GTP, leading to the 
association of the heterotrimeric G proteins; 3) further production and signaling of 
second messenger systems; and 4) termination by GRKs that phosphorylate the 
GPCR and promote binding of β-arrestin and internalization into CCPs; is too 
simplified and incomplete. Research, conducted over the last ten years, revealed that 
β-arrestins are not only regulators for the internalization and desensitization of 
GPCRs, but are adaptor proteins with the ability to signal via many pathways. 
Pathways, targeted by β-arrestin signaling, include mitogen-activated protein kinase 
(MAPKs), tyrosine kinase SRC, nuclear factor κB (NF- κB) and PI3K [34].  
Figure 37. Western Blots showing the effects of Panel A, GPER specific agonist (G1; 10 nmol/L and 
100 nmol/L) and Epidermal Growth Factor (EGF; 100 ng/ml) on the phosphorylation of MEK. Pre-
starved HUVECs were treated with G1 (10 nmol/L or 100 nmol/L) for an increasing time. EGF, a 
positive control, was applied for 30min. Panel B, Western Blot showing the effects of increasing 
concentrations of G1 on the phosphorylation of MEK. Pre-starved HUVECs were treated with G1 (10-
1000 nmol/L) or with EGF (100 ng/ml) for 30 min; EGF was used as a positive control. 
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Activation of SRC and downstream ERK was the first reported example of β-arrestin 
mediated signaling [327, 328], and was shown to be responsible for preventing 
apoptosis and increasing mitogenic signals [328]. Subsequently, other studies 
showed that PAR2 and AT1A receptors signal via β-arrestins to activate ERK [329], 
MEK1 and ERK1/2 [330]. This β-arrestin-dependent ERK activation was shown to be 
important for chemotaxis and cytoskeletal rearrangements [331, 332]. 
Because MAPKs are activated upon β-arrestin signaling and we wanted to assess 
whether GPER activation induces bias signaling, we studied whether treatment with 
G1 activates MEK in HUVECs. MEK1 is also known as MAPK/ ERK kinase, and is 
responsible for controlling cell growth and differentiation. 
We observed a time-dependent decrease in phosphorylation of MEK upon treatment 
with G1 for 30 min to 12 hours. This time frame was chosen because studies suggest 
that β-arrestin mediated activation is delayed and 100% activation of MEK due to β-
arrestin signaling attained after 30 min [333]. Hence, in the next experiment we 
treated HUVECs for 30 min with increasing concentrations (10–1000 nmol/L) of G1. 
We detected no increase in pMEK at any concentration of G1 used, suggesting that 
GPER activation with G1 does not induce β-arrestin-mediated activation of MEK. 
Based on these observations bias signaling for GPER upon activation with G1 in 
HUVECs seems unlikely. 
Several GPCRs, including β1- and β2- adrenergic, AT1A-, µ-opiod, D2 dopamine- and 
GPR109A-receptors, have already been described to perform bias signaling and 
therefore intensively studied [34]. This new research field has immense implications 
for designing drugs, which target GPCRs. More in depth studies are needed to fully 
understand bias signaling and to identify GPCRs capable of bias signaling. Although 
we could not detect activation of MEK upon GPER activation with G1, bias signaling 
of GPER cannot be completely excluded. Therefore, and because GPER seems to 
be a good target for new therapies against CVD, more studies in different models are 
required to elucidate if GPER has the ability to perform bias signaling. Finally, the 
relevance and explanation for our observation that treatment with G1 downregulated 
pMEK is unclear and can only be speculated. It is feasible that G1 competes with an 
endogenous GPCR ligand and blocks its stimulatory effects on MEK. Further studies 
are required to investigate this possibility. 
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 GPER Activation inhibits Smooth Muscle Cell Function  4.7
Objective 
Abnormal growth of SMCs contributes to the vascular remodeling processes 
associated with CVDs. Estrogens abrogate neointimal thickening in part by inhibiting 
SMC growth. Although the role of ERα and ERβ in mediating the growth inhibitory 
effects of estrogen on SMCs is well established, the relative role of the membrane 
receptor GPER is unclear. Here, we examined effects of GPER activation on the 
function of SMCs. 
Introduction 
Endothelial dysfunction [63] and abnormal differentiation and growth of VSMCs [64] 
is associated with the initiation of atherosclerosis and the progression of CVDs. 
Findings from several studies provide strong evidence that estrogens induce 
vasoprotective actions by abrogating the pathological vascular remodeling processes 
[92] by inhibiting VSMC proliferation in vivo in carotid arteries [228, 229] and VSMC 
migration and proliferation in vitro [105, 106]. Additionally, it has been shown that 
treatment with estrogens decreases myointimal hyperplasia following aortic 
allografting [88] and in balloon-injured arteries [87]. Because antiproliferative effects 
of E2 are not lost in VSMCs of ERα and ERβ double knockout mice [123], a potential 
role for GPER mediating these effects was suggested. Hence, in this study we 
investigated the effects of GPER on SMC function. We addressed this question by 
assessing cell proliferation and migration of Human Coronary Aortic Smooth Muscle 
Cells (HCASMCs). 
Methods 
As described in section 3.2. 
Results 
 GPER Activation reduces Proliferation 4.7.1
PDGF (20 ng/ml) was employed to induce SMC proliferation, whereas treatment with 
GPER specific agonist G1 (250 nmol/L), 17β-estradiol E2 (250 nmol/L), GPER 
specific antagonist (G15; 1 µmol/L), ER-unspecific antagonist ICI 182,780 (ICI; 1 
µmol/L) and ERα specific antagonist (MPP; 1 µmol/L) was used to dissect the role of 
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GPER in mediating SMC growth. As shown in Figure 38A, G1 decreased PDGF-
stimulated cell proliferation from 100±2.5% to 67±2.7% (p<0.05 relative to control). 
This inhibitory effect of G1 was significantly reversed in the presence of the GPER 
specific antagonist G15, the ER unspecific antagonist ICI 182,780 or the ERα specific 
antagonist MPP from 67±2.7% to 89±4.3%, 93±5.7% and 95±1.6%, respectively 
(p<0.05 relative to G1 treated HCASMCs). Similar results were obtained by E2, 
which reduced PDGF-induced cell proliferation from 100±5.7% to 69±3%. Moreover, 
the ER antagonists G15, ICI and MPP abrogated the inhibitory effect of E2 from 
69±3% to 92±7.8%, 133±9.4% and 120±8.4%, respectively (p<0.05 relative to E2 
treated HCASMCs, Figure 38B). 
Next, we silenced GPER in HCASMCs, by transfecting them with GPER specific 
siRNA (50 nmol/L). As shown in Figure 39A, siRNA significantly reduced GPER 
protein expression by 64% (p<0.05 compared to scrambled control). Moreover, 
silencing of GPER attenuated the inhibitory effect of G1 (250 nmol/L) on PDGF-
stimulated cell proliferation from 166±5.1% to 156±12.9% compared to GPER 
silenced control (Figure 26B). In contrast to HCASMCs treated with GPER siRNA, G1 
decreased cell number in SMCs treated with scrambled siRNA from 100±5.3% to 
72±4.3% (p<0.05 relative to scrambled control, Figure 39B). These findings suggest 
that GPER activation induces anti-mitogenic effects on HCASMCs. Although 
inhibition of SMC growth by G1 suggests that the effects are specifically due to 
GPER activation, however, the finding that G1 effects were reversed by the ERα 
specific antagonist MPP suggests that the effects of GPER on SMC growth are in 
part dependent of a cross reaction with ERα.  
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Figure 38. Bar graphs showing the effects of GPER activation on cell proliferation in HCASMCs. 
Cell proliferation was induced by PDGF (20 ng/ml) and the cells were treated with or without Panel 
A) GPER specific agonist (G1; 250 nmol/L), Panel B) estradiol (E2; 250 nmol/L) and in presence or 
absence of GPER specific antagonist (G15; 1 µmol/L), ER-unspecific antagonist ICI 182,780 (ICI; 1 
µmol/L) and ERα specific antagonist (MPP; 1 µmol/L). HCASMCs were plated 80 000 cells/ well in 
a 12-well plate and grown for 24 h, followed by serum-starving overnight, subsequently cells were 
pre-treated for 30 min with antagonist, followed by adding the agonists, all in the presence of PDGF 
(20 ng/ml). Treatment was renewed every 48 h and on day7 cell counting was performed using the 
Coulter Counter. Values represent mean±SEM, n=5, *P<0.05 relative to control, §P<0.05 relative to 
G1 or E2 treated HCASMCs, using ANOVA test.  
Figure 39. Panel A, Bar graphs and representative Western Blot, showing the efficacy of GPER 
silencing in HCASMCs using the transfection with scrambled siRNA (50 nmol/L) and GPER siRNA (50 
nmol/L). Values represent mean±SEM, *P<0.05 relative to scrambled control using ANOVA test. Panel 
B, Bar graphs depicts the effects of GPER specific agonist (G1; 250 nmol/L) on cell proliferation in 
HCASMCs, transfected with GPER siRNA or scrambled siRNA. HCASMCs were plated 80 000 cells/ 
well in a 12-well plated and grown for 24h, followed by serum-starving overnight, subsequently the cells 
were transfected with siRNA and after 9 h treated for 30 min with G1, in presence of PDGF (20 ng/ml). 
Treatment was renewed 2x the following 48h. On day3 cell count was performed using the Coulter 
Counter. Values represent mean±SEM, n=3, *P<0.05 relative to control using ANOVA test.  
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 GPER Activation reduces Migration 4.7.2
Migration of SMCs from media to neointima leads to vascular remodeling and 
neointima formation following vascular injury. Therefore, it is important to investigate 
and identify mechanisms that can prevent increased migration of SMCs. Here we 
studied the effect of GPER activation by performing a wound closure assay using 
HCASMCs. A monolayer of HCASMCs, stimulated with PDGF (20 ng/ml), was 
scratched and treated with G1 (250 nmol/L). We observed that G1 reduced wound 
closure from 100% to 57±4.7% (p<0.05 relative to control). Moreover, G1-reduced 
wound closure was blocked by G15 (1 µmol/L) and ICI 182,780 (1 µmol /L) from 
57±4.7% to 115±8.2% and 108±8.2%, respectively (p<0.05 relative G1 treated 
HCASMCs; Figure 40). Our findings suggest that GPER activation reduces the 
proliferation of HCASMCs and thereby decreases the possibility of vascular 
remodeling and neointima formation, leading to CVDs. 
 
 
 
 
Figure 40. Bar graph and representative photomicrographs showing the effects of GPER activation on 
wound closure. Wound closure was monitored after scratching a confluent monolayer of HCASMCs, 
cultured in M231 medium, supplemented with PDGF (20 ng/ml), GPER specific agonist (G1; 250 
nmol/L), GPER specific antagonist (G15; 1 µmol/L) or ER-unspecific antagonist ICI 182,780 (ICI; 1 
µmol/L). Cells were pretreated with antagonists for 30 min, and subsequently G1 was added and cells 
were incubated for 24 h. Pictures were taken at time point 0 and 24 h afterwards and analyzed using 
Excellence Pro software. Values represent mean±SEM, *P<0.05 relative to control, §P<0.05 relative to 
G1 treated HCASMCs, using ANOVA test using ANOVA test. 
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Discussion 
Although the impact of estrogens on the cardiovascular system is well studied, the 
mechanisms involved are still unclear. Protective effects of endogenous human 
estrogens and estrogen replacement therapy against the progression of CVDs have 
been supported by multiple studies and small clinical trials [78, 79]. The controlled 
and balanced interaction between ECs and SMCs is essential in preventing CVDs 
[74]. In this context, acceleration of the endothelial integrity by estrogen contributes 
to the attenuation of SMC proliferation. This anti-mitogenic effect of estrogens on 
SMCs is mediated by increasing NO, cGMP [103], cAMP [104] and decreasing CA2+ 
levels [105]. Another protective effect of estrogen is the inhibition of SMCs migration 
[105, 106], leading to a reduction of myointimal hyperplasia following injury [87, 88].  
Vascular SMCs do not only express ERα [230] and ERβ [231], but also GPER [112, 
113]. Based on the finding that 17-β-estradiol decreased the proliferation of VSMCs 
lacking ERα and ERβ i.e. from double knockout mice [123], an important role of 
GPER in mediating antiproliferative effects by estrogens on SMCs was suggested. 
Hence, in this present study we assessed the impact of GPER on SMC function.  
We investigated the effect of GPER specific agonist G1 and E2 on the proliferation of 
HCASMCs and observed a significant reduction in PDGF-induced cell proliferation, 
which is in line with studies in human and rat VSMCs [110, 113]. These anti-
proliferative effects of G1 and E2 on HCASMCs proliferation were reversed by the 
GPER specific antagonist G15, the ER unspecific inhibitor ICI 182-780 or the ERα 
specific inhibitor MPP. Because G15 abrogated the inhibitory effects of both G1 and 
E2, our observation suggests that GPER indeed mediates the antiproliferative effects 
of estrogens on HCASMCs. In contrast to other groups, who have detected agonistic 
actions of ICI 182,780, i.e. inducing GPER signaling in breast cancer cell lines [40, 
253], we observed a significant abrogation of the antimitogenic effects of G1 by ICI 
182,780 in HCASMCs. The differences in the type of cells used might be a possible 
explanation for these discordant observations. Furthermore, our findings that MPP 
also reversed the anti-mitogenic effects of G1 and E2, suggests that a crosstalk 
between GPER and ERα may be necessary to fully elicit the inhibitory signals of 
estrogen on HCASMCs. Indeed, a crosstalk between GPER and ERα has been 
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demonstrated in BG-1 ovarian cancer cells, uterine epithelial cells [251, 252] and 
HUVECs (our observation). 
To further elucidate the impact of GPER, HCASMCs were transfected with GPER 
specific siRNA. Upon silencing of GPER the inhibitory effects of G1 on PDGF-
induced HCASMCs proliferation were lost. In contrast, G1 significantly decreased the 
proliferation of HCASMCS, transfected with scrambled siRNA. Nevertheless, when 
GPER silenced control was compared to scrambled control we observed a significant 
increase in the proliferation of HCASMCs. Contrary to our findings, Li et al. showed 
that the inhibition of human and porcine CASMCs proliferation by G1 treatment was 
abolished upon GPER silencing [334] and other studies using GPER siRNA 
observed a significant decrease in G1-stimulated effects in CAFs [258] and SKOV3 
cells [259]. A possible explanation for these contrasting outcomes could be the use of 
different cell types and different GPER siRNAs, although a pooled siRNA was used 
within this study. GPER is a classical GPCR and possess different subtypes of the 
heteromeric G proteins Gα/β/γ, which elicit specific signaling. Hence, another 
plausible explanation for the discordant findings may be that upon GPER silencing, 
still unknown pro-mitogenic or pro-survivor subunits of GPER have been exposed, 
thereby leading to this increase in cell number of HCASMCs. However, upon GPER 
silencing, the inhibitory effects of G1 were lost, indicating the importance of GPER`s 
role in mediating the inhibitory effects of estrogen on HCASMCs proliferation. 
Next, we studied whether GPER activation affects the migration of HCASMCs by 
using the well established in vitro scratch assay [261]. Treatment with G1 significantly 
decreased the PDGF-induced wound closure of HCASMCs, demonstrating that G1 
inhibits the migratory properties of SMCs and mimics the effects of estrogens, as also 
observed by others [105, 106]. We showed that the inhibitory effects of G1 on wound 
closure were blocked upon treatment with G15 and ICI 182,780, indicating a role and 
high specificity of GPER in attenuating HCASMC migration.  
Recent studies further underline the importance of GPER`s function in vascular 
smooth muscle and in the regulation of vascular tone, by inducing the relaxation of 
vascular arteries [295, 335-337]. Moreover, G1–infusion lowered blood pressure of 
normotensive [114] and hypertensive rats [108] and G1 treatment improved diastolic 
dysfunction, cardiac hypertrophy and decreased myocyte size [129]. All these studies 
emphasize the positive effects of GPER in the cardiovascular system. With regard to 
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our results in HCASMCs, we suggest a prominent role of GPER in mediating the 
effects of estrogen on VSMC function, by inhibiting proliferation and migration of 
SMCs. In conclusion, we propose that GPER might play an essential role in 
mediating the effects of estrogen in preventing hyperplasia and neointimal thickening 
by inhibiting SMC function and thereby protecting against vascular remodeling 
associated with vasoocclusive disorders.  
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 The PI3K/Akt Pathway mediates Antimitogenic Effects of GPER 4.8
in Smooth Muscle Cells 
Objective 
The PI3K/ Akt pathway is a prominent pathway, which regulates multiple cellular 
functions including metabolism, growth, survival, transcription, protein synthesis and 
cell proliferation. Moreover, inhibitory effects of estrogens on PI3K/ Akt abrogate 
SMC proliferation and neointima formation. Hence we wanted to investigate whether 
there is an association between GPER mediated inhibition of HCASMCs proliferation 
and PI3K/ Akt signaling.  
Introduction 
Abnormal differentiation and growth of VSMCs is associated with vascular 
remodeling, atherosclerosis and the progression of CVDs [64]. Moreover, the PI3K/ 
Akt pathway plays a central role in controlling vascular cell growth [181]. Studies in 
Akt deficient mice have reported reduced proliferation, migration and protection 
against oxidative stress-induced apoptosis of VSMCs [201, 202]. This suggests a 
potential regulatory role of PI3K/ Akt signaling in response to acute or repetitive 
injuries to the arterial wall, which contributes to restenosis and atherosclerosis. 
Interestingly, estrogen abrogates the pathological remodeling processes leading to 
atherosclerosis [92]; inhibits VSMC proliferation and neointima formation in carotid 
arteries in vivo [228, 229, 338-340]; and the migration and the proliferation of cultured 
VSMCs [105, 106]. Recent studies suggest that vasoprotective and physiological 
actions of estrogens are, in part, mediated via rapid, non-nuclear signaling pathways, 
involving the regulation of specific protein kinases [341, 342]. Ueda et al. reported 
that PI3K/ Akt is a rapid non-nuclear estrogen signaling target, via which estrogen 
reduces Akt phosphorylation and is responsible for the inhibition of VSMC 
proliferation [343]. Based on our findings that GPER-mediated estrogen signaling 
inhibits the proliferation of HCASMCs, we wanted to investigate whether PI3K/ Akt 
signaling is the plausible molecular mechanism via which GPER inhibits HCASMCs 
proliferation. 
 
Methods 
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As described in section 3.2. 
Results 
 Role of PI3K/ Akt in Proliferation 4.8.1
To examine the role of PI3K/ Akt in SMC proliferation we employed the PI3K-inhibitor 
LY294002 (LY; 5 µmol/L). Treatment with LY abrogated PDGF (20 ng/ml) - induced 
phosphorylation of Akt from 100% to 16±1.5% in HCASMCs (p<0.05 relative to 
control, Figure 41A). In agreement with this finding, LY also inhibited PDGF-
stimulated cell proliferation from 100% to 61±3%, moreover G1 also inhibited 
proliferation to a similar extent i.e. 70±2.4% (p<0.05 relative to control; Figure 41B). 
These observations suggest that GPER activation decreases HCASMC proliferation 
by affecting the PI3K/ Akt pathway.  
 
 
 
 
 
 Inhibition of PI3K/ Akt Pathway 4.8.2
In order to determine if GPER activation affects PI3K/ Akt in HCASMCs, the cells 
were treated with G1 (100 nmol/L). We observed a significant reduction in PDGF-
induced Akt phosphorylation by G1 from 100±9.3% to 65±5.9% (p<0.05 relative to 
control). Moreover, the inhibitory effects of G1 were significantly reversed upon pre-
Figure 41. Panel A, Bar graph and representative Western Blot showing the effect of PI3K-inhibitor 
LY294002 (LY; 5 µmol/L) on PDGF (20 ng/ ml)-induced phosphorylation of Akt. Pre-starved HCASMCs 
were treated for 30 min with LY in presence of PDGF. Values represent mean±SEM, n=3, *P<0.05 
relative to control using ANOVA test. Panel B, Bar graph depicts the effects of GPER specific agonist 
(G1; 250 nmol/L) and PI3K-inhibitor LY294002 (LY; 5 µmol/L) on HCASMCs proliferation. Cell 
proliferation was induced by PDGF (20 ng/ml) and the cells were treated with G1 and LY. HCASMCs 
were plated 80 000 cells/ well in a 12-well plate and cultured for 24h, subsequently serum-starved 
overnight and on day0 cells were treated with LY or G1, all in presence of PDGF (20 ng/ml). Treatment 
was renewed every 48h and on day 7 cell count was performed using the Coulter Counter. Values 
represent mean±SEM, n=4, *P<0.05 relative to control using ANOVA test.  
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treatment with G15 (500 nmol/L) and ICI 182,780 (500 nmol/L), from 65±5.9% to 
92±7.9% and 102±6.7%, respectively (p<0.05 relative to G1 treated HCASMCs, 
Figure 42A). Furthermore, pre-treatment with MPP (500 nmol/L) reversed G1-
inhibited phosphorylation of Akt from 32±6.8% to 105±6.9% (p<0.05 relative to G1 
treated HCASMCs, Figure 42B). Based on these results we suggest that GPER 
inhibits HCASMC proliferation via abrogation of the PI3K/ Akt pathway and this effect 
may in part be dependent on a crosstalk with ERα. 
 
 
 
 
Discussion 
Abnormal differentiation and growth of VSMCs contributes to the vascular remodeling 
processes associated with atherosclerosis, coronary artery diseases and restenosis 
following balloon angioplasty [64]. The highly conserved PI3K/ Akt pathway controls 
vascular cell viability [180, 181] and importantly regulates the proliferation of SMCs 
[199, 200]. This notion has been confirmed by in vivo studies in Akt1 knockout mice, 
which showed reduced proliferation, migration and protection against oxidative 
stress-induced apoptosis of VSMCs [201, 202]. These findings suggest an essential 
regulatory role of PI3K/ Akt signaling in vascular cell responses to acute or repetitive 
injuries, which contribute to restenosis and atherosclerosis. Similarly, estrogen 
treatment has been shown to delay/ abrogate these pathological remodeling 
Figure 42. Bar graphs and representative Western Blots showing the effects on Akt phosphorylation. 
Panel A, depicts the effects of GPER specific agonist (G1; 100 nmol/L), GPER specific antagonist 
(G15; 500 nmol/L), ER-unspecific antagonist ICI 182,780 (ICI; 500 nmol/L), and Panel B, depicts the 
effects of G1 and ERα specific antagonist (MPP; 500 nmol/L). Pre-starved HCASMCs were treated 
for 30 min with the antagonist, followed by 45 min with G1, all in presence of PDGF (20 ng/ml). 
Values represent mean±SEM, n=3, *P<0.05 relative to control, §P<0.05 relative to G1 using ANOVA 
test. 
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processes, leading to vasooclussive disorders in CVD [92]. Indeed, inhibition of PI3K/ 
Akt activity with pharmacological inhibitors LY294002 and Wortmannin has been 
shown to prevent neointimal thickening following balloon injury and PAH [344, 345]. 
Likewise, estrogen inhibits PI3K/ Akt as well as VSMCs proliferation in carotid 
arteries in vivo [228, 229, 338-340], VSMCs migration and proliferation in vitro [105, 
106] and abrogates myointimal hyperplasia following injury [87, 88].  
It is well documented that estradiol inhibits PI3K/ Akt phosphorylation in SMCs via 
ERα [343]. However, in addition to the conventional mechanisms, estrogen mediated 
vasoprotective and physiological responses are also mediated via rapid, non-nuclear 
signaling pathways, involving the regulation of specific protein kinases [341, 342]. 
Ueda et al. reported that estrogen mediated inhibition of VSMCs proliferation is 
mediated by rapid non-nuclear signaling targeting PI3K/ Akt [343]. This contention is 
confirmed by several other groups as well as by the results of the present study that 
GPER mediates the inhibitory effects of estrogen on the proliferation of SMCs [110, 
113, 334]. Hence, we wanted to investigate whether PI3K/ Akt signaling is the likely 
molecular mechanism, which mediates the inhibitory actions of GPER on HCASMC 
proliferation. 
Our findings that LY294002, a specific PI3K inhibitor, inhibited PDGF-induced Akt 
phosphorylation and proliferation of HCASMCs, provides evidence that PI3K/ Akt 
signaling regulates HCASMCs proliferation, as also reported by others [199, 200]. 
More importantly, our finding that GPER specific agonist G1 mimicked the effects of 
LY294002 in reducing the proliferation of HCASMCs, implies that its effects may also 
be PI3K/ Akt mediated. To elucidate whether GPER activation targets PI3K/ Akt 
signaling in HCASMCs, we assessed the effect of G1 on Akt phosphorylation. 
Indeed, treatment with G1 significantly reduced PDGF-stimulated pAkt in HCASMCs. 
This observation is supported by Li et al. findings, who showed that G1 decreased 
phosphorylation of Akt and ERK1/2 in human and porcine CASMCs, thereby reducing 
proliferation in both cell types [334], but these effects could also be unspecific due to 
the very high G1 concentration (10 µmol/L) used in this study. In contrast to Li et al., 
the G1 concentration used in our study was several fold lower, 100 nmol/L, and 
resembles the physiological level of estrogens in premenopausal women [346]. 
Moreover, the specificity of GPER`s mediated effect on Akt de-phosphorylation was 
confirmed upon pre-treatment with GPER specific antagonist G15 and ER unspecific 
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antagonist ICI 182,780, both of which reversed the inhibitory effects of G1 on pAkt in 
HCASMCs. Our findings indicate that GPER mediated estrogen signaling may 
stimulate de-phosphorylation of pAKT possibly by activating PP2A, as reported by 
Ueda et al. [343]. Our observation that MPP, an ERα specific antagonist, abrogated 
the inhibitory effects of G1 on PDGF-induced pAKT, suggests a potential crosstalk of 
GPER and ERα is involved in the inhibition of PI3K/ Akt pathway by estrogens in 
HCASMCs. The importance of ERα in mediating estrogenic inhibitory effects on 
VSMCs has been reported by other studies, for example ERα knockout mice did not 
benefit from estrogen`s protective effects on vascular injury [338], while ERβ-
deficient mice were still protected [347]. Furthermore, the essential role of GPER in 
mediating the anti-proliferative effect of estrogens on SMCs was identified by using 
ERα/ ERβ double knockout mice, which still exhibited E2 mediated reduction of 
VSMCs proliferation [123]. In summary, our findings suggest that GPER and ERα are 
important regulators of SMC growth. More importantly, we propose that this GPER/ 
ERα crosstalk mediates the inhibitory effect of estrogens on PI3K/ Akt signaling 
which abrogates HCASMC proliferation and initiates vasoprotective actions. 
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 The ALK1/ SMAD1/5/8 pathway does not mediate Antimitogenic 4.9
Effects of GPER in Smooth Muscle Cells 
Objective  
Due to the relevance for the ALK1/ SMAD1/5/8 pathway in mediating GPER 
dependent growth effects in ECs, we also wanted to investigate the role of this 
pathway in the anti-mitogenic action of GPER in HCASMCs. 
Introduction 
The TGFβ superfamily has recently also been shown to play an essential role in 
vascular homeostasis by influencing VSMC function. TGFβ and BMPs regulate the 
differentiation and proliferation of SMCs by inducing Matrix-Gla protein (MGP), α-
smooth muscle actin (α-SMA) and calponin [168-171, 348]. Although SMCs mainly 
express the TGFβ type I receptor ALK5, the TGFβ type I receptor ALK1 has been 
shown to play an important role in modulating phenotype transition in SMCs [164]. 
Moreover, the interplay between ALK1 and ALK5 seems to be necessary to modulate 
the effects of TGFβ and BMPs in all vascular cell types, including the SMCs [151, 
165]. Additionally, vascular cells have been shown to express other TGFβ type I 
receptors, such as BMP type I receptors ALK3 and ALK6 [349]. However, 
contradictory effects of BMP2 on SMC proliferation have been reported. For example, 
BMP2 is expressed in atherosclerotic lesions and mediates SMC growth [171, 350], 
whereas findings of Kretzschmar et al. suggest no mitogenic activity of BMP2 [351].  
Based on the above findings, we assessed the effect of BMP2 on HCASMCs. 
Moreover, we investigated whether GPER can modulate ALK1/ SMAD1/5/8 signaling 
and whether this pathway or the ALK5 pathway contributes to GPER-mediated 
antimitogenesis in HCASMCs. 
Methods 
As described in section 3.2. 
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 Role of BMP2/ ALK5/ ALK1 in Proliferation 4.9.1
First we determined the role of BMP2 in regulating HCASMCs proliferation by 
studying its effect in the presence of Noggin, an endogenous antagonist of BMP2 
which inhibits the binding of BMP2 and BMP4 to its receptor and their signaling [266]. 
As shown in Figure 43, treatment with BMP2 (10 ng/ml) increased PDGF-stimulated 
cell proliferation from 100±2% to 118±7.5% (p<0.05 relative to control). BMP2-
induced mitogenesis was significantly abrogated by pre-treatment with Noggin (200 
ng/ml) from 118±7.5% to 80±3.5% (p<0.05 relative to BMP2 treated HCASMCs). 
Next we studied whether the ALK1/ SMAD1/5/8 or the ALK5 pathway is involved in 
BMP2-induced proliferation of HCASMCs by applying SJN2511, a specific ALK5 
inhibitor and ALK1Fc, an ALK1 neutralizing antibody. As shown in Figure 43, BMP2- 
stimulated proliferation was significantly decreased by SJN (200 nmol/L) from 
118±7.5% to 61±5.3%, whereas pre-treatment with ALK1Fc (200 ng/ml) had no 
modulatory effect and was 94±7% (p<0.05 relative to BMP2 treated HCASMCs, 
Figure 30). Our findings provide evidence that BMP2 induces HCASMC proliferation. 
Moreover, our observation that BMP2 induced proliferation was blocked by Noggin 
and SJN, but not by ALK1Fc, suggest the involvement of ALK5/ SMAD2/ 3 and not 
ALK1/ SMAD1/5/8 in mediating the proliferative effects of BMP2 in SMCs. 
 
 
 
 
 
Figure 43. Bar graph showing the effects on cell proliferation in HCASMCs. Cell proliferation was 
induced by PDGF (20 ng/ml) and the cells treated with or without TGFβ Receptor II specific agonist 
BMP2 (10 ng/ml), and BMP inhibitor (Noggin, 200 ng/ml) or ALK5 specific antagonist (SJN; 200 
nmol/L) or ALK1 specific antagonizing antibody (ALK1Fc; 200 ng/ml). HCASMCs were plated 80 
000 cells/ well in a 12-well plate and cultured for 24 h. Followed by serum-starvation overnight, 
subsequently cells were pre-treated for 30 min with antagonists or inhibitor and then BMP2 was 
added, all in the presence of PDGF (20 ng/ml). Treatment was renewed every 48 h and on day 7 
cell counting was performed using the Coulter Counter. Values represent mean±SEM, n=3, 
*P<0.05 relative to control, §P<0.05 relative to BMP2 using ANOVA test.
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 Activation of ALK1/ SMAD1/5/8 Pathway 4.9.2
Next we assessed the effects of G1 (250 nmol/L) on the SMAD1/5/8 phosphorylation 
in HCASMCs. Treatment with G1 significantly increased phosphorylation of 
SMAD1/5/8 from 100% to 269±7% (p<0.05 relative to control, Figure 44A). Moreover, 
the inhibitory effects of G1 on cell proliferation were not reversed by SJN (200 
nmol/L) or by ALK1Fc (200 ng/ml) and changed from 70±2.4% to 75±3.4% and 
61±3%, respectively (p>0.05 relative to G1 treated HCASMCs, Figure 44B).  
In summary, our findings provide evidence that BMP2 induces HCASMC proliferation 
via ALK5/ SMAD2/3. This finding, together with our observation that activation of 
GPER with G1 induced SMAD1/5/8 phosphorylation and inhibited HCASMC 
proliferation and that the antimitogenic effect of G1 was not reversed by ALK5 or 
ALK1 blockers, suggest that the inhibitory effects of G1 are not mediated via ALK1 
nor ALK5, but via some alternative mechanism. 
 
 
 
 
 
 
Figure 44. Panel A, Bar graph and representative Western Blot showing the effect of GPER specific 
agonist (G1; 100 nmol/L) on the phosphorylation of SMAD1/5/8. Pre-starved HCASMCs were 
treated for 45 min with G1 in the presence of PDGF (20 ng/ml). Values represent mean±SEM, n=3, 
*P<0.05 relative to control using ANOVA test; Panel B, Bar graph showing the effects of GPER 
specific agonist (G1; 250 nmol/L), in the presence or absence of ALK5 specific antagonist (SJN; 200 
nmol/L) and ALK1 specific antagonizing antibody (ALK1Fc; 200 ng/ml) on HCASMC proliferation. 
Cells were plated 80 000 cells/ well in a 12-well plate and cultured for 24h, followed by serum-
starvation overnight. Subsequently cells were pre-treated for 30 min with antagonists and then G1 
was added, all in the presence of PDGF (20 ng/ml). Treatment was renewed every 48h, and on day 
7 cell counting was performed using the Coulter Counter. Values represent mean±SEM, n=3, 
*P<0.05 relative to control using ANOVA test. 
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Discussion 
BMPs belong to the TGFβ superfamily, which plays an important role in vascular 
development and vascular disorder [143]. TGFβ signals via distinct transmembrane 
receptors known as type I and type II receptors. Activation of these receptors leads to 
the phosphorylation of different SMADs, which triggers downstream responses, 
depending on the cell type [262-264]. VSMCs express ALK5, the main TGFβ type I, 
although presence of ALK1 has also been reported [164], moreover both receptors 
have to interact, to fully elicit TGFβ and BMP signaling in SMCs [151, 165]. 
Additionally, the expression of BMP type I receptors ALK3 and ALK6 was 
demonstrated in vascular cells [349]. However, the effect of the ALK3/ ALK6 ligand 
BMP2 on SMCs proliferation remains unclear. Some studies state that BMP2 is an 
important mediator in SMC regulation [171, 350], while others suggest that BMP2 is 
lacking mitogenic activity [351]. Based on the discordant findings, there is need for 
ascertaining the role of BMP2 in regulating SMC growth. Hence, in this study we 
assessed its growth regulatory role in HCASMCs.  
We observed a significant increase in HCASMCs number following treatment with 
BMP2 (10 ng/ml), and pre-treatment with Noggin blocked this effect. Noggin is an 
endogenous sequestering molecule, which inhibits the binding of BMP2 and BMP4 to 
their receptors and blocks their downstream signaling [266]. Therefore, the growth 
stimulatory effect of BMP2 observed in HCASMCs are highly specific and confirm the 
observations of Willette et al., who reported induction HASMCs proliferation following 
BMP2 treatment [171]. 
To study the role of the ALK1 and ALK5 pathways in mediating growth effects in 
HCASMCs, we used pharmacological inhibitors for ALK1 and ALK5. BMP2 
stimulated proliferation of HCASMCs, and this effect was significantly blocked by 
ALK5- inhibitor SJN2511, but not by ALK1Fc, a neutralizing antibody for ALK1. Our 
finding suggests that ALK5 signaling plays an important role in inducing SMC 
proliferation and suggests that BMP2 signaling is not only mediated via ALK3 and 
ALK6 [265, 282], but potentially involves ALK5. The importance of ALK5 in SMC 
proliferation was recently emphasized by Tang et al., who reported that TGFβ 
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induced HASMC differentiation by activating the phosphorylation of SMAD2/3 and 
SMAD1/5/8 in an ALK5-, but not in an ALK1-dependent manner [348]. 
Based on the importance of SMAD1/5/8 phosphorylation in HASMC differentiation 
[348], together with our findings that GPER activation reduces HCASMC proliferation, 
we assessed whether ALK1- or ALK5- signaling contributes to this effect and whether 
G1 affects SMAD1/5/8 phosphorylation in HCASMCs. Surprisingly, we found that 
treatment with G1 significantly induced SMAD1/5/8 phosphorylation and this was 
accompanied with inhibitory effects on HCASMC proliferation. Based on the fact that 
SMAD1/5/8 phosphorylation is important for HASMC differentiation [348], together 
with our finding that BMP2 induces HCASMCs growth; we expected GPER activation 
would result in inhibition of SMAD1/5/8 phosphorylation, however we observed 
contrary effects. Moreover, GPER mediated reduction of HCASMC proliferation was 
not reversed by SJN2511, an inhibitor for ALK5, nor by ALK1Fc, a neutralizing 
antibody for ALK1. These results, suggest that GPER stimulates ALK1/ SMAD1/5/8 
signaling in HCASMCs, but that neither the ALK1- nor the ALK5- pathway contributes 
to the inhibitory effects of GPER on HCASMCs proliferation.  
In summary, our findings provide evidence that BMP2 is an important mitogenic 
activator, which potentially mediates its effects via ALK5-signaling, moreover the 
inhibitory effects of GPER on HCASMC proliferation are not mediated via activation 
of ALK1/ SMAD1/5/8 or the ALK5 pathway. 
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 Differential Role of GPER Activation on Endothelial and Smooth 4.10
Muscle Cell Function 
Objective 
Impaired endothelial function and abnormal differentiation and growth of VSMCs 
contribute to the onset and progression of vascular remodeling associated with 
CVDs. The beneficial effects of estrogens on the cardiovascular system are well 
established; however the mechanisms involved are not completely clear. Treatment 
with estrogen improves endothelial function and may play a key role in inducing 
cardiovascular protection, and the controlled and balanced interaction between ECs 
and SMCs may be essential. Since acceleration of the endothelial recovery by 
estrogen contributes to the attenuation of SMCs proliferation and migration, we 
investigated in this study the role of GPER in mediating the protective effects of 
estrogens and the molecular mechanisms underlying these effects. In this section we 
provide a summary of the differential effects of estrogen mediated via GPER 
signaling on HUVECs and HCASMCs. 
Introduction 
Dysbalance in the homeostasis between endothelium and VSMC activity plays a 
dominant role in the pathophysiology of vascular remodeling leading to vasoocclusive 
disorders in CVDs. Endothelial dysfunction, induced by mechanical force or 
inflammation, initiates biochemical/ molecular signals, which trigger SMCs to 
abnormally differentiate and proliferate and subsequently lead to neointimal 
thickening, occlusion of blood vessels, elevated blood flow and high blood pressure, 
all hallmarks for CVDs [64]. Although many different pathways are involved in 
mediating these highly complex vascular actions, in this study we solely focused on 
assessing the role of ALK1/ SMAD1/5/8 and PI3K/ Akt pathway. Both of these 
pathways are highly conserved and are involved in diverse functions such as growth, 
adhesion, migration, apoptosis and differentiation of vascular cells [142, 180, 181].  
Several studies have demonstrated an important regulatory role of PI3K/ Akt in 
postnatal blood vessel formation and processes related to angiogenesis [181, 189, 
190]. Moreover, PI3K/ Akt has been shown to control the proliferation of cultured 
SMCs [199, 200]. Role of PI3K/ Akt has also been confirmed by in vivo studies, 
where VSMCs of Akt1 knockout mice showed reduced proliferation, migration and 
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protection against oxidative stress-induced apoptosis [201, 202]. These findings 
suggest a regulatory role of PI3K/ Akt signaling in regulating vascular function in 
responses to acute or repetitive injuries, leading to vasoocclusive disorders. 
The ALK1/ SMAD1/5/8/ pathway plays a key role of in embryonic angiogenesis and 
mutations in ALK1 and SMADs lead to severe defects in embryogenesis and early 
lethality [176-178]. This pathway is importantly involved in maintaining homeostasis 
within the vasculature. For example patients with HHT suffer from telangiectiasis, 
arteriovenous malformation, nose bleeding and gastrointestinal bleeding, show 
mutations in ALK1 [144]. Although SMCs mainly express ALK5, ALK1 has also been 
reported to be important for modulating phenotype transition in SMCs [164]. 
Moreover, interplay between ALK1 and ALK5 seems to be necessary in modulating 
the effects of its endogenous ligands TGFβ and BMPs on vascular cells [151, 165]. 
Epidemiological studies suggest a protective role for endogenous estrogens and 
estrogen replacement therapy on the progression of CVDs [78, 79]. In vivo studies 
provide strong evidence that estrogens induce their vasoprotective actions by 
inhibiting SMC growth [92] and promoting endothelial function (growth, proliferation, 
capillary formation) [99, 102, 245]. Estrogen signaling is known to be elicited via two 
different nuclear receptors ERα, ERβ [78, 102]; moreover the recently identified 
membrane ER, called GPER, has also been shown to play an active role [38]. GPER 
is expressed in the vasculature [248], intact arteries [112], ECs [25, 249] and SMCs 
[112, 113] and has been suggested to mediate important regulatory and protective 
actions of estrogens within the cardiovascular system. 
In the present study we assessed the role of GPER activation on regulating the 
function of HUVECs and HCASMCs. Moreover, we investigated whether GPER 
mediates the effects of estrogen on HUVECs and HCASMCs by modulating ALK1/ 
SMAD1/5/8 and PI3K/ Akt pathways.  
Methods 
As described in section 3.2. 
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Our findings provide evidence that GPER activation differentially modulates EC and 
SMC function. In this context, GPER induces EC and inhibits SMC growth by 
differentially regulating the PI3K/ Akt and ALK1/ SMAD1/5/8 pathways. Here, we 
summarize our results from HCASMCs and HUVECs, which highlight the different 
effects of GPER (described previously under section 4.1-4.9) 
Activation of GPER with G1 and E2 abrogated PDGF-induced proliferation of 
HCASMCs, but induced the formation of new microvessels in HUVECs (Figure 45A/ 
B). Interestingly, investigation of downstream molecular mechanisms revealed that 
PI3K/ Akt is importantly regulated in both cell types. In this context, GPER activation 
differentially modulates PI3K/ Akt in SMCs and ECs. GPER activation by G1 leads to 
a reduction of AKT phosphorylation in HCASMCs, but induces AKT phosphorylation 
in HUVECs. Inhibition of PI3K by LY294002, a specific PI3K inhibitor, mimicked the 
effects of G1 and reduced proliferation of HCASMCs and abrogated G1-stimulated 
capillary formation by HUVECs. Our findings demonstrate that the ALK1/ SMAD1/5/8 
pathway is important in mediating the effects of GPER on capillary formation by 
HUVECs and does not regulate HCASMC proliferation. Consistent with this notion, 
we observed that GPER activation with G1 activated ALK1/ SMAD1/5/8 signaling by 
increasing the phosphorylation of SMAD1/5/8 in both HCASMCs and HUVECs. 
However, blocking ALK1 abrogated the growth effects of G1 in ECs, but not in SMCs. 
Taken together, our findings suggest that the capillary-inducing effects of GPER in 
ECs are ALK1/ SMAD1/5/8 and PI3K/ Akt mediated, whereas the inhibitory effects of 
GPER in SMCs involve the PI3K/ Akt pathway. 
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Figure 45. Summary of Bar graphs and representative Western Blots showing the differential effects 
of GPER specific agonist and estradiol on the function of HCASMCs and HUVECs. Panel A, Data 
from HCASMCs. Bar graphs and representative Western Blots showing the effects of G1 and E2 on 
cell proliferation and phosphorylation of AKT and SMAD1/5/8. Cell proliferation and phosphorylation 
of AKT and SMAD1/5/8 was induced by PDGF (20 ng/ml) and the cells were treated with G1, E2, in 
presence or absence of G15, ALK1Fc or LY294002. Values represent mean±SEM, n=3-5, *P<0.05 
relative to control using ANOVA test. Panel B, Data from HUVECs. Bar graphs and representative 
Western Blots showing the effects of G1 and E2 on capillary formation and on phosphorylation of 
AKT and SMAD1/5/8 of G1 and E2. Cells were treated with G1, E2, in presence or absence of G15, 
ALK1Fc or LY294002. Values represent mean±SEM, n=5-6, *P<0.05 relative to control using ANOVA 
test.  
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Discussion 
Although estrogens actively regulate the cardiovascular system, the mechanism(s) 
involved remain unclear. Protective effects of endogenous estrogens and estrogen 
replacement therapy against the progression of CVDs are supported by multiple 
epidemiological studies and small clinical trials [78, 79]. The beneficial actions of 
estrogen on the endothelium may play an important role in cardiovascular protection 
[102], furthermore the controlled and balanced crosstalk between ECs and SMCs via 
autocrine/ paracrine factors may be essential [74]. Indeed, acceleration of the 
endothelial repair/ growth by estrogen has been shown to attenuate SMC 
proliferation. The pro-angiogenic effects on EC and the anti-mitogenic effects of 
estrogens on SMCs are mediated via second messengers like NO, cGMP [103], 
cAMP [104] and Ca2+ [105]. Vascular cells do not only express the nuclear receptors 
ERα [230] and ERβ [231], but also a membrane receptor, GPER [112, 113], which 
has been suggested to play an important regulatory role within the cardiovascular 
system. GPER has been postulated to mediate the anti-proliferative effects of 
estrogens on SMCs, since the inhibitory effects of 17-β-estradiol on VSMC 
proliferation were not lost in cells from ERα/ ERβ double knock out mice [123]. 
Therefore, in the present study we assessed the impact of GPER on HCASMC and 
HUVEC function by studying cell proliferation and vasculogenesis, respectively.  
We observed a significant reduction in PDGF-induced HCASMC proliferation by 
GPER specific agonist G1 and E2, which is consistent with earlier findings in human 
and rat VSMCs [110, 113]. Matrigel-based vasculogenesis assay was used to assess 
the impact of GPER on endothelial function. We observed a significant stimulation of 
microvessel formation by HUVECs following G1 and E2 treatment, which is 
consistent with the observations of De Francesco et al. and Baruscotti et al. [100, 
250]. In summary, our findings suggest that GPER plays an important role in 
mediating the differential effects of estradiol on SMC and EC function. 
Recently, it has been suggested that estrogen mediated physiological and 
vasoprotective responses are exhibited via rapid, non-nuclear signaling pathways, 
involving specific protein kinases [341, 342]. Ueda et al. reported inhibition of VSMCs 
proliferation by estrogen is mediated via rapid non-nuclear signaling targeting PI3K/ 
Akt. Indeed, estrogen inhibits Akt phosphorylation and abolishes VSMCs proliferation 
[343]. Furthermore, GPER mediated estrogen signals are transduced via the PI3K/ 
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Akt pathway, induce survival of MCF-7 cells [306] and migration of renal carcinoma 
cells [307]. Hence, we wanted to investigate whether PI3K/ Akt signaling is a 
potential common molecular mechanism, which regulates the effects of GPER on 
HCASMCs proliferation and capillary formation by HUVECs. 
G1 significantly reduced PDGF-stimulated pAkt, implying that GPER activation 
targets PI3K/ Akt signaling in HCASMCs. Our contention is supported by the findings 
of Li et al. [334], however in contrast to the high G1 concentration used by Li et al., 
ours was within the physiological range of estrogen in premenopausal women [346]. 
The finding that pre-treatment with GPER specific antagonist G15 reversed the 
inhibitory effects of G1 on pAkt in HCASMCs suggests that the effects of GPER on 
Akt dephosphorylation are specific. Indeed, treatment with LY294002, a specific PI3K 
inhibitor, abrogated PDGF-induced HCASMC proliferation, implying that the inhibition 
of PI3K/ Akt signaling is associated with the reduction of HCASMCs proliferation, as 
also reported by others [199, 200]. Since G1 mimicked the inhibitory effect of 
LY294002 on HCASMC proliferation, our findings suggest that estrogen triggers the 
de-phosphorylation of pAKT, which subsequently inhibits HCASMC proliferation, via 
GPER. 
Contrary to SMCs, in HUVECs we observed a significant increase in Akt 
phosphorylation followed by G1 treatment, indicating that PI3K/ Akt signaling is 
activated. This observation is in line with the findings of Guan et al., who reported 
that G1 treatment specifically increased Akt phosphorylation in renal carcinoma cells 
and promoted metastasis [307]. The stimulatory effect of G1 on Akt phosphorylation 
was blocked by G15, indicating that GPER specifically activates PI3K/ Akt signaling. 
Although the regulatory role of PI3K/ Akt signaling in estrogen-mediated 
angiogenesis is already proven [100, 240, 241], to our knowledge, we were the first 
to report the impact of PI3K/ Akt pathway in GPER mediated vasculogenesis. 
Moreover, G1-stimulated microvessel formation was blocked by LY294002 and 
reaffirms the role of PI3K/ Akt in mediating the effects of GPER in HUVECs. This is 
consistent with the findings that LY294002 abrogated G1-induced upregulation of 
MMP9 in AHCN and OS-RC-2 cells [307], and that wortmannin (another specific PI3K 
inhibitor) significantly abolished G1-stimulated functional recovery and G1-mediated 
reduction of infarct size in isolated hearts of Sprague Dawley rats [109]. In summary, 
the above findings indicate an essential role of the PI3K/ Akt pathway in mediating 
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the vasoprotective effects of estrogens via GPER. Importantly, via GPER, estrogen 
differentially regulates PI3K/ Akt in HCASMCs and HUVECs. GPER signaling inhibits 
proliferation and PI3K/ Akt pathway in HCASMCs most likely by activating PP2A as 
suggested by Ueda et al. [343], whereas estrogen activates the PI3K/ Akt pathway 
via GPER and induces vasculogenesis in HUVECs. 
The TGFβ superfamily plays an important role in vascular development as well as 
vascular disorders [143]. TGFβ actively signals via two sets of distinct 
transmembrane receptors known as type I and type II receptors, which induce further 
responses by phosphorylating different SMADs (depending on cell type) [262-264]. In 
VSMCs, ALK5 is the major TGFβ type I receptor expressed, although ALK1 has also 
been identified [164]. Moreover, both receptors have been shown to interact, to fully 
elicit TGFβ and BMP signaling in SMCs [151, 165]. ALK1/ SMAD1/5/8 signaling has 
been shown to regulate HASMC differentiation [348] and endothelial function [160, 
267-269]. Furthermore, this pathway has been reported to be essential in the human 
embryogenesis by regulating angiogenic processes. Mutations in ALK1 or 
SMAD1/5/8 caused early lethality due to vascular abnormalities in murine embryos 
[176-178]. Several studies have also demonstrated a prominent role of ALK1/ 
SMAD1/5/8 in modulating postnatal angiogenesis [160, 267-269]. Hence, in this 
study we assessed whether ALK1/ SMAD1/5/8 signaling is another potential 
molecular mechanism, which regulates the effects of GPER on HCASMCs 
proliferation and on capillary formation by HUVECs. 
Surprisingly, in HCASMCs treatment with G1 induced SMAD1/5/8 phosphorylation, 
which has been previously shown to be important for HASMC differentiation [348]. As 
described in section 4.9.1, we have demonstrated that BMP2 stimulates the 
proliferation of HCASMCs. Other studies have also reported findings of induction of 
pSMAD1/5/8 in vascular cells [283] and stimulation of cell proliferation in HASMCs 
[171] following BMP2 treatment. Since G1 inhibits HCASMC proliferation, we 
expected it to inhibit SMAD1/5/8 phosphorylation, however we observed contrary 
effects. Interestingly, GPER mediated inhibition of HCASMC proliferation of 
HCASMCs was not reversed using ALK1Fc, an ALK1 neutralizing antibody. Based 
on the above findings, we can conclude that the anti-proliferative effects of GPER on 
SMCs are not mediated via the ALK1/ SMAD1/5/8 pathway, but rather involve PI3K/ 
Akt signaling. 
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In HUVECs treatment with G1 significantly increased SMAD1/5/8 phosphorylation 
and this effect was significantly inhibited by the GPER specific antagonist G15, 
implying that GPER specifically activates ALK1/ SMAD1/5/8 signaling. While 
Matsumoto et al. previously demonstrated the stimulatory effects of estrogens on 
SMAD1/5/8 phosphorylation [271, 272], to our knowledge, we are the first to 
demonstrate a regulatory role of GPER in phosphorylating SMAD1/5/8. This 
contention is further supported by the fact that we were able to block G1-stimulated 
capillary formation by HUVECs with ALK1Fc, an ALK1 neutralizing antibody. Our 
observations are consistent with other studies, which demonstrated that ALK1Fc 
blocks angiogenesis by HMVECs [174] and downregulates the expression of ID-1, a 
downstream product of ALK1 [149, 174, 273]. In summary, our findings provide 
evidence that GPER activates ALK1/ SMAD1/5/8 signaling in both HCASMCs and 
HUVECs. Furthermore, the ALK1/ SMAD1/5/8 pathway does not contribute to the 
inhibitory effects of GPER on HCASMCs proliferation, but plays an essential role in 
regulating GPER-induced vasculogenesis by HUVECs.  
Based on our findings on HCASMCs and HUVECs, as depicted in Figure 46, we 
propose that GPER mediates the differential effects of estrogen by inhibiting SMCs 
activity and inducing/ improving EC function. More importantly, GPER differentially 
regulates the PI3K/ Akt signaling pathway, i.e. G1 inhibits this pathway in HCASMCs, 
but activates it HUVECs. The impact of GPER on ALK1/ SMAD1/5/8 signaling is 
identical in HCASMCs and HUVECs, as G1 stimulated SMAD1/5/8 phosphorylation 
in both cell types. However, based on our finding that ALK1Fc, an ALK1 neutralizing 
antibody blocked capillary-inducing effects in HUVECs, but not the anti-proliferative 
effects in HCASMCs, we propose that ALK1/ SMAD1/5/8 plays a crucial role in 
GPER-induced capillary formation by ECs and is not involved in GPER-mediated 
inhibition of SMCs proliferation. In conclusion, GPER may play an important role in 
mediating the protective effects of estrogen on the cardiovascular system by 
differentially mediating VSMCs and ECs function. Moreover, agonists for GPER, such 
as G1, may be of therapeutic relevance in treating CVDs in postmenopausal women, 
as GPER activity remains unchanged in ageing vessels.  
Results 
 
137 
 
 
Figure 46: Differential effect of GPER mediated estrogenic signaling on HCASMC and HUVEC. 
Following GPER activation, the PI3K/ Akt signaling pathway is inhibited in HCASMCs, but stimulated 
in HUVECs. The differential regulation of this pathway by G1 results in decreased proliferation of 
HCASMCs, but increased vasculogenesis by HUVECs. 
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5 Conclusion and Perspectives 
Increased life expectancy is also accompanied with ageing associated diseases and 
highlights the need for research to understand and improve the quality of life and to 
prevent age-related diseases. Compared to premenopausal women, the prevalence 
of CVDs is much higher in aging/ postmenopausal women. Moreover, declining 
estrogen levels correlate with increased incidence of CVDs, suggesting that estrogen 
protects younger women against CVDs. Indeed, the protective effects of endogenous 
and therapeutic estrogens against the progression of CVDs are supported by 
epidemiological/ observational studies, small clinical trials [78, 79]; and selective data 
of women treated within five years of menopause-onset in the randomized WHI and 
HERS trials [81, 82]. Estrogens prevent vascular remodeling processes associated 
with vasoocclusive disorders [92] by improving endothelial growth and function [102] 
and inhibiting VSMC proliferation [228, 229] [105, 106]. However, estrogens/ HRT 
can also induce deleterious effects and are implicated in the development of breast 
and uterine cancer, as well as venous thromboembolic events [136, 137]. Hence, it is 
essential to pharmacologically separate the beneficial effects on the vasculature from 
the harmful effects of estrogens on reproductive organs. This may be feasible by 
selectively targeting ERs with specific agonists, which do not elicit the negative side 
effects of estrogens. Thus, in depth research is required, to elucidate the complexity 
of estrogen signaling within the vascular cells and delineate their downstream 
molecular mechanisms to find an appropriate target. In this study, we investigated the 
role of GPER mediated estrogen signaling on the function of HUVECs and 
HCASMCs and the underlying molecular mechanisms. 
We demonstrate that GPER activation improves endothelial function by stimulating 
vasculogenesis, sprouting, migration and proliferation of HUVECs. Our findings 
provide evidence that GPER can mediate the protective effects of estrogens by 
accelerating the recovery of damaged endothelium and preventing the vascular 
remodeling processes leading to CVDs. Importantly, we demonstrate that GPER 
activation stimulates ALK1/ SMAD1/5/8 signaling by inducing the secretion of BMP2. 
In summary, the ALK1/ SMAD1/5/8 pathway is partly responsible for GPER-induced 
capillary formation in HUVECs and ECFCs.  
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We further discovered that GPER stimulation increases cAMP synthesis in HUVECs, 
which mediates the beneficial effect of GPER on vasculogenesis. In this context, we 
revealed that GPER stimulates PKA, which is downstream from cAMP and activates 
the ALK1/ SMAD1/5/8 signaling cascade, consequently stimulating capillary 
formation by HUVECs. It has been shown that GPER activation stimulates PI3K/ Akt/ 
NO/ VEGF signaling, which is partly responsible for GPER-induced capillary 
formation by HUVECs. However, whether VEGF-A secretion by ECS in response to 
G1 is responsible or contributes to GPER-induced vasculogenesis, in the long term, 
remains to be further elucidated and confirmed. Here, we demonstrate that ALK1/ 
SMAD1/5/8 and PI3K/ Akt signaling crosstalk with each other to promote 
vasculogenesis. 
Apart from endothelial damage and dysfunction, the abnormal differentiation and 
growth of VSMCs contributes to neointima formation and vascular remodeling 
processes leading to vasoocclusive disorders. Our findings provide evidence that 
GPER activation alters HCASMC function by inhibiting their proliferation and 
migration. Hence, GPER activation abrogates key processes contributing to vascular 
remodeling leading to vasoocclusive disorders in CVDs. We further investigated the 
potential molecular mechanisms and identified that GPER activation inhibits PI3K/ 
Akt signaling, but stimulates ALK1/ SMAD1/5/8 signaling. Moreover, we demonstrate 
that inhibition of PI3K/ Akt, but not ALK1/ SMAD1/5/8 activation contributes to the 
reduced HCASMC proliferation by GPER. Furthermore, we provide evidence that a 
crosstalk between GPER and ERα is responsible for the inhibitory effects of 
estrogens on PI3K/ Akt signaling, proliferation and migration of HCASMCs. 
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Figure 47: Descriptive Chart of this Study`s Conclusions. Panel A: The role of GPER activation on 
endothelial function and regulating molecular mechanisms, in HUVECs. Panel B: The role of GPER 
activation on SMC function and regulating molecular mechanisms, in HCASMCs. 
 
In summary, our findings demonstrate that GPER plays an important role in 
mediating the protective effects of estrogen against vasoocclusive disorders 
associated with CVDs, by improving endothelial function and inhibiting SMC 
proliferation and migration, as depicted in Figure 47. Our findings suggest that GPER 
might be an interesting candidate for developing new therapeutic agents to treat 
CVDs in post-menopausal women, without exhibiting the negative side effects of 
hormones currently used for replacement therapy. Additionally, GPER function 
remains unaltered in ageing vessels, in contrast to ERα and ERβ. Therefore GPER 
ligands/ agonists may be superior to the currently used estrogen therapies in 
inducing vasoprotective actions. Moreover, GPER agonists do not exhibit the 
feminizing effects of estrogens and may be considered therefore as a new treatment 
strategy against CVDs in both genders.  
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